¥xÆW¥¼¤W¥«ªÑ²¼ °]¸gºô 

¥¼¤W¥«  

¥¼¤W¥«ªÑ²¼¦æ±¡,¿³ÂdªÑ²¼¶R½æ,¥¼¤W¥«ÂdªÑ²¼¬d¸ß,§Ö³t´x´¤¥¼¤W¥«ªÑ²¼¶R½æ¯ß°Ê

Åwªï¨Ó¨ì¥²´Iºô ¤â¾÷ª© ¥[¤J·|­û µn¤J ­º­¶
¥¼¤W¥«ÂdªÑ²¼¦æ±¡¬d¸ß,¥¼¤W¥«ªÑ²¼¶R½æ¹L¤á,¿³ÂdªÑ²¼¦æ±¡¬d¸ß¡ã§K¥I¶O±M½u¡G0800-035-178
°Q½×°Ï>ÃĵØÂåÃÄ
ªø´Á«ù¦³¥Ø¼Ð»ù500¤¸¥H¤W     µoªí·s¸ÜÃD ¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¥ý¶i10000164  µoªí®É¶¡:2014/7/22 ¤W¤È 09:05:58
ÃÒ¥æ©Ò­«¤j°T®§¤½§i

(6446)ÃĵØÃĤ½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Ö­ã¡C

1.¨Æ¹êµo¥Í¤é:103/07/21

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î

5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«ö­pµe¶i¦æ(¥ç§Y¬ü°êFDA®Ö­ã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç­pµe)¡C

6. ¦]À³±¹¬I:¶i¦æ¤½§i¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©x­û«Øij¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C

(2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C



¶}ª©·|­û¡u¥ý¶i¡v½Ðºô¤Íµo¨¥µÛ­«©ó²z©Ê°Q½×·sÃĶi«×¡AµL¿×¤£²z©Êªº¥´À£¡A½Ð¦Ü¨ä¥Lª©°Ï¡A¤À¬y¬O¬°¤F¦³§Q§ë¸ê¤H·j´M

·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2019/1/15 ¤U¤È 06:18:46²Ä 5869 ½g¦^À³
§Ú»{¬°®³¨ì«áÃÄÃÒ,¥²¶}ªk»¡

ªk»¡¤º®e¤~·|¨M©wªÑ»ù¤è¦V

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GEric10147757  µoªí®É¶¡:2019/1/15 ¤U¤È 05:52:46²Ä 5868 ½g¦^À³
Oh my god

5¤é/10¤é/20¤é/60¤é/120¤é/240¤é

³£ªÈµ²¦b³o174~175,µ²³Âªá÷

¥X¤j¨Æ¤F

­nµo°Ê¤F

©¹¤W?©¹¤U?

3¤Ñ¤º¦³µª®×

¬Ý©x­Ì

¶R±i¼Ö³z§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2019/1/14 ¤U¤È 08:56:23²Ä 5867 ½g¦^À³
¤pªL¤j:

¤Q¤À·PÁÂ

ªº½T­^¤å¦h¤F­Óother´N®t«Ü¦h

³æ¬Ý¤¤¤å¡A©ú©úPV¬OMPN¨ä¤¤¤@¶µ¡A«o¥uÁ¿¤FPV...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2019/1/14 ¤U¤È 07:17:15²Ä 5866 ½g¦^À³
§ë¸ê¬ö«ß¤j¡A

MPN§Y¥]¬A¤FPV¡BET¡BMF¤TÃþ¡A¦pªG¬Ý­^¤å·s»D½Z´N·|²M·¡¤F¡C(other MPNs)

PharmaEssentia out-licensed the exclusive rights to develop and commercialize ropeginterferon alfa-2b to AOP Orphan Pharmaceuticals AG (AOP Orphan) in PV, other MPNs, and CML for European, Commonwealth of Independent States (CIS), and Middle Eastern markets.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2019/1/14 ¤U¤È 05:34:17²Ä 5865 ½g¦^À³
n.yam.com/Article/20190110425597

ÃĵØÂåÃÄ»PAOP Orphan¦b¼Ú·ùªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯gªºBesremi(TM)ÀòCHMP¿n·¥·N¨£

¬ü³qªÀ¡þinfo@prnasia.com 2019.01.10 08:23

°¨ÂĽѶë¦{¨Uº¸·æ©i2019¦~1¤ë10¤é¹q /¬ü³qªÀ/ -- ¤@®a­P¤O©ó¶}µo©M±À¼s¨u¨£¯e¯fªvÀø·sÀøªkªº¥þ²y¥Íª«¨îÃĤ½¥qÃĵØÂåÃĪѥ÷¦³­­¤½¥q¡]PharmaEssentia¡^«Å¥¬¡A¤H¥ÎÂåÃIJ£«~©e­û·|¡]CHMP¡^ªö¯Ç¤F¤@¶µ¿n·¥·N¨£¡A«Øij§å­ã¥Î©óªvÀøµL¯gª¬µÊ¸~¤j¯u©Ê¬õ²Ó­M¼W¦h¯gªºÃĥ⣫~Besremiªº¥«³õ±ÂÅv¡CBesremiªº¥Ó½Ð¤½¥q¬OAOP Orphan Pharmaceuticals AG ¡]²ºÙAOP Orphan¡^¡C

ÃĵØÂåÃÄ­º®u°õ¦æ©xªL°êÁé¡]Kochung Lin¡^³Õ¤hªí¥Ü¡G¡u³o¬OÃĵØÂåÃÄ¥H¤Î§Ú­Ì­P¤O©ó¶}µo©M±NropeginterferonÀ³¥Î©óPV±wªÌ©Ò§@§V¤O¦V«eÁÚ¥Xªº¤@¤j¨B¡C°£¤F¿n·¥ªºCHMP·N¨£¥~¡A§Ú­ÌÁÙ¦b»PFDA¶i¦æ°Q½×¡A±´°Q¦p¦óÅý¬ü°êªº±wªÌ¯à°÷¨Ï¥Îropeginterferon alfa-2bªº³Ì¨Î³~®|¡C¦P®É¡A§Ú­Ì¤]¦b»P¤¤¤é¨â°ê¦³Ãö³¡ªù°Q½×¦p¦ó¨Ï³o¨Ç°ê®aªºPV±wªÌ¤]¯à¨Ï¥ÎRopeg¡C¡v

Besremi¥i§@¬°ª`®g¥Î·»²G¡]250·L§J/0.5²@¤É©M500·L§J/0.5²@¤É¡^¡CBesremiªº¬¡©Êª«½è¬O¦b¥xÆW¥x¤¤¬ì¾Ç¶é®Ú¾ÚPIC/S cGMP³W­S¨î³yªºropeginterferon alfa-2b¡C³o­Ó¬ì¾Ç¶é©ó2018¦~1¤ë³q¹L¼Ú¬wÃÄ«~ºÞ²z§½¡]EMA¡^¶i¦æªºGMP»{ÃÒ¡C

Besremiªº¦n³B¬O¥¦¯à°÷¦b¯u©Ê¬õ²Ó­M¼W¦h¯g±wªÌ¤¤Àò±o§¹¥þ¦å²G¾Ç¤ÏÀ³¡C³Ì±`¨£ªº°Æ§@¥Î¬O¥Õ²Ó­M´î¤Ö¡B¦å¤pªO´î¤Ö¡BÃö¸`µh¡B¯h³Ò¡B¬y·P¼Ë¯e¯f©M¦Ù¦×µh¡C

Ãö©ó¨Ï¥ÎBesremiªº¸Ô²Ó«Øij±N¦b²£«~¯S©Ê·§­n¡]SmPC¡^¤¤¥[¥H»¡©ú¡A¸ÓºK­n±N¦b¼Ú¬w¤½¦@µû¦ô³ø§i¡]EPAR¡^¤¤¤½¥¬¡A¨Ã¦b¼Ú¬wÁp·ù©e­û·|¡]EC¡^§å­ã¾P°â³\¥i«á¥H¼Ú¬wÁp·ù©Ò¦³¥¿¦¡»y¨¥´£¨Ñ¡C¦pªG±o¨ì¼Ú·ù©e­û·|ªº§å­ã¡ABesremiªºÀç¾P±ÂÅv±N³Q±Â¤©©Ò¦³¼Ú¬wÁp·ù¡]¼Ú·ù¡^¦¨­û°ê¡B®¿«Â¡B¦B®q©M¦C¤ä´°¤hµn¡C

¿n·¥ªºCHMP·N¨£«Ø¥ß¦b¥ÑAOP OrphanÃÙ§UªºPROUD-PV/CONTINUATION-PVÁ{§É¶}µo¶µ¥Øªººî¦X¼Æ¾Ú°ò¦¤§¤W¡CÃĵØÂåÃĤw¸g±N¥Î©óªvÀøPV¡B°©Åè¼W´Þ©Ê¸~½F¡]MPN¡^©MCMLªºRopeginterferon alfa-2b©ó¼Ú¬w¡B¿W¥ß°ê®aÁp¦XÅé¡]CIS¡^¤Î¤¤ªF¥«³õªºÅv§Q¿W®a±ÂÅvµ¹AOP Orphan¡C

Ropeginterferon alfa-2b²¤¶

Ropeginterferon alfa-2b¬O¤@ºØ·s«¬ªø®Ä«¬¡]>98%¡^³æ­×¹¢²ã®ò»Ä¤zÂZ¯À¡]ATC L03AB15¡^¡A¨ã¦³§ïµ½ªºÃÄ¥N°Ê¤O¾Ç¯S©º¨Ã´£¨Ñ«e©Ò¥¼¦³ªº¾¯¶q©M­@ÃÄ©Ê¡C¨C2©P ª`®g¤@¦¸©ÎªÌªø´Áºû­×´Á¶¡¨C4©P¤@¦¸¡A¹w­p³o±N¬O¥@¬É¤W²Ä¤@­Ó§å­ã¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯gªº¤zÂZ¯À¡C

Ropeginterferon alfa-2b¥ÑÃĵØÂåÃĦb¥x¤¤ªº¤@®a¤u¼tµo²{©M¥Í²£¡A¸Ó¤u¼t©ó2018¦~1¤ë³q¹L¼Ú¬wÃÄ«~ºÞ²z§½¶i¦æªºGMP»{ÃÒ¡C

Ropeginterferon alfa-2b¦b¼Ú·ù¡B·ç¤h©M¬ü°ê¾Ö¦³©t¨àÃĸê®æ»{©w¡A¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¡C

¯u©Ê¬õ¦å²y¼W¥Í¯g²¤¶

¯u©Ê¬õ²Ó­M¼W¥Í¯g¬O°©Å褤³y¦å²Ó­Mªº¤@ºØÀù¯g¡A¥D­n¬O¬õ¦å²y²Ó­M¡B¥Õ¦å²y²Ó­M©M¦å¤pªOªººC©Ê¼W¥[¡C³oºØ±¡ªp¥i¯à¤Þµo´`Àô¨t²Î¯e¯f¡A¦p¦å®ê¯g©M®ê¶ë¡A¬Æ¦Ü´c©ÊÂà¤Æ¬°°©ÅèÅÖºû¤Æ©Î¥Õ¦å¯f¡CÁöµM¯u©Ê¬õ²Ó­M¼W¥Í¯g­I«áªº¤À¤l¾÷¨î¤´¦³«Ý²`¤J¬ã¨s¡A¦ý¥Ø«eªº¬ã¨sµ²ªG«ü¥X¤F¤@¨t¦CÀò±o©Ê¬ðÅÜ¡A¨ä¤¤³Ì­«­nªº¬OJAK 2ªº¬ðÅܧΦ¡¡C

---------------------------------------------------------------------------------------------------

ÃĵØÂåÃĤw¸g±N¥Î©óªvÀøPV¡B°©Åè¼W´Þ©Ê¸~½F¡]MPN¡^©MCMLªºRopeginterferon alfa-2b©ó¼Ú¬w¡B¿W¥ß°ê®aÁp¦XÅé¡]CIS¡^¤Î¤¤ªF¥«³õªºÅv§Q¿W®a±ÂÅvµ¹AOP Orphan¡C

³o¤@¬q¨S¦³´£¨ìET¡A½Ð°Ý¦U¦ì¤j¤j­n«ç»ò¸ÑŪ?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2019/1/14 ¤U¤È 01:39:20²Ä 5864 ½g¦^À³
©Î³\¤w¦³¤j¤j¦bÃöª`³o­ÓMPN Voice.

¤pªº¬Ý¤F¤j¥b¦~.³Ìªñ¤~ª¾¹D­ì¨ÓUK¬O­^°ê....

Ãø©ÇAOP¤£«æµÛ¶}©l¼Ú¬wET¸ÕÅç..

¤@¥¹P1101¦b¼Ú¬w¶}©l¨Ï¥Î.Âå¥Í¤@©w·|¥Î¨ÓªvÀøET...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2019/1/10 ¤U¤È 04:29:13²Ä 5863 ½g¦^À³
¥»¤ë¬ã¨s¦¬¤Jª÷ÃB¸û¥h¦~¦P´Á¼W¥[
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2019/1/10 ¤U¤È 04:23:41²Ä 5862 ½g¦^À³
§ó¥¿AOP
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2019/1/10 ¤U¤È 04:17:31²Ä 5861 ½g¦^À³
p1101«Ü¥i¯à¤w¸g¶}©l¥X³f

¦]¬°½æµ¹apo´N¶}©l¦C»{À禬

12¤ëÀ禬2316¸U

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2019/1/10 ¤U¤È 12:21:24²Ä 5860 ½g¦^À³
Darren ¤j¤]³\Á¿¨ì¤@¨Ç­«ÂI

´N¬OªvÀøªº¯f¬O§_¬°¤£ªvÀø·|¦º¥B¤j®a¼ô±xªº

¦ý§Úı±o³o¥u¬O°w¹ï¤@¯ë§ë¸ê¤H(©M°ê¤ºªk¤H)

©M¤£°÷¥Î¤ßªº´CÅé

¦pªG¬O¥~¸êªk¤Hªº±M·~¾÷ºc

À³¸Ó¤£·|¥Ç³o­Ó¿ù

©Ò¥H¦U¦ì¥h¬Ý¥h¦~¶R³Ì¦hªº´N¬O¥~¸ê

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2019/1/10 ¤W¤È 01:34:07²Ä 5859 ½g¦^À³
¥H¤U¤Û·Q..

¤pªº»{¬°¶V¦­¥´¶}B.C¨xªº¾AÀ³¯g.¯à¶V¦­ÅýPegasys°±²£.(¶V¤jªº¤½¥q.¶V¤£¯à¾iÂû¦ØÃÄ).PVªº³¡¤À´N¶V®e©ö±À..

¤­¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G¨Ì²{¦³ªººC©ÊC«¬¨xª¢¯f¬rªºªvÀø¤è¦¡¡A¹Á¸Õ§ä¥X

¾A¦X¥»ÃÄ«~ªº¯f¤H±Ú¸s¡C

©Î³\¥D¥´¥«³õ¥i¥H©ñ¦b..HBV©MHCVÂù­«·P¬V.

....Sovaldi¦b国际¤W«U称¡§¦N¤@¥N¡¨¡BHarvoni¦b国际¤W«U称¡§¦N¤G¥N¡¨¡BEpclusa¦b国际¤W«U称¡§¦N¤T¥N¡¨¡C­È±oª`·Nªº¬O¡A3Ïúªº¬ü国药ª«标签¤¤ªþ带¦³¤@个¶Â®Øĵ§i¡A´£¥Ü该药¦b¤þ¨x/¤A¨x¡]HCV/HBV¡^¦@·P¬Vªº±wªÌ¤¤¡A¥i¯à¦³导­P¤A¨x¯f¬r¡]HBV¡^¦A«×¿E¬¡ªº风险¡C¡]¥Íª«¨¦Bioon.com¡^

­z评|ª½±µ§Ü¯f¬r药ª«时¥NHBV/HCV­«叠·P¬Vªºªv疗

news.medlive.cn/liver/info-progress/show-129236_35.html

...HBV/HCV­«叠·P¬V²v为0.7%¡ã16%...

³o¥«³õºâ°_¨Ó..¥xÆW¼Æ¸U..¤¤°ê¼Æ¤d¸U..

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2019/1/9 ¤U¤È 01:29:40²Ä 5858 ½g¦^À³
¥ý¤£»¡®ø®§­± ¦nÃa ¥ú¬O¨C¤Ñ¶q¯à ´N©ú©ú¥Õ¥Õªº«ü¥X ¤º¸ê´²¤á ®Ú¥»¤£·R

¥~¸ê°¸º¸¨Ó´ê¼ö¾x ¤]¥u¯à±a°Ê¤@¤U¤l

¤¤¸Î¨C¤Ñ¤£ºÞº¦¶^³£¦³¤W¤d±i¶q¯à ¦Ó¸ò¥L¥u®t¤T»õ¦hªÑ¥»ªº ÃÄµØ «o¥u¦³¦Ê±i¥XÀY¶q....

§ÚÁöµM¬Ý¦nÃÄµØ ¦ý³o¶q¯à ¥Ø«e¨Ó»¡¤£¤Ó¦æ...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2019/1/9 ¤W¤È 09:37:35²Ä 5857 ½g¦^À³
¬°¦ó¥h¦~¥|¤ëªº¨Æ¡A²{¦b¤~¤½§i¡H

·d¤£À´⋯⋯

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2019/1/9 ¤W¤È 09:33:28²Ä 5856 ½g¦^À³
1.¨Æ¹êµo¥Í¤é:107/04/25

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q·sÃÄP1101¥Î©óªvÀøC«¬¨xª¢¯f¬r°ò¦]Åé²Ä¤@«¬¤§²Ä¤G´ÁÁ{§É¸ÕÅç³ø§i

§¹¦¨¨ÃÀò±o¥xÆW½Ã¥ÍºÖ§Q³¡®Ö­ãµ²®×¡C

¥»¤½¥q¯÷´N¸Ó¤º®eºK­n»¡©ú¦p¤U¡G

¤@¡BÁ{§É¸ÕÅç³]­p¤¶²Ð

(¤@)¸ÕÅç­pµe¦WºÙ¡Gµû¦ô P1101¨Ö¥Î Ribavirin¹ï©ó¥¼±µ¨üªvÀø¤§·P¬V C«¬

¨xª¢¯f¬r°ò¦]²Ä 1«¬±wªÌªº§Ü¯f¬r¬¡©Ê¡B¦w¥þ©Ê»PÃĪ«°Ê¤O¾Ç¤§¶}©ñ©Ê

¡BÀH¾÷¤À°t¡B¦³®ÄÃĹï·ÓªºÁ{§É¸ÕÅç

(¤G)¸ÕÅç¥Øªº¡G¥»¸ÕÅç¥D­n¥Øªº¬°§ä¥XP1101·f°tribavirin¦bªvÀøºC©ÊC«¬

¨xª¢²Ä¤@«¬·P¬V¯f±w¤§³Ì¨Î¾¯¶q¡C

(¤T)¸ÕÅ綥¬q¡G II

(¥|)ÃÄ«~¦WºÙ¡GRopeginterferon alfa-2b (P1101)

(¤­)«Å¶Ç¾AÀ³¯g¡G ºC©ÊC«¬¨xª¢°ò¦]²Ä 1«¬

(¤»)µû¦ô«ü¼Ð:

1.¥D­nÀø®Ä«ü¼Ð(Primary Endpoint)¡G°lÂÜ´Á²Ä24¶g«ùÄò¯f¬r¤ÏÀ³ (SVR24)

2.¦¸­nµû¦ô«ü¼Ð¡G§Ö³t¯f¬r¤ÏÀ³¡A°lÂÜ´Á²Ä12¶g«ùÄò¯f¬r¤ÏÀ³¡A¤£¨}¤ÏÀ³µ¥

(¤C)¸ÕÅç­pµe¨ü¸ÕªÌ¤H¼Æ¡G106¤H

¤G¡B¥D­n¤Î¦¸­nÀø®Ä«ü¼Ð¤§²Î­pµ²ªG¤Î²Î­p·N¸q

²Ä¤G´ÁÁ{§É¸ÕÅç¥D­n«ü¼Ð¬°Àø®Ä³Ì¨Î¥B°Æ§@¥Î§Cªº³Ì¨Î¸ÕÅçÃÄ«~¤§¾¯¶q¡C¥»¸ÕÅç

ÃÄ«~P1101 ¦b¨Ö¥Î ribavirin¤§¤U¡A¨C¶g¬I¥´¤@¦¸ P1101 180, 270 ·L§J©Î¨C¨â

¶g¬I¥´¤@¦¸P1101 450 ·L§J¬Û¸û©ó¨C¶g¬I¥´¤@¦¸ ¹ï·ÓÃÄ«~PEGASYS 180 ·L§J¡A

¨äÀø®Ä»P¦w¥þ©Ê¬Û¦ü¡C¤j³¡¤Àªº°Æ§@¥Î¬°»´«×¡A¨Ã¥B¯f¤H¹ïP1101¬I¥´¨ì450·L§J

ªº­@¨ü©Ê¤´µM¨}¦n¡C

¤T¡B³æ¤@Á{§É¸ÕÅçµ²ªG(¥]§t¥D¡B¦¸­nµû¦ô«ü¼Ð¤§²Î­p¾Ç¤W¬O§_¹FÅãµÛ·N¸q)¡A¨Ã¤£

¨¬¥H¥R¤À¤Ï¬M¥¼¨Ó·sÃĶ}µo¤W¥«¤§¦¨±Ñ¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

6.¦]À³±¹¬I:µL¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

¤@¡B¬ãµo·sÃĦWºÙ©Î¥N¸¹¡GP1101

¤G¡B¥Î³~¡GHCV GT1

¤T¡B¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¥Ø«e¥¿¦b¶i¦æºC©ÊC«¬¨xª¢¯f¬r°ò¦]«¬²Ä¤G«¬ªº¤T´Á

Á{§É¸ÕÅç¡A±Nµû¦ô¾A¦X©ó¥»²£«~ªº¯f¬r°ò¦]«¬²Ä¤@«¬ªº¯S®í±Ú¸s¡C

¥|¡B¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

(¤@)´£¥X¥Ó½Ð/³q¹L®Ö­ã/¤£³q¹L®Ö­ã¡G¤£¾A¥Î

(¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î

(¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î

(¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G«O»Ù¤½¥q¤Î§ë¸ê¤HÅv¯q¡A¬G¤£¤©¤½¶}´¦ÅSµL

¤­¡B±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G¨Ì²{¦³ªººC©ÊC«¬¨xª¢¯f¬rªºªvÀø¤è¦¡¡A¹Á¸Õ§ä¥X

¾A¦X¥»ÃÄ«~ªº¯f¤H±Ú¸s¡C

¤»¡B¥«³õ²{ªp:

¦b¨xª¢ªvÀø¤è­±¡A¾Ú¥@¬É½Ã¥Í²Õ´¦ô­p¡A¥þ¥@¬ÉB«¬¨xª¢±wªÌ¬ù¦³4»õ¤H¤f¡AC«¬

¨xª¢±wªÌ¬ù¬°1»õ7000¸U¤H¡Cµo®i P1101 ¬°ªvÀø¨xª¢¥ÎÃĪºµ¦²¤¡A·|µÛ­«¦b¤½

¦@½Ã¥ÍÁٻݥ[±jªº°ê®a¡F ¦p¤¤°ê¤Î¨ä¥L·s¿³°ê®a¡C¥þ²y¨xª¢¥ÎÃÄ¥«³õ¶W¹L100»õ

¬üª÷¡C¦ý¬O¦]¤zÂZ¯ÀÃÄ«~ªº¤£¨}°Æ§@¥Î¡A¨Ï¨ä¨Ï¥Î¤§¾¯¶q¨ü­­¡CP1101 ¬°³Ì·s«¬

ªø®Ä¥B°Æ§@¥Î§C¤§¤zÂZ¯ÀÃĪ«¡A¨ä¦bªvÀøºC©Ê¨xª¢ªº¥Î³~©|¦³³\¦hµo®iªº¼ç¤O¡C

¤C¡B·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A ¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI

¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2019/1/8 ¤U¤È 05:27:31²Ä 5855 ½g¦^À³
²³æ¨Ó»¡ ´N¬O¤j®a ·R¥hª£ ¦³¦W®ðªº·sÃÄ ·R´þ¯f¸òÀù¯g

³£¤w¸g¶}½æ¦h¤[ ÁÙ¦bÁ«·l ª÷ÃBÁÙ­Ë°hÂP §Ú¶R¤£¤U¥h ¬Ý¥LªÑ»ùº¦ ´Nª¾¹D¬O¤H¬°ª£§@

¦ÓÃĵØÃÄ ´N¬O¨S¤H®ð ¤j³¡¤Àªº§ë¸ê¤H ­þÀ´ªºªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g ³o¬OÔ£?

§Ú¤]©ú¥Õªº»¡§Ú¤£À´ ¤µ¤Ñºâ¬O¦³¤p§Q¦h Ãĵؤ]¹³¤@Åu¦º¤ô ¦¨¥æ¶q¤Öªº¥i¼¦

§Ú¬Ý¥u¦³¥L¯uªºÁȨì¿ú §Ú¬Ý§ë¸ê«È¤~·|¬Ý¹L¨Ó «s

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°±¤î©I§l10142179  µoªí®É¶¡:2019/1/8 ¤U¤È 05:07:47²Ä 5854 ½g¦^À³
ªÑ²¼­nº¦¡A´N¬O¨S¤Hµo¨¥¤@°}¤l¡A¤j®a³£¶]¤~·|º¦
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2019/1/8 ¤U¤È 02:03:49²Ä 5853 ½g¦^À³
¯E¹©¸òÃĵخt¤£¦h®É¶¡¿ì²z²{¼W

¯E¹©¼È©w»ù²{¼W135¡A²{¦b³£165¤F

¦]¦¹ÃĵتºªÑ»ù¯uªº¬O³Q²{¼WÀ£¤U¨Óªº¶Ü¡H

¦pªG¬Oªº¸Ü«ç¤£¨£¯E¹©³QÀ£¡H

¦³¤¤¸Îªº¨Ò¤l«á¡A·sÃĪѦbÀ禬¤j´T¦¨ªø¤§«e

¤@¤ÁÁÙ¬OÄw½X©w»ù

¦³¨S¦³§ë¸ê¤Hªº·R⋯¯uªº®t«Ü¦h

¤£ª¾¹DÃĵئ³¨S¦³¥h°Ñ¥[¤µ¦~

JP Morgan Healthcare Conference

¦³ªº¸Ü¥i­n¦n¦nÂǦ¹±À¾P¤@¤U¦Û¤v¤~¬O

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gwu701610136601  µoªí®É¶¡:2019/1/8 ¤W¤È 08:41:05²Ä 5852 ½g¦^À³
¤½§i¥»¤½¥qªvÀø¬õ¦å²y¼W¦h¯g¤§·sÃÄ¥D¦¨¥÷Ropeginterferon alfa-2b¤Î·sÃÄ¥D¦¨¥÷¥DÀÉ®×(DMF)¤wÀò½Ã¥ÍºÖ§Q³¡®Ö­ã

1.¨Æ¹êµo¥Í¤é:108/01/07

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥qªvÀø¬õ¦å²y¼W¦h¯g¤§·sÃÄ¥D¦¨¥÷Ropeginterferon alfa-2b¤Î

·sÃÄ¥D¦¨¥÷¥DÀÉ®×(DMF)¤wÀò½Ã¥ÍºÖ§Q³¡®Ö­ã¡C

6.¦]À³±¹¬I:

¥»¤½¥q¥Ó½ÐªvÀø¬õ¦å²y¼W¦h¯g¤§·sÃÄ¥D¦¨¥÷Ropeginterferon alfa-2b

³\¥iÃÒ¡A©ó¤µ¤é±µÀò½Ã¥ÍºÖ§Q³¡¨Ó¨ç³qª¾¤w¥i¨úÃÒ¡A³\¥iÃÒ¦r¸¹:

¡u½Ã³¡µß¬Ì»s¦r²Ä000142¸¹¡v¡A¤¤¡B­^¤å«~¦W: ¡u»E¤A¤G¾J²ãÓi»Ä

¤zÂZ¯Àalfa-2b(ROPEGINTERFERON ALFA-2B 2MG/ML)¡v¡A¾AÀ³¯g:

¡u¬õ¦å²y¼W¦h¯g¡v¡A¨Ã©ó¤µ¤é¦P®É¨ú±o½Ã¥ÍºÖ§Q³¡¨Ó¨ç¦P·N·sÃÄ

¥D¦¨¥÷¥DÀÉ®×(DMF)¨ú±o®Ö­ã¡A½s¸¹:DMF(00)2921¡C

¥»¤½¥q¨ú±o½Ã¥ÍºÖ§Q³¡¤W­z³\¥iÃÒ¡A¥Nªí¥»¤½¥q¥i©ó¥xÆW»s³y¤Î³c°â

¾AÀ³¯g¬°¬õ¦å²y¼W¦h¯g¤§¡u»E¤A¤G¾J²ãÓi»Ä¤zÂZ¯Àalfa-2b

(ROPEGINTERFERON ALFA-2B 2MG/ML)¡v·sÃÄ¥D¦¨¤À¡A¥Ñ©ó·sÃÄ¥D¦¨¥÷

¥DÀɮס]DMF)¬O¤@®MÃÄ«~¥Í²£©M«~½èºÞ¨îªº¤å¥ó¡A¥Ñ¥Í²£¼t´£¨ÑÃÄ«~

¥Í²£¹Lµ{¥]¬A¥Í²£¡B¥[¤u¡B¥]¸Ë¡BÀx¦sªº¸ê®Æ¥H½T«OÃÄ«~¥Í²£¹Lµ{¬O

²Å¦XcGMPªº­n¨D¡A¤µ²Å¦Xªk³W³W½d¨ú±o½Ã¥ÍºÖ§Q³¡¦P·N®Ö­ã·sÃÄ¥D¦¨

¥÷¥DÀÉ®×(DMF)¡A¦¹¬°¥»¤½¥q¥¼¨Ó¥Ó½Ð¾AÀ³¯g¬°¬õ¦å²y¼W¦h¯g¤§

Ropeginterferon alfa-2b (P1101¡^°w¾¯ÃÄ«~¨ú±o·sÃĤW¥«³\¥i¥²­n

±ø¥ó¡C

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A ¦¹µ¥¥i¯à¨Ï

§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gj310142799  µoªí®É¶¡:2019/1/4 ¤W¤È 09:22:17²Ä 5851 ½g¦^À³
TO¡GµLµß®ñ¤j ²Ä5819 ½g

1.µo¯f²v¬Oªí¥Ü¯S©w¤H¸s¦b¤@©w®É¶¡¤º(¤@¯ë¬°1¦~¡^,¬Y¤H¸s¤¤µo¥Í¬Y¯f[·s¯f¨Ò]ªºÀW²v¡C

2.©Ò¥H»¡µo¯f²v¥u¼Æ¨C¦~·s¼W¥[ªº¯f¨Ò¡A¦]¦¹PV©ÎPE¼Ú¬ü¤§¯f±wÁ`¤H¼ÆÁÙ¬OÀ³¥H¤½¥q»¡ªk¬°·Ç¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gmtalps200110147181  µoªí®É¶¡:2019/1/3 ¤U¤È 08:38:20²Ä 5850 ½g¦^À³
¤µ¤Ñª¬ªp¤£¿ù¡I¶qÁöµM¤Ö¤F¨Ç¡A¦ý¬O¦³¤îíªº·Pı¡]­Ó¤H¥DÆ[ªº·Pı¡^.

§Æ±æ¯à¶}©lºCºC¦a¦^¨ì¥h¦~11¤ë«á174¡ã180ªº½L¾ã½d³ò.

¤]´Á«Ý2¤ë©³®É¯à¤£¨ü¤j½L¦]¯À¼vÅT¡A·|¦³¤@ªi¡A©Ô°ª´«¤â¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2019/1/3 ¤U¤È 06:23:59²Ä 5849 ½g¦^À³
¤µ¤Ñ´X­Ó¥~¸ê ³£¦³µÛ¾¥¶R¤F¤@¨Ç ¦Ó¤µ¤Ñ§ë«H¯¸¦b½æ¤è ¤£µMªÑ»ù¦]¸Ó¤£·|¦p¦¹Ãø°Ê

¤£¹L¥~¸ê¶}©l¦³°Ê§@ ¬O¦nªº¶}©l

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2019/1/3 ¤U¤È 05:21:07²Ä 5848 ½g¦^À³
lee-sen¤j»¡ªº¤]¬O¨Æ¹ê

¤£ºÞ¬Oªk¤H©Î¬O§ë¾÷©Î¬O½ä«È

³£³ßÅwªi°Ê¤jªº

ªi°Ê¤Ó¤p´NÃþ¦ü¨¾¿m«¬ªºªÑ²¼

¦ý¤S¤£¬O¯uªºÃþ¦ü¹q«HÃþªÑ©Î¬O¥Á¥ÍÃþªÑ¨º»òí

¥xªÑ«Ü¦h¥»¯q¤ñ§C©ó10­¿,¨C¦~°t®§´Þ§Q²v¤]¤ñ©w¦s°ª«Ü¦hªºªÑ²¼

¦ý´N¬OªÑ»ù«Üí

³o¨ÇªÑ²¼ªº¦@¦P¯S½è´N¬O¦¨¥æ¶q§C,ªÑ¥»¤p,¥«­È¤p

¯uªº§Æ±æÃĵؤ£­n¨«³o¼Ëªº¸ô

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GUPGO99910144849  µoªí®É¶¡:2019/1/3 ¤U¤È 03:09:54²Ä 5847 ½g¦^À³
¬Y¤j¤j ¤µ¤Ñ³QªÑ»ù¥´Áy
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Glee-sen10145657  µoªí®É¶¡:2019/1/3 ¤U¤È 01:14:50²Ä 5846 ½g¦^À³
¬Ý¤FÃĵØÃÄ¡A¤S¬Ý¨ì¤¤¸Î¡B¯E¹©¡K¡K¤ß¤¤Á`¬O´e°Ú¡I

·Q½Ð±Ð¦U¦ì¡G¬O³ßÅw¦³°ª¦³§Cªº¤¤¸Î¡B¯E¹©?

ÁÙ¬OªÑ»ù¬Û¹ï¥­²HµL¨ýªºÃĵØÃÄ?

¤ß¤¤´e¡A¥u·QÁ¿Á¿¸Ü²á²á¤Ñ¦Ó¤w¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2019/1/3 ¤W¤È 10:50:40²Ä 5845 ½g¦^À³
¯E¹©ÀÀ¿ì²{¼W ¥ýº¦´X­w¼y¯¬¤@¤U Ãĵؿì²{¼W....
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2019/1/2 ¤U¤È 05:38:11²Ä 5844 ½g¦^À³
¤µ¤Ñ¥É¤s°ª¶¯½æ¥ú¤F

12/12 ¶}¶R, ³o¨â¤Ñ²M¥ú

¶R¶i§¡»ù189.93

½æ¥X§¡»ù171.79

140±i¥ª¥k

§Ú·Q³o¨Ç½ä½L

¯uªº­n¥þ²M¥ú¤F¤~·|¤îí

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2019/1/2 ¤U¤È 03:08:17²Ä 5843 ½g¦^À³
¥~¸ê¤µ¤Ñ§C±µ¤F50±i¥u½æ1±i

²n²n¾ß«K©y

¤Ï¦Ó¬O´²¤á³£³Q°ê¤º¤j¤á¬~¨ì¨S«H¤ß¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2019/1/2 ¤U¤È 02:19:31²Ä 5842 ½g¦^À³
¤½¥q¦³¤@­Ó¦¨¥\ªº¬ãµo¥­¥x..±µ¤U¨Ó­n°µªº.¥i¥H°µªº..

­É¥Î¤j³°ªº¸ê®Æ..

¡i长®Ä¤Æ³J¥Õ²`«×报§i¡jBiobetter药ª«¥¿当时¡A长®Ä¤Æ³J¥Õ蓝®ü«Ý±¸ª÷

www.sohu.com/a/221935033_354900

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2019/1/2 ¤U¤È 02:03:05²Ä 5841 ½g¦^À³
­èºÃ´bªº¦A¥Î­pºâ¾÷«ö¤F¤@¤U

25000±i*160¤¸=40»õ!¨S¿ù§a@@

³o»ò¿N¿ú?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2019/1/2 ¤U¤È 01:53:05²Ä 5840 ½g¦^À³
¦V¿ú¨«¤j

´£¨ìªºÀ£§CªÑ»ùµ¥¨ì¥«³õ©ñ±ó«á¦A¬¢¯S©w¤H

¦pªGÃĵجO³o¼Ëª±§ËªÑªFªº¤½¥q

¨º§Úı±o¯uªº¦³°ÝÃD

²¦³º¦pªG­n¬¢¯S©w¤H

¥i¥H±Ä³æ¤@¨p¶Ò

©Î¬O®ü¥~GDR

¦Ó¤£»Ý­n·d³o¨Ç¤p°Ê§@

¥Ø«e¤â¤W¦³²{ªÑ¤j·§11±i¥i¥H»{¨ì¤@±i

¥B·|¶Rªº¤H³£¶R¤F

²{¦b·Q¥[½X³£·|¿ï¾Ü160ªº»ù®æ¦Ó¤£¬O²{¦b³o­Ó»ù®æ

²{¦b·|¶RªÑ²¼ªº¥u¬O½ä¤½¥q·|¦]¬°­n²{¼W¦Ó©Ô©ïªÑ»ùªºµu½u«È¦Ó¤w

11¤ëªì³Ð¿ì¤H/¸³¨Æªø/Á`¸g²z ½è©ãªÑ²¼ªº±i¼Æ´«ºâ¤U¨Óªºª÷ÃB

®t¤£¦h©M¥¦­Ì¥Ø«e¤â¤W«ùªÑ¯à°÷»{Áʪº±i¼Æª÷ÃB®t¤£¦h

¤j®a¥i¥H«ä¦Ò¬Ý¬Ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2019/1/2 ¤U¤È 01:40:27²Ä 5839 ½g¦^À³
ªþ©M¦w¼w´Ë¤j~

¥»¦¸²{¼W25000±i,¨ä¤¤10% ªº2500±i­û¤u»{ÁÊ,10% ªº2500±i¹ï¥~¤½¶}©Ó¾P,80% ªº20000±i­ìªÑªF»{ÁÊ.....

»¡©ú10.

·î¹sªÑ¤Î¹O´Á¥¼»{Áʪѥ÷¤§³B²z¤è¦¡:­ìªÑªF»{Áʤ£¨¬¤@ªÑ¤§·î¹sªÑ¡A¥ÑªÑªF¦Û°±¤î¹L¤á°_¤­¤é¤º¦Ü¥»¤½¥qªÑ°È¥N²z¾÷ºc¿ì²z«÷´ê¤@¾ãªÑ»{ÁÊ¡C­ìªÑªF¡B­û¤u©ñ±ó»{ªÑ¤§ªÑ¥÷©Î«÷´ê¤£¨¬¤@ªÑ¤§·î¹sªÑ³¡¥÷¡A±ÂÅv¸³¨Æªø¬¢¯S

©w¤H«öµo¦æ»ù®æ»{Áʤ§¡C

©Ò¥H¤]¦³¥t¤@ºØ¤â¬q¬O¥«³õ»ù®æÅý²Å¦X²Ä¤@¶¥¬q¸ê®æªÌ±óÅv«á,¦A¥Ñ°ª¼h¬¢ ¯S©w¤H ³B²z.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2019/1/2 ¤U¤È 01:22:17²Ä 5838 ½g¦^À³
´²¤á¤£´±.ªk¤H¤£«æ..¤j¤áµ¥§C±µ.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2019/1/2 ¤U¤È 01:17:00²Ä 5837 ½g¦^À³
¬JµM¤j®a­n²z©Ê´N²z©Ê§a.

¤pªº­×¥¿»¡ªk¤£¬O°¾¨£¬O¡¦²z©ÊªºÃöª`

¥u¬O³o²z©ÊªºÃöª`°w¹ïÃĵØ....

¦b¨º¦h¥Í§ÞªÑ§Q¦hº¦°±®É..¤j®a³£¬O«Ü²z©Êªº.

¤U­Ó¤ë´N¦³EMA³\¥iÃÄÃÒ...ªÑ»ù...«¢«¢«¢..

´¿¸g¬Ý¹L¤@½g¤½¥q½Í¨ì..¤À¼í+ÃÄ«~¬ù¥i¤À3¦¨(­è­n§ä³sµ²¦ý§ä¤£¨ì.´N·í¹Ú¨ìªº.¤Å«H)..

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2019/1/2 ¤U¤È 12:56:32²Ä 5836 ½g¦^À³
¬Ý¨Óª½±µ¶^¯}²{¼W»ù¤]¤£¬O¤£¥i¯àªº¥ô°È¡A§âªÑªF·í¥Õ·ö­A¡AÃø©Çº¦¤£¤W¥h¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°±¤î©I§l10142179  µoªí®É¶¡:2019/1/2 ¤W¤È 11:38:41²Ä 5835 ½g¦^À³
·Q¤F¸Ñ¤@¤U

ÃĵØÃĦۤvªº³J¥Õ½è¤u¼t

½æµ¹¶ø¦a§QAOP..ÁÙ­n¤À¼í¶Ü?

²£«~¥Í²£§Q¼í·|¤ñ·sÃıÂÅv¤À¼í16%¦h¶Ü?

¬O²£«~+¤À¼í=¤~¬OÃĵØÁȪº¶Ü??ÁÙ¬O¤w¸g¦X¦b¤@°_16%

½æ150¸U..²£«~»s³y¦¨¥»20¸U(ÃĵØÁȪº).

³Ñ130¸U..AOP(84%) ÃĵØ(16%)

¤£À´...¨ä¥¦®a³£¤£¬O¦Û¦æ¥Í²£..¥u¦³Ãĵئۦæ¥Í²£..

·sÃįuªº«ÜÃøÀ´~~~¨S¦³ªø®É¶¡¬ã¨s...¯uªº«ÜÃøÀ´

¬Û«H§ë¸êªÌ¯u¥¿À´ªº100­Ó¤H¥u¦³¤£¨ì5%À´§a!..

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2019/1/2 ¤W¤È 10:56:52²Ä 5834 ½g¦^À³
­Ó¤H«Ü·q­«ª©¤Wªº¦U¦ì«e½ú~

¦ý¬OµL¤j¤j,±z¦³°ª²`½×­z¦ý¬Oµ²½×¨ì©³¬O¤°»ò?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2019/1/2 ¤W¤È 10:39:46²Ä 5833 ½g¦^À³
¼ÒÀÀ¥X¡uÁÙ­nÁ«¨â¦~¡v³y¦¨¤µ¤Ñªº§½­±?§Ú¬O©¹¦Û¤vÁy¤W¶Kª÷¡C

¤£¹L³o¸Ì­±¥i¯à¦³ª¼ÂI,ª¼ÂI¤]³\´N¬O«´¾÷¡C

¨º¨Ç¤j°Ê§@¦Û§@Áo©úªº¤H¬OµLºÖ®ø¨üªº!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2019/1/2 ¤W¤È 09:59:47²Ä 5832 ½g¦^À³
¥D­nÁÙ¬O¦]¬°ªk¤H¨S¦³¶i¨Ó

¦³°µ¥\½Òªº·íªì¦bCHMP¶}·|«e

³£¥[½Xªº®t¤£¦h¤F

¤j®a³£·Q¥ý¶i³õµ¥¤H©ï»ù

¥i¬Oªk¤H°¾°¾¹ï6446¿³½ì¯Ê¯Ê

¨ä¥L§ë¸ê¤H¤@µo²{¨SÃÄÃҦ污´N³°Äò°±·l±þ¥X

©Ò¥H²{¦b­«ÂI´N¦b©óªk¤H·Q¶i³õªº®É¶¡ÂI

¬O¦bEMAÃÄÃÒ¨ú±o«á¡H FDA°e¥óBLA«á¡H

ÁÙ¬O²{¼W§¹Äw½Xí©w«á¡H©Î¬O®Ú¥»¤£¶i³õ¡H

¨S¤Hª¾¹D

¦Ó¥~¸êªº¬ã¨s³ø§i¤]¬Ý¬Ý´N¦n

¥h¦~³Í°òªº³ø§i¥Ø¼Ð»ù250

¦³¬Ý¨ì³Í°ò¨g¶R¶Ü¡H¤]¨S¦³

¥Ø«e¤ñ¸ûÅý¤H¯à°÷´Á«Ýªº¤j·§¬O

ªk¤H³£ÁÙ¨S¦³°Ê§@¦Ó¤£¬O¶}©l­Ë³f

±À´ú¬O¦bµ¥¬Y­Ó®É¶¡ÂI¶i³õ¡H

¾a¤j®a¦Û¤v¸ÑŪ¤F¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2019/1/2 ¤W¤È 09:45:47²Ä 5831 ½g¦^À³
³o¼Ëªº¨«¶Õ¨Ã¤£·N¥~,«Ü²³æ,¹w­pÁÙ­nÁ«¨â¦~,³\¦h§ë¸ê¤H¦Û»{Áo©ú,¥ýºM¨«¸êª÷¥hª±§Oªº¡C¥L­Ì»{¬°¨â¦~«á¦A¶i¨Ó¤£¿ð¡C

§Ú°O±o¤j¥ß¥ú¦b´X¦Ê¤¸ªº®É­Ô,§Ú¤]¤@ª½¦bª`·N,¥i¬Oªk¤H¤¶¤J¬O¤S«æ¤S¥û,¤@¤U¤l¨S´X¤Ñ´N©Ô¤W¤d¤¸¤F,§Ú¬O±¹¤â¤£¤Î¡C

ªk¤H¤°»ò®É­Ô·|°Ê?§Ú»{¬°¬O¦b½T»{·sÃÄ¡u±N¨Ó·|¤j½æ¡vªº®É­Ô¡C¦b·sÃĶ}½æ¤§«áÆ[¹î¨ìÂå®v¶}ÃĪº«´¾÷,³o«´¾÷¦³¥i¯à¬O¶}½æ«á¤@­Ó¤ë,¤]¦³¥i¯à¬O¦b¶}½æ¨â¦~«á,¦pªG©¡®É§PÂ_±N¤j½æ´NºÆ¨g¶R¶i,¦ýµL½×¦p¦ó³£¤£·|¨Æ¥ý³qª¾,¬Æ¦Ü¦³¥i¯à¥ý§Ë¥X­Ó¥­²HªºÃa®ø®§¨Ó¡C

§Úªº¹ïµ¦¬O°ò¥»«ùªÑ©ñµÛ³£¤£°Ê¥¦,¬Ý¨ì·sªº®ø®§´N¥ý©¹¤Ï­±«ä¦Ò,³o¼Ë¦Ó¤w¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2019/1/2 ¤W¤È 09:17:44²Ä 5830 ½g¦^À³
¤@­Ó´X¥G¥i¥HÃÄÃÒ ´X¥G¥i¥H»¡¬O§Ö®³¨ì¤âªº ½æÀ£©~µM¬O¦p¦¹¤§­« »¡¬O¦³¼y¯¬¦æ±¡»ò? ®Ú¥»¤]¨S ¯u¬O²Ö ¤@°ï¥¿­t ¨¥½× ·dªº§ë¸ê¤H

§ó¬O¶Ã

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2019/1/2 ¤W¤È 08:54:17²Ä 5829 ½g¦^À³
Á¿¥y¹ê¸Ü

·Q¶R¸Ó¶Rªº¤@¯ë§ë¸ê¤H³£¤W¨®¤F

¦^ÅU2018³o¤@¦~

±q1/2~12/28 ,¤Wº¦¬ù30¤¸

¤j·§20%¥ª¥k

¨ä¹ê³o¼Ëªºº¦´T¬Û¹ï©ó®³¨ì·ÇÃÄÃÒªº§Q¦h

µ¥©ó¬O«Ü®t,·íµM¦pªG¸ò¾ã­ÓOTC«ü¼Æ¶^ 16% ¨Ó¬Ý

°ß¤@¤ñ¸û¦nªº¸ÑÄÀ´N¬Oªk¤H«ùªÑ¼W¥[¤F9¤d¦h±i

§_«h³o¤@¦~¤j¦h¬O¤pÃB§ë¸ê¤H¦b´«¤â

¤j®a³Ì¦b·Nªº²Ä¤@ª÷°ª¶¯

2018 ¶R¶i4607, ½æ¥X4364 , total balance = +243±i x 175.82

¤£¹L¦^ÅU¤¤¸Î

¨ä¹êÀ禬¤]°_¨Ó¤F

¦ýªÑ»ù³o¼Ë¶^,

³Ì­«­n¤]¬Oªk¤H½æ¶W¤F5¤d±i¥ª¥k

=======================================

¥H¤WÁ¿¤F³o»ò¦h¼o¸Ü

­«ÂI´N¦b©óªk¤H¶R½æ

ªk¤H¶R½æ°£¤F¬ã¨s³ø§i¤§¥~

³Ì­«­nªº´N¬O¹w´Á

©Ò¥H§Ú¤]Àµ¨D³oÃ䪺¦U¦ì¤j¤j

¦pªG¦³ªk¤H¹w´Áªº¼Æ¾Ú©M¬Ýªk

¯à°÷¸ò¤j®a¤À¨É

§_«h¤j¦h¬O¥H°ò¥»­±§@¬°°Q½×

°ò¥»­±¤j®a¤]ª¾¹D¦n´Î´Î

¦ýªÑ»ù³o¼Ë´N¬Oªk¤H¤£¶R³æ

¹ï§a

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gboss10144665  µoªí®É¶¡:2019/1/2 ¤W¤È 08:20:37²Ä 5828 ½g¦^À³
³Â·Ð½Ð°Ý¦U¦ì¤j¤j. Ãĵسo¦¸ªº²{ª÷¼W¸ê,³Ì«á¹L¤á¤é©w¤F¶Ü? ¦]¬°§Ú§ä¤£¨ì. ÁÂÁ¦U¦ì¤j¤j
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2019/1/1 ¤U¤È 11:22:41²Ä 5827 ½g¦^À³
§Ú©Ò¼ÒÀÀªº¼Æ¾Ú¥u¬O¤@­Ó±À´ú,±À´ú¤j¬ù·|¦³³o¼Ëªº¹Lµ{,¤j¬ù·|¦³³o¼Ëªº¼Wªøª¬ªp¦Ó¤w¡C

¥¿¦p­«¼CµL¾W¤j©Ò»¡,¤]³\±À¶iªº®Éµ{¡A¤S¤ñ¬ü°êºC6­Ó¤ëµ¥µ¥¦]¯À¤zÂZ,¤d¸U¤£­n®³³o­Ó¼Æ¾Ú¨ÓÀËÅç·Ç¤£·Ç,¦pªG108¦~11¤ë¤~¶}©l¥X³f©O?³o¼Æ¾Ú°Z¤£ÄY­«¥¢¯u?©ÎªÌ»¡¦pªG108¦~3¤ë´N¶}©l¥X³f©O?¤]¬OÄY­«¥¢¯u?

¥¿­±¤Ï­±?ªÑ»ù¤S¤£¬O¥¿­±¨¥½×´N·|º¦¤Ï­±¨¥½×´N·|¶^¡C¦³¤H¬Ýµu«o¦³¤H¬Ýªø,§ó¦³¤H¬Ý¦hµo²{¿ù¤F§ï¬ÝªÅ,¤]¦³¤H¬ÝªÅµo²{¿ù¤F§ï¬Ý¦h¡C

³Ì­«­nªº¬O¯à²z¥X­Ó¥¼¨ÓÀYºü,¤~¯àª¾¹D¦p¦ó¦]À³,¤~¯à¤£¨üªÑ»ùÅܤƼvÅT¦Ó¯à²H©w¾Þ§@¡C

¥ý²z¥X­ÓÀYºü,¦AÆ[¹î¬O§_·Ç½T,¬O§_¸Ó­×¥¿,³o¼Ë¤~¤£·|¤H¤ª¥ç¤ª,¤~¤£·|¨ü¨ì§O¤H¦ü¬O¦Ó«Dªº¨¥½×¾Þ§Ë¡C

¦Ü©ó¤@¨¥°ó¦üªº¨¥½×,µL½×¦hªÅ¨º¥u¬Oµu½u«äºû¡C

¬Y¤ÀªR®v©Î¬Yºô©Î§Ú­Ì³o­Ó°Q½×°Ï¦hªÅªº¨¥½×,¬O¤£¥Î­t¥ô¦ó³d¥ôªº,¥u¦³¦Û¤v¹ï¦Û¤vªº¿ú­t³d,·Q­n§O¤H¨Ó°t¦X¦Û¤v,ÁÙ¤£¦p¦Û¤v¥h°t¦X§O¤H²³æ¡C

ÃĵØÃħâ¤À¤l³s±µ¤@­Ó¤p¤À¤l(pegylation)¦Ó§ï³y¥X¤@­Ó·s¤À¤l,¨Ã¶i¦æ¯Â¤Æ,³o©Û§Ú¬Oı±o«Ü§®¡C

¦³ÂI¹³¬Û¦ü¾Ç¦WÃÄ,«o¬O·sÃÄ¡C¥¦¤S¥h°µ¨S¦³¤H»{ÃÒ¹Lªº¯e¯f,¦¨¥\´N·|ÅÜ·sÃÄ,³o¤]«Ü¦³½ì¡C

¬õ¦å²y¤Ó¦h,¬õ¦å²y¤Ó¤Ö,¦å¤pªO¤Ó¦h,¥Õ¦å²y¤Ó¤Ö³£¥Î³o­Ó§Þ³N¥h§ï³y¤À¤l¡C

³o¯u¬O¤@­Ó«D±`¦nªº¤½¥q,¬J¥iÀ°§U¤HÃþ,¤S¥iÁȤj¿ú,¤@Á|¨â±o!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¨}¥²«L10147410  µoªí®É¶¡:2019/1/1 ¤U¤È 08:15:50²Ä 5826 ½g¦^À³
To ¤p¶Â¤j¡G

§Ú¬O§Q¦h¬£¡A§Ú¤]¬Oªø´Á«ù¦³ªÌ¡A¥u¬O¦hªÅ¨¥½×°T®§³£·|°Ñ¦Ò

©Ò«üªº¹ï¦¹ªO¤ñ¸û¦n¡A¤£¬O«üªÑ»ù¡A¥u«ü¦hªÅ¤ÀÃþ°Q½×

§ë¸êªÌ¥i°Ñ¦Ò©Ò»Ý­n¡A¤£»Ý­n¦P¤@°Ï¶ô¤£¦P·N¨£ª§°õ¤£¥ð

µu´Á§QªÅ®ø®§¡A¤£¤@©w¹ï§ë¸ê¤H¬OÃaªº¡A

¥u­nªø´Áµo®i¦Ó¨¥¬O¥¿­±ªº¡A§CÂI¶R¶iÀò§Q¤~·|¤j¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¶Â10145930  µoªí®É¶¡:2019/1/1 ¤U¤È 06:40:38²Ä 5825 ½g¦^À³
¨}¥²«L¤jªº´£Ä³¯u¦n.

¹³Ãĵسo»ò¦nªº¤½¥q.«ç»ò¥i¥H³£¬O§Q¦h©O?

·íµM­n§â¥LªºÁô¼~.¥tÅP°Q½×°Ï.µM«á¶°¦U®aÅã·LÃè¨Ó´¦ÅS»P§åµû

©Î³\¹ï¦¹ª©·|¤ñ¸û¦n??????????

¸ò¸Î§Ì.¯E­ô¤@¼Ë¦³¥¿¤ÏÂù¤è°Ï°ì¡K¡K..

µM«á¡K

¯E­ô:2017/2/6 ·sª©¶}¹õ291¡K..«á¨Ó12/8´N¬Ý¨ì135¤F!

¸Î§Ì:2018/7/26·sª©¶}¹õ263.5¡K«Ü§Ö11/15´N¬Ý¨ì139.5¤F!

§Ú¯uªºÀ~ÄݤF~~~~~~~~~~~~XD!!

µS°O12/14¨º±ß8:43¤pªL¤j¤W¶Ç¤F¦n®ø®§.¯u¬O·PÁÂ¥L¡K

¤~¶}¤ß¤£¨ì12¤p®É.´N¦³¦Û³\±M·~»{¯uªÌ´£¥X.°ª¦ôEPS¤F.°ª¦ô±wªÌ¤H¼Æ¤F.µÊ¸~¤jªº°ÝÃD­n¸Ñ¨M

³o»òÄY¥H«ß¤v¤F.ÁÙ©ÈGºô¨SÃD§÷¥´À£ÃĵØ?

ÁöµM¦³«Ü¦h¤j¤j.·¥¤O·¥¤OÆZ¯î¤§¤Oªº¸ÑÄÀ.(·P°Ê)

§Y«K¦p§Ú¦p¦¹ªº¦º©¾.¬Ý¨ì¹j¤Ñ¶}½L.§Ú¤]°Ê·n¤F.

....¦pªG.¨S¦³¹³§Ú¦p¦¹¦º©¾ªº¸ô¤H¥Ò.¤£ª¾¹D·|¤£·|¨ü¼vÅT?·|¤£·|¦³½æÀ£?

¯u¬OXXXXXX!!

´N¤£¯àÅý¤l¼u(§Q¦h)­¸¤@¤U¤U¶Ü?

·íµM.°Q½×°Ï¬O¦Û¥Ñªº.½Ö³£¥i¥H¶}­Ó¯Q¾~ª©¡K.

§Ú¬O­Ó¬Ý¦hªº¦ÑÀY¡K..¤ßŦ¤£¦n.©Ò¥H¤£³ß§QªÅ¨¥½×

¥H¤W¡K..¯ÂÄݨcÄÌ.

ª©¤W¥ß½×¦³¾Ú.µL¨p©^Ämªº¤j¤j­Ì.¦A¤@¦¸«D±`¯u¤ßªº·PÁ±z­Ì

¯¬±z­Ì2019³£µo¤j°]

µù:­«¼C<§L¾¹ÃбƦW>®õºÖ¼È¦C²Ä¤@(2017/10/17)³o½g¤j§@¼g±o¯u¦n.¤Þ¥Î¤F«Ü¦h¼Æ¾Ú..........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¨}¥²«L10147410  µoªí®É¶¡:2019/1/1 ¤U¤È 02:53:01²Ä 5824 ½g¦^À³
·sªº¤@¦~¶}©l¤F

®¥³ß­«¼C¤j·m±o¥²´Iºô©Ò¦³°Q½×°ÏÀY­»

2019¦~²Ä¤@¦^ÂÐ

¤À¨É´N¬O¬ü¼w¡AµL½×¦nÃa§Æ±æ¤j®a³£¯à§NÀR¬Ý«Ý¤å³¹¡A

¦pªGÃĵدà¦A°Ï¤À¤@­Ó°Ï¶ô¨Ó°Q½×Áô¼~ªº³¡¤À¡A

©Î³\¹ï¦¹ªO·|¤ñ¸û¦n¡A

¸ò¸Î§Ì¡A¯E­ô¤@¼Ë¦³¥¿¤ÏÂù¤è°Ï°ì

¬Ý¬O§_¦³¨º­Ó½å¼w¤§¤H¡A¶}­ÓªO¤À¨É

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2019/1/1 ¤W¤È 09:20:39²Ä 5823 ½g¦^À³
­«¼C¤jªº¤ÀªR,

°Ñ¦Ò°Ñ¦Ò´N¦n ( ¨ä¼Æ¾Ú³£¬O¨Ó¦Ûú³°Ó§ë¸ê¤ÀªR,«Ü¦h³£¬O°²³]­È)

¤@´Â³Q³D«r ( ¯E¹©¤¤¸Î)

®Æ¼Ä±q ¡§¼e¡¨ ¿m¼Ä±q ¡§ÄY¡¨ µL¥i«p«D

¦ý±N¤¤¸Î¸òÃĵØÃþ¤ñ,«h¤£´±­e¦P (¬[ºc¦b ¡§Å޿表 & ¡§¾ú¥v¸gÅ硨 (¤¤¸ÎboomingºC)

2019 ÃĵحY­p¤J½æµ¹AOPªºÃĤΤÀ¼í

­Ó¤H¹w¦ô 1.2-3 »õ¤£¬O°ÝÃD

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­«¼CµL¾W10030199  µoªí®É¶¡:2019/1/1 ¤W¤È 07:21:49²Ä 5822 ½g¦^À³
2019.0101

·s¦~§Ö¼Ö !

2018°ê¾ä«ÊÃö¡AÃĵؤW¶Ç¤½¶}»¡©ú®Ñ¡C ¡§µLµß®ñºô¤Í¡¨ ²Ó²Ó±ÀºV¡C

²×©ó¸û¹Gªñ ¡§²{¹êª¬ªp¡¨¡A that is ¡A¤£­n¤@¨ý¼ÖÆ[¡A®Æ¼Ä±q ¡§¼e¡¨ ¿m¼Ä±q ¡§ÄY¡¨ (¤§«e¤å³¹¡A¤G¦r»~´Ó¡A¯Õ¯Õ©óÃh¡AÄy¦¹¾÷·|°É»~ ¶¶«Kµo¤å¤])

¤Þ¥ÎµLµß®ð : ¡§§Ú»{¬°108¦~12¤ëÀ禬¦pªG¯à¹F¨ì1000¸U´Nºâ¬Oªì´Á¹F°}¡C«áÄò¦AÄ~ÄòÆ[¹î¡C¡¨

¡÷ ³o­Ó1000¸UÀ禬ªº¹w¦ô¡AÁÙ¤ñ§»»·ÃҨ骺12¤ë 1700¸U¹w¦ô¡A¤j´T°¾§C©O !

§Ú¤£¸T¹Ä®§: «ç»ò §Ú¤§«e¦b ¦Û®aBlog ¦Û§ç¡A¤´©Û¨Óºô¤Í ¤j¸v§åµû¡A¬Æ¦Ü ¡§«Iªù½ñ¤á¡¨ ¨ìblog ¼H릯º½|: °¨«á¬¶¡A§ó¦³¬ÆªÌ (¤w½òªk«ß¬õ½u¡A´`ip¬O¥i¥H§ä¨ì¤Hªº) ¡A¤½µM«ü³d¸s»Eª£§@ªÑ²¼ #$%^& !

¨p¤U»{ÃѪºªB¤Í³£ª¾¹D¡A ­«¼C ¬O : data ¼Æ¾Ú ¨g¡A¦U¦¡Àɮ׸ê®Æ¤W¤d¥ó!!¡A ¥B¡A ¡§¥Ã¯d¦s¡¨ !!

§Úªº½×­z³£¤£¬O ¡§¦Û¤v¥Î·Q¹³¡¨ªº¡A

§Æ±æºô¤Í¯à ¡§±µ¨ü¡¨ or ¡§§Ô¨ü¡¨ : ¦³ÅÞ¿è ¦³¼Æ¾Ú ªº ¤£¦P¬Ýªk ¡A «h§ë¸ê¤W©Î¥i¥H´î¤Ö«Ü¦h¶Ë®`¤]¡C

¦]¬°¤£¦Pºô¤Í¡A¦b¤£¦Pª©ªº¨g¼ö¡A Åý§Ú(&´X¦ìªB¤Í) ¡A¦b¥²´Iºô¾¶Án¤£·Qµo¤å¤]¡C

¨¥Âk¥¿¶Ç ¡A2019ÃĵØÃį঳¦h¤Ö¼Ú¬wÀ禬¡A§Ú¤@ª½¨S¦³ ­q¤U¼Æ¦r¡C

¬[ºc¦b ¡§Å޿表 & ¡§¾ú¥v¸gÅ硨 (¤¤¸ÎboomingºC) ¡Aµ¹ ¡§µLµß®ñ¡¨ ¥S¥x°Ñ¦Ò :

¡§¼Ú¬w:108¦~¦¬¤J¡÷ 4.21E À禬¡÷x14%=0.58E¡÷¥­§¡¤ëÀ禬483¸U¡¨

¡÷ ¥S¥x³o­Ó¦ô­È¡A¥H¼Ú¬w vs ¬ü°ê¡A ¡§¥«³õ¡¨ ¬Û·í¨Ó±Àºâ ¡A¬Ookªº¡C

¦ý©¿²¤±¼¤@­Ó§Ú¤§«e´£ªºfactor ¡C (§Ú¬Û«H³o­Ófactor¬O¥¿½Tªº) :

¼Ú¬wªñ30­Ó°ê®a¡A¥BEMAºÞ²zÃÄ»ù¡C ©Ò¥H±À¶iªº®Éµ{¡A¤S¤ñ¬ü°êºC6­Ó¤ë (?)

HOWEVER ¡A§Ú«D±`»{¦P : 108¦~12¤ëÀ禬¦pªG¯à¹F¨ì1000¸U´Nºâ¬Oªì´Á¹F°}¡C

§Ú§V¤O¬ã¨sµo±¸¡A´X®a¥Í§Þ¤½¥qªº¤@¨ÇÃD§÷¡A³£±N(¤j)µo»Ã !

2019¥Í§Þ¸s¥²¦³Âà¾÷ !! ·s¦~§Ö¼Ö !!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/31 ¤U¤È 10:46:07²Ä 5821 ½g¦^À³
°²¦p§â¬ü°êªºÀ禬´£¦­¤@¦~·í¼Ú¬wªºÀ禬¨Ó¦ô­p:

¬ü°ê:

109¦~¦¬¤J¡÷ 4.21E À禬

110¦~¦¬¤J¡÷ 27.22E À禬

111¦~¦¬¤J¡÷ 95.22E À禬

112¦~¦¬¤J¡÷197.81E À禬

¼Ú¬w:

108¦~¦¬¤J¡÷ 4.21E À禬¡÷x14%=0.58E¡÷¦X¨Ö¼Ú¬w¥H¥~-? = -?E

109¦~¦¬¤J¡÷ 27.22E À禬¡÷x14%=3.78E¡÷¦X¨Ö¼Ú¬w¥H¥~-19.06=-15.28E

110¦~¦¬¤J¡÷ 95.22E À禬¡÷x14%=13.3E¡÷¦X¨Ö¼Ú¬w¥H¥~-1.19=12.11E

111¦~¦¬¤J¡÷197.81E À禬¡÷x14%=27.69E¡÷¦X¨Ö¼Ú¬w¥H¥~+25.54=53.23E

¦n¹³¦Ü¤Ö¥²¶·½ä¨â¦~¤~¯àª¾¹Dµ²ªG¡CÄ@½äªA¿é¡C

¿é:¨S·Ó¤½¥q¹w´Á¨«,§¹³J!

Ĺ:¦³·Ó¤½¥q¹w´Á¨«,112¦~§óÅå¤H!¦]¬°ET¥[¤J,³°¤éÁú¥x¥[¤J¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/31 ¤U¤È 09:40:05²Ä 5820 ½g¦^À³
°²¦p§â¬ü°êªºÀ禬´£¦­¤@¦~·í¼Ú¬wªºÀ禬¨Ó¦ô­p:

¬ü°ê:

109¦~¦¬¤J¡÷ 4.21E À禬

110¦~¦¬¤J¡÷ 27.22E À禬

111¦~¦¬¤J¡÷ 95.22E À禬

112¦~¦¬¤J¡÷197.81E À禬

¼Ú¬w:

108¦~¦¬¤J¡÷ 4.21E À禬¡÷x14%=0.58E¡÷¥­§¡¤ëÀ禬483¸U

109¦~¦¬¤J¡÷ 27.22E À禬¡÷x14%=3.78E¡÷¥­§¡¤ëÀ禬3150¸U

110¦~¦¬¤J¡÷ 95.22E À禬¡÷x14%=13.3E¡÷¥­§¡¤ëÀ禬1.108»õ

111¦~¦¬¤J¡÷197.81E À禬¡÷x14%=27.69E¡÷¥­§¡¤ëÀ禬2.3»õ

¦]¦¹,§Ú»{¬°108¦~12¤ëÀ禬¦pªG¯à¹F¨ì1000¸U´Nºâ¬Oªì´Á¹F°}¡C«áÄò¦AÄ~ÄòÆ[¹î¡C

(¦¹¬°¦Ê¤H¦³¦ÊºØºâªkªº¨Æ,¤£¥²´£°Ý¡C)¨Ó¸ó¦~§a!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/31 ¤U¤È 07:09:22²Ä 5819 ½g¦^À³
­Y¨Ì·Ó¤½¥q¦ô­p2023¦~(¥Á°ê112¦~)¼Ú¬w¥~ªºÀ禬198»õ(¬°¤è«K¥H200»õ­pºâ,§Æ±æ¤£·|¦³§j¤ò¨D²«ªÌ¸õ¥X¨Ó....¥H¤U¼Æ¦r¦P¬°¤j¬ù¼Æ)

¬ü°êµo¯f±µ¨üªvÀø3000¤H(¥i¯à´N¬O²{¦b¨Ï¥ÎjakafiªÌ§a?)°²³]¦³50%1500¤H¨Ï¥ÎBesremi¨C¥b¤ë¤@°w,¤@¦~ÃĶO200¸U=30»õ¥x¹ô,

¥t170»õ¥x¹ô¨Ó¦Û¡u¥¼µo¯fªÌ¡v¨C¤ë¤@°w¤@¦~ÃĶO100¸U,«h»Ý­n1.7¸U¤H,1.7¸U/15¸U=11.3%,

¤]´N¬O¡u±w¯f«o¥¼µo¯fªÌ¡v¦³11.3%¥ª¥kªº¤ñ²v±µ¨üBesremiªvÀø¡C

³o­Ó¤ñ²v¬Ý°_¨ÓÁÙºâ¦X²z§a?

¥t¥~,200»õÀ禬¤ò§Q¬ù¦³177»õ(¦ô),Àç§Q­°¦Ü46»õ,131»õ¬O§ë¤J¦æ¾P¬ãµo©M¸ÕÅç¶Ü?³o·|­pªºªF¦è§Ú¤£À´

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/31 ¤U¤È 05:30:14²Ä 5818 ½g¦^À³
www.chinatimes.com/newspapers/20141017000312-260210

¥Ø«e¬ü°êªºET¯f±w¬ù¦³15¸U¤H¡A¯f±w¼Æ¬ù»PPV¬Û·í¡A¦X­pªñ30¸U¤H

read01.com/JjnRz8.html#.XCna4lwzY2w

ET¦~µo¯f²v¬°0.59¦Ü2.53 / 100,000©~¥Á¡A

¦è¤è°ê®aªº±w¯f²v¬°30 / 100,000

=======================================

¨º»ò,¥«³õ¤j¤pÀ³¸Ó¥H¡uµo¯f²v¡v©Î¡u±w¯f²v¡v¦ô­p¤~·Ç½T©O?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/31 ¤U¤È 05:18:48²Ä 5817 ½g¦^À³
¦³­ÓºÃ°Ý:§Ú¬dºô¸ô¤Wªº¸ê°T¦³:

¡u100 ÉE¤H¤f¤¤¦³ 2¡ã10 ¦ì红细­M¼W¦h±wªÌ¡v

¡u2000¦~«×¼Ú¬w©Ò¦³¤H¸sPVªºµo¯f²v0.74/10¸U¡C¡v

(¦]¬°¤£¯àÂà¸ü,©Ò¥H¦³¿³½ìªÌ½Ð¦Û¦æGoogle),

­Y¤j¬ù¨Ì·Ó1/10¸Uªº¤ñ²v±Àºâ,

¼Ú¬w¤]¥u¦³8000±wªÌ,

¬ü°ê¥u3000±wªÌ,

¤¤°ê¥u¦³1.3¸U±wªÌ,

¤é¥»¥u¦³1200±wªÌ¡C

¦Ó¤w,«ç»ò©M¤½¥qºô¤W¦ô­p(¼Ú¬w+¬ü°ê¬ù30¸U¤H)ªº®t¨º»ò¦h?®t¤F30­¿?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2018/12/31 ¤U¤È 02:50:46²Ä 5816 ½g¦^À³
µL²á¬Ý¬Ý..¥«³õ¤j¦ÛµMÄvª§ªÌ²³

¸~½F§K¬ÌªvÀø¡]I-O¡^¡GPD-(L)1³æ§Ü¾U¤£¥i·í¡AÁp¦X¥ÎÃĦA¨D¬ð¯}

­ì¤åºô§}¡Gread01.com/Q3j78dJ.html

I-OªvÀøªº­«­n«ä¸ô: Áp¦X¥ÎÃÄ¡]Combination¡^

¥Ø«e¡A¸~½F§K¬ÌªvÀøªº¤@­Ó­«­n«ä¸ô¬OÁp¦XªvÀø¡C±q¤wµn°OªºÁ{§É¸ÕÅ籡ªp¨Ó¬Ý¡AI-OªºÁp¦XªvÀø¦h¼Æ¬OPD-(L)1³æ§Ü»P¥t¥~¤@ºØÀøªk¶i¦æ²Õ¦X¡CºI¦Ü17¦~5¤ë¡A»PPD-(L)1Àøªk¦³Ãöªº²Õ¦XÀøªk¬ãµo¶µ¥Ø°ª¹F765¶µ¡C

­ì¨Ó¬YÁû¬P¬P.¯uªº¥u¬OÁc¬P¤¤¤F¤@Áû..

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/30 ¤U¤È 01:13:36²Ä 5815 ½g¦^À³
P1101¥Î©ó¦å¤pªO¼W¥Í¯g(ET)¡G ¥»¤½¥q P1101 ªvÀø PV ¤w³q¹L EMA ¼f¬d­ã³\¤W¥««á¡A±N¥[³t¶i¦æP1101 ªvÀø ET ªºÁ{§É¸ÕÅç¡A¥»¦¸¼W¸ê ­p¹º©ó¬ü°ê¡B¥xÆW¡B¤é¥»¡B¤¤°ê¤ÎÁú°êµ¥¤­°ê°õ¦æ¥þ²y©Ê²Ä¤T´Á¤HÅé¸ÕÅç

-----------------

ET²Ä¤T´Á¤HÅé¸ÕÅ礣¥]§t¼Ú¬w¤Î­^°ê ? ¬O§_¤§«e¤w±ÂÅvAOP ? ¸òPV¤@°_±ÂÅvAOP. AOP¦b¼Ú¬wET¤]°µ²Ä¤T´Á¤HÅé¸ÕÅç ?

¥i¥H¸òAOP¾ã¦XET²Ä¤T´Á¤HÅé¸ÕÅç¥H­°§C¶O¥Î?

¤U­±°T®§¨Ó¦ÛAOP ³Ìªñ·s»D½Z

Ropeginterferon alfa-2b was discovered by PharmaEssentia, a long-term partner of AOP Orphan. In 2009, AOP Orphan has in-licensed from PharmaEssentia Corporation the exclusive rights for clinical development and commercialization of Ropeginterferon alfa-2b in PV, other MPNs and CML for European, Commonwealth of Independent States (CIS), and Middle Eastern markets.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/30 ¤U¤È 12:29:35²Ä 5814 ½g¦^À³
(A)¦å²G類

a.P1101 ¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)¤§¼Ú¬w¤T´ÁÁ{§É¸ÕÅçµ²ªG¡A¤w©ó 107 ¦~ 12 ¤ëÀò±o¼Ú·ù¤HÅé¥ÎÃÄ©e­û·|(CHMP)µ¹¤©±ÀÂˤW¥«³\¥i¤§¥¿­± ·N¨£¡A¤½¥q¨Ã¤w»P¬ü°ê FDA ¶}©l°Q½×¨Ï¥Î¨ä¼Ú¬w²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç ¼Æ¾Ú¤Î¤å¥ó¦V¬ü°ê FDA ¥Ó½ÐÃÄÃÒ¤§¥i¦æ©Ê¡C¥»¦¸¼W¸ê­pµe¶i¤@¨B±N PVÁ{§É¬ã¨sÂX®i¦Ü¨È¬w¦a°Ï¡A¨Ã¤wÀò±o¤é¥»(PMDA)¤Î¤¤°ê°ê®aÃÄ«~ºÊ·þ ºÞ²z§½¡]CFDA¡^®Ö­ã¶i¦æ²Ä¤@´Á¤HÅéÁ{§É¸ÕÅç¡A§¹¦¨«á±N¥H¸Ó¦a°Ï²Ä ¤@´ÁÁ{§É¼Æ¾Ú¤ÎP1101©ó¼Ú¬w²Ä¤T´Á¤HÅéÁ{§É¸ÕÅ礧¼Æ¾Ú¤Î¤å¥ó¥Ó½Ð¤é ¥»¤Î¤¤°ê PV ¤W¥«³\¥i¡C

• ¼Ú¬w:107 ¦~ 12 ¤ëÀò±o¼Ú·ù¤HÅé¥ÎÃÄ©e­û·| (CHMP)µ¹¤©±ÀÂˤW¥«³\¥i¤§¥¿­±·N¨£

• ¬ü°ê:·Ç³Æ²Ä¤T´ÁÁ{§É¸ÕÅç(Phase III)¼Æ¾Ú¤å ¥ó¤Î¥Ó½ÐÃÄ«~¤W¥«¬dÅçµn°O(BLA)

• ¥xÆW:·Ç³Æ¶i¦æ¾ô±µÁ{§É¸ÕÅç

• ¤é¥»:¶i¦æ²Ä¤@´ÁÁ{§É¸ÕÅç(Phase I)

• ¤¤°ê:¶i¦æ²Ä¤@´ÁÁ{§É¸ÕÅç(Phase I)

b.P1101¥Î©ó¦å¤pªO¼W¥Í¯g(ET)¡GET»PPV¬Ò¬°¨u¨£¦å²G«¬¯e¯f¡A¥»¤½¥qP1101 ¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)¤ÎªvÀø¦å¤pªO¼W¥Í¯g(ET)¬Ò¤w³q¹L¬ü°ê¨u ¨£¯e¯f¥ÎÃÄ»{ÃÒ¡F¥B¤w©ó 105 ¦~¤w»P¬ü°ê FDA ·¾³q P1101-ET ªºÁ{§É¸ÕÅç ¬ÛÃö¨Æ©y¨Ã°Q½× ET ¸ÕÅç³Ì¨Î¤§¶i®i¤è¦V¡A¥»¤½¥q P1101 ªvÀø PV ¤w³q¹L EMA ¼f¬d­ã³\¤W¥««á¡A±N¥[³t¶i¦æP1101 ªvÀø ET ªºÁ{§É¸ÕÅç¡A¥»¦¸¼W¸ê ­p¹º©ó¬ü°ê¡B¥xÆW¡B¤é¥»¡B¤¤°ê¤ÎÁú°êµ¥¤­°ê°õ¦æ¥þ²y©Ê²Ä¤T´Á¤HÅé¸ÕÅç¡A ÅçÃÒ©ó¤w±µ¨ü¹L hydroxyurea(HU)ªvÀø¦ý¥¼¹F¹w´ÁÀø®Ä©ÎªvÀø¥¢±Ñªº ET ¯f ¤H±Ú¸s¡AÆ[¹î P1101 ªºªvÀø®ÄªG¡C¥»¤½¥q¹w­p©ó 108 ¦~²Ä¤@©u¶}©l²Ä¤T´Á Á{§É¸ÕÅç¡C

• ¥þ²y:¥Ó½Ð²Ä¤T´ÁÁ{§É¸ÕÅç¼f¬d(IND)

c.PEG-EPO ªø®Ä«¬¬õ¦å²y¥Í¦¨¯À¡GºC©ÊµÇ¯f(Chronic Kidney Disease¡A²ºÙ CKD)±wªÌ¦b¬~µÇ¹Lµ{¤¤±`µo¥Í³h¦å¡A¤@¯ë»{¬°¬õ¦å²y¥Í¦¨¯Àªº´î¤Ö¬°¥D­n ¯f¦]¡C³h¦å·|´î¤Ö²Õ´ªº®ñ¿é°e¾É­P¯h³Ò¡A¥ç·|³y¦¨»{ª¾¥\¯à¨ü·l¤Î§K¬Ì ¥\¯à¤U­°©M¤ßŦ¥\¯à¨ü·l¡A±w¦³ CKD ©M³h¦å±wªÌ»Ý­n²×¥Í¬I¥´¬õ¦å²y¥Í¦¨ ¯À¿E¬¡Ãľ¯ªvÀø¡C¥Ø«e¥Î©óªvÀøºC©ÊµÇ¯fªº¬õ¦å²y¥Í¦¨¯À¬I¥´ÀW²v¬°¨C¶g ¤@¦¸¡A¥»¤½¥q¬ãµo¤§ªø®Ä«¬¬õ¦å²y¥Í¦¨¯À¡A¥i±N¬I¥´ÀW²v½Õ­°¬°¨C¨â¶g¤@ ¦¸©Î¨C¥|¶g¤@¦¸¡A¹ï©ó¬ÛÃö¯e¯f±wªÌ¹ê¬°§U益¡C¥»¤½¥q¹w­p©ó 108 ¦~¶i¦æ ¤p³W¼Ò¸Õ¶q²£¤Î°Êª«¸ÕÅç¡A¨Ã©ó 109 ¦~¶i¦æ GMP Á{§É¸ÕÅç¥Í²£¤Î IND ¥Ó ½Ð¡A¨Ã©ó 110 ¦~²Ä¥|©u¶}©l¶i¦æ²Ä¤@´ÁÁ{§É¸ÕÅç¡C

• «Øºc²Ó­M®è¤Î»sµ{¶}µo

d.PEG-GCSF ªø®Ä«¬¥Õ¦å²y¥Íªø¿E¯À¡GGCSF ¬°¤HÅ餤¦ÛµM²£¥Íªº³J¥Õ½è¡A ¯à¨ë¿E°©Å褺Áû²É©Ê¥Õ¦å²y¥Íªø¤Àµõ¡A¼W¥[¥Õ¦å²y¼Æ¥Ø¡A¨Ï¨­Å骺©è§Ü¯à ¤O´£°ª¡C¥»¤½¥q§Q¥Î±M§Q¾Ö¦³ªº»E¤A¤G¾J¤Æ¤ÏÀ³¥­¥x¤Î°ò¦]¤uµ{§Þ³N¦Û¦æ ¬ãµo¥Í²£­«²Õ¤HÁû²É©Ê¥Õ¦å²y¸s¸¨¥Íªø¦]¤l¡A¬ãµo¥Í²£ªø®Ä«¬¡A¥Ø¼Ð¬°¹F ¨ì¤Q¥|¤Ñ¥H¤W¡A¬Æ¦Ü¤@­Ó¤ëª`®g¤@¦¸¡C¥»¤½¥q¹w­p©ó 108 ¦~¶i¦æ¤p³W¼Ò¸Õ ¶q²£¡A¨Ã©ó 109 ¦~¶i¦æ°Êª«¸ÕÅç¡A110 ¦~²Ä¤G©u¥Ó½Ð IND¡A¹w­p©ó 111 ¦~ ²Ä¤G©u¶}©l¶i¦æÁ{§É¤@´Á¸ÕÅç¡C

• «Øºc²Ó­M®è¤Î»sµ{¶}µo

(B)¨xª¢

a.C «¬¨xª¢°ò¦]Åé²Ä¤G«¬(HCV GT2)¡A©ó 104 ¦~¨ú±o TFDA ¥xÆW²Ä¤T´ÁÁ{ §É¸ÕÅç³\¥i¡A¤w©ó 105 ¦~²Ä¤@©u¥¿¦¡±Ò°Ê¤T´Á¦¬®×¡AÁú°ê¥ç¦P®É¨ú±oÁú°ê ­¹«~ÃĪ«ºÞ²z¸p(Ministry of Food and Drug Safety²ºÙMFDS)®Ö­ã¦P·N¶i¦æ ²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç¡A¹w­p©ó 109 ¦~²Ä¥|©u¥i§¹¦¨²Ä¤T´Á¤HÅé¸ÕÅç¡C b.P1101 ¥Î©óªvÀøºC©ÊB «¬¨xª¢¡A©ó 101 ¦~¨ú±o TFDA ¥xÆW²Ä¤G´ÁÁ{§É¸ÕÅç³\¥i¡A¥HP1101³æ¿W¨Ï¥Î¶i¦æªvÀøB«¬¨xª¢ªºÁ{§É¸ÕÅç¡A¥Øªº«Y±´¯Á P1101 ¤§³Ì¾A¾¯¶q¡A¤w©ó 106 ¦~²Ä¥|©u§¹¦¨¸ÕÅç¡C¥»¤½¥q±N©ó 108 ¦~²Ä¤@©u¦P®É ¦V¥xÆW¡BÁú°ê¡BªF«n¨È¡B¤¤°ê¤Î¬ü°êµ¥¦a¥Ó½Ð¥H P1101 ªvÀø B «¬¨xª¢ e §Ü ­ì¶§©Ê¯f¤H¤§¦h°ê¦hÁ{§É¤¤¤ß¶i¤J²Ä¤T´Á¤HÅé¸ÕÅç¡C

B «¬¨xª¢ • ¥Ó½Ð²Ä¤T´ÁÁ{§É¸ÕÅç¼f¬d(IND)

C «¬¨xª¢ • ¶i¦æ²Ä¤T´ÁÁ{§É¸ÕÅç Phase III

B «¬¨xª¢+ C «¬¨xª¢ • ÀÀ¥Ó½Ð²Ä¤T´ÁÁ{§É¸ÕÅç¼f¬d(IND)

B «¬¨xª¢+ D «¬¨xª¢ • ÀÀ¥Ó½Ð²Ä¤G´ÁÁ{§É¸ÕÅç¼f¬d(IND)

(C)Àù¯g

§Ü PD-1 §ÜÅé¡A«Y¤@ºØ§K¬ÌÀˬdÂI§í¨î¾¯¡A¥i¥Î©óªvÀø¥]¬A´c©Ê¦â ¯À½F¡B«D¤p²Ó­MªÍÀù¡B±ß´ÁµÇÀùµ¥¦hºØ´c©Ê¸~½F¡A·¥¤jµ{«×¤W´£°ª¤FÀù ¯g±wªÌªº¦s¬¡²v¡A±©¥Ø«e¸ÓÃÄ»ù¤Q¤À©ù¶Q¡A¹ï¤@¯ë®a®x¹êÄݨH­«¤§­t¾á¡A ¥»¤½¥qÀÀÂǨä¥Íª«ÃĬãµo¸gÅç¤Î¥Í²£®Ä²v¤Î«~½è±±ºÞªº±Mªø¡A¬ãµo¥X«~ ½è°ª¥Bí©wªº§Ü PD1 §ÜÅé¡Aµo®i³æ®è§ÜÅé·sÃĶ}µo¥­¥x¡A¨Ã­°§C¥Í²£¦¨ ¥»¡A´î§C¯f±w¤§°]°È­t¾á¡C¥»¤½¥q³W¹º 108 ¦~¶i¦æ¤p³W¼Ò¸Õ¶q²£¡A¨Ã©ó 109 ¦~¶i¦æ°Êª«¸ÕÅç¡A110 ¦~¥Ó½Ð IND¡A¨Ã¹w­p©ó 111 ¦~²Ä¤G©u¶}©l¶i¦æ ²Ä¤@´ÁÁ{§É¸ÕÅç¡C

¥¼¨ÓÂX®i P1101 ªºªvÀø½d³ò¡A±N¨ä¹B¥Î©ó´c©Ê¶Â¦â¯ÀÀù¡BT cell ²O¤ÚÀù¡B¤ò ²Ó­M¥Õ¦å¯f¤Î¨xÀùµ¥¾AÀ³¯g¡C

• «Øºc²Ó­M®è¤Î»sµ{¶}µo

¤fªA¾¯«¬µµ§ü¾J Oraxol Oraxol ¬°¤fªA¾¯«¬ªºµµ§ü¾J(Paclitaxel)¡Cµµ§ü¾J³Q¼sªxÀ³¥Î©óªvÀø±ß ´Á§Z±_Àù¡B¨ÅÀù¡B«D¤p²Ó­M¤Î¤p²Ó­MªÍÀùµ¥¦hºØÀù¯g¡COraxol «Y¥Ñ¬O¥ÑÁú°ê Hanmi »sÃĤ½¥q©Ò¬ãµo¡A¨Ã±ÂÅvµ¹¬ü°ê Athenex Inc.(§ï¦W«e¬° Kinex Pharmaceuticals, LLC¡A¥H¤U²ºÙ Athenex ¤½¥q)¶i¦æÃÄ «~¶}µo¡AÄÝ 505b(2)·s¾¯«¬·sÃÄ¡C¬ü°ê Athenex ¤½¥q¤w©ó 102 ¦~ 12 ¤ë±Â¤© ¥»¤½¥q¿W®a¦b¥xÆW¡B¶V«n©M·s¥[©Y°õ¦æ¶}µo Oraxol® (¤fªAµµ§ü¾J)©M Oratecan® (¤fªA³ß¾ðÆP)ªºÅv§Q¡AOraxol® ©M Oratecan® ¸g¥Ñ¤fªAªºµ¹ÃÄ¤è ¦¡Åý¤HÅé§l¦¬¡A·~¸g¤HÅé¹êÅçÃÒ©ú¨ä¦bÅ餺¿@«×¥i¥­Ã­¤W¤É¦Ó¥B¯àºû«ù¸û ¤[¡A¦]¦Ó¤j´T´î§C¦b¯f¤H¨­¤Wªº°Æ§@¥Î¡C¥Ñ©ó Oraxol ¤w¦bÁ{§É¸ÕÅ綥¬q Àò±o¦b¦w¥þ©Ê»P¦³®Ä©Ê¨S¦³ºÃ¼{ªºµ²ªG¡A¹w­p107¦~§¹¦¨ÃÄ°Ê/Á{§É¸ÕÅç¡A ¥¼¨Ó±N¦X¨Ö Athenex «n¬üÁ{§É¤T´Á´Á¤¤¤ÀªR¸ê®Æ¡A¨Ã·f°t¬ü°ê¡B­^°ê¡B¿D ¬w¤Î¯Ã¦èÄõªk³W°e¼fµ¦²¤¡A¦b¥xÆW¥Ó½ÐÃÄÃÒ¡CAthenex ©ó 107 ¦~ 9 ¤ë¤½¥¬ Oraxol ªvÀøÂಾ©Ê¨ÅÀù²Ä¤G¦¸´Á¤¤¤ÀªR¡A¥Ñ¿W¥ßÃĪ«¦w¥þºÊ·þ©e­û·| ¡]DSMB¡^¶i¦æ¤ÀªR¤Î¼f¬d¡CDSMB ¨Ã°w¹ï Athenex ¦¬®×§Ö³t¥B¹F¨ì«D±` ¥¿­±ªºµ²ªG¡Aµ¹¤©°ª«×ªºªÖ©w¡CDSMB «ü¥X¥Ø«e¤w¦³¶W¹L 320 ¦ì¨ü¸ÕªÌ¦¬ ®×¡A¨Ã«ØijÄ~Äò¦¹Á{§É¸ÕÅç¨Ã§¹¦¨¨ü¸ÕªÌ¦¬®×¡C

¨ÅÀù

• ¥xÆW:§¹¦¨¦w¥þ©Ê¾ô±µ¸ÕÅç

• «n¬ü¬w¡G¥Ñ¦X§@¹Ù¦ñ Athenex ¤½¥q©ó«n¬ü¬w ¶i¦æ¤HÅé²Ä¤T´ÁÁ{§É¸ÕÅ礤

(D)¤û¥ÖÅ~¥ÎÃÄ KX01

¤û¥ÖÅ~¤SºÙ°®Å~©Î»È®h¯f¡A¥¦¬O¤@ºØºC©Ê¤S®e©ö´_µoªº§K¬Ì½Õ¸`©Ê¥Ö½§ ¯e¯f¡A¼vÅT¬ù¥þ²y 2-3¢Hªº¤H¤f¡C

¥»¤½¥q»P¬ü°ê Athenex ¤½¥q¦X§@¶}µoªvÀø¤û¥ÖÅ~ªº³n»I»s¾¯ KX01¡A¥Ø «eÅé¥~¸ÕÅçµo²{¨ä¦P®É¨ã¦³§Ü¼W´Þ©Ê(antiproliferative) ¡B§í¨î¤H¨¤½è(§Î¦¨)²Ó ­Mªº¥Íªø(keratinocyte)¡B§Ü·s¦åºÞ§Î¦¨(neovascularization) ¡B¨ã§K¬Ì§í¨î (immunosuppressive)¥H§í¨î T ²Ó­Mªº²¾°Êµ¥ªº¯S©Ê¡A¦]¦¹¹w¦ô¦bÁ{§É¸ÕÅ礤 ±NÃÒ¹ê KX01 ¹ï¤û¥ÖÅ~¦³°ª«×ÂåÀø®ÄªG¡C¥»¤½¥q¦V Athenex ¤½¥q¨ú±o KX01 ¤Æ¦Xª«¦b¥xÆW¡B¤¤°ê¤j³°¡B´ä¿D¡B¬P°¨µ¥¦a°Ïªº±ÂÅv¡A¥H°w¹ï¤û¥ÖÅ~¾AÀ³¯g ¶}µo¥Ö½§¥~¥Î¾¯«¬¡AÄÝ©ó·s¦¨¥÷·sÃÄ¡CKX01 ªº¤fªA¾¯«¬¤w¦b¬ü°ê¶i¤J²Ä¤G ´ÁÁ{§É¸ÕÅç¡AÃÒ¹ê¨ä¦b¤HÅ骺¦w¥þ©Ê¡A´î¤Ö§ë¸ê­·ÀI©Ê¡AKX01 ªvÀø¤û¥ÖÅ~ ªº¾÷¨î»P²{¤µ¥«­±¤WÃĪ«¤£¦P¡A¥[¤W³n»I¾¯«¬¨Ï¥Î¤è便¡C¥»¤½¥q¹w­p¦¹·s«¬ ªº¤û¥ÖÅ~ÃĪ«¯à°÷¶¶§Q¦a¶i¤J¤j¤¤µØ¥«³õ¡C

¤û¥ÖÅ~ • ¥xÆW:¶i¦æ²Ä¤@´ÁÁ{§É¸ÕÅç Phase I

=========================================================================================

²{¦b»ÝÆ[¹îªº¬O:¼Ú¬wPV©M¬ü°êPV,¨ä¥Lªº³£¬O¥¼¨Ó¦¡¡CÁÙ­n´£¨¾§ë¸ê¤H¥¢¥h­@¤ß±þ¥Xªº½æÀ£¡C

108¦~¤@©wÁ«·l,109¦~Á«·lªº¾÷·|«Ü¤j,110¦~´Á±æ·l¥­,111¦~¦³¥i¯à¤jÁÈ,112¦~¦³¥i¯à¶WÁÈ,113¦~¯àª§¤ý¡C¦³³oºØ¦@ÃÑ¥BÄ@·N§Ô¨ü®M¨c·Î¼õªº§ë¸ê¤H¤~¯à«ù¦³¡C¥|¦~ªºµ¥«Ý¬O³Ì°ò¥»ªº¡C

·íµM,³o´Á¶¡·|¦³¦UºØÃĪ«ªº¶i®i,¦ý¤]¤£«OÃҪѻù·|°µ¦óºØ¤ÏÀ³¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2018/12/30 ¤W¤È 01:48:12²Ä 5813 ½g¦^À³
³o½g¤£ª¾¯à¥[±jP1101+PD-L1 ¬Oº¡¦³·dÀYªº...

«ÜÃøÀ´..¦³¨S¦³¤j¯àÀ°¦£...¦n·Q©I¥sCliff¤j...

Interferon-£\ Up-Regulates the Expression of PD-L1 Molecules on Immune Cells Through STAT3 and p38 Signaling

www.ncbi.nlm.nih.gov/pmc/articles/PMC6190899/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/29 ¤U¤È 11:04:52²Ä 5812 ½g¦^À³
©Ó¾P»ù®æ­pºâ¤§»¡©ú

1.¸Ó¤½¥q¥»¦¸²{ª÷¼W¸êµo行·sªÑ®×·~¸g107 ¦~12 ¤ë11 ¤é¸³¨Æ·|¨Mij³q¹L¿ì²z¡C¥H¸Ó¤½

¥q107 ¦~12 ¤ë27 ¤é¦Vª÷¿ÄºÊ·þºÞ²z©e­û·|´£¥X¥Ó³ø¿ì²z²{ª÷¼W¸êµo行·sªÑ·í¤é¬°°ò

·Ç¤é¡A¨ä©óÃÒ¨é¥æ易©Ò¤§«e¤@¡B¤T¡B¤­­ÓÀç·~¤é¤§´¶³qªÑ¦¬½L»ù²³æºâ³N¥­§¡¼Æ¦©°£

µLÀv°tªÑ°£Åv«á¤§¥­§¡ªÑ»ù¤À§O¬°172 ¤¸¡B174 ¤¸¡B175.5 ¤¸¡A¤TªÌ¾Ü¨ä¤@ªÌ¡A¨ú¨ä«e

¤­­ÓÀç·~¤é¥­§¡¦¬½L»ù¦©°£µLÀv°tªÑ°£Åv«á¤§¥­§¡ªÑ»ù175.5 ¤¸§@¬°­pºâ¤§參¦Ò»ù®æ¡C

2.®Ú¾Ú¤W­z參¦Ò»ù®æ¡A¸g¦Ò¶q¥«³õ¾ãÅ鱡§Î¡A¥B參°u¸Ó¤½¥q¤§¸gÀçÁZ®Ä¤Î¥¼來®i±æ¡A¸g

¥»©Ó¾P°Ó»P¸Ó¤½¥q¦@¦Pij©w¥»¦¸²{ª÷¼W¸ê¼È©wµo行»ù®æ¬°¨CªÑ160 ¤¸¡A¸g®Öºâ¥e«e­z

參¦Ò»ù®æ175.5 ¤¸¤§91.17%¡A¨ä©Ó¾P»ù®æ¤§­q©w«Y²Å¦X¡u©Ó¾P°Ó·|­û»²¾Éµo行¤½¥q¶Ò

¶°»Pµo行¦³»ùÃÒú³¦Û律³W«h¡v²Ä六±ø¤§³W©w¡A¨ä©Ó¾P»ù®æ¤§­q©wÀ³©|ÄݦX²z¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gellelin10138869  µoªí®É¶¡:2018/12/29 ¤U¤È 03:13:08²Ä 5811 ½g¦^À³
³o¦¸²{ª÷¼W¸ê20000000ªÑ¯dµ¹­ìªÑªF

¥Ø«eªÑ¥»:21.92»õ>>>>­±ÃB10¤¸¡BÁ`ªÑ¼Æ219200000

­ìªÑªF»{ªÑ20000000/Á`ªÑ¼Æ219200000=0.09124

¨C1000ªÑ*0.09124=91ªÑ¥ª¥k³o¼Ëºâ¹ï¶Ü?

ºâ¿ù¤Å©ÇXD

½Ð¤j¤j­Ì«ü¥¿

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gellelin10138869  µoªí®É¶¡:2018/12/29 ¤U¤È 02:56:05²Ä 5810 ½g¦^À³
½Ð°Ý¦U¦ì¤j¤j

³o¦¸ªº²{ª÷¼W¸ê

­ìªÑªF¤@±i¤j·§¯à»{´XªÑ©O?

ÁÂÁÂ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GSirius10142542  µoªí®É¶¡:2018/12/29 ¤U¤È 12:56:45²Ä 5809 ½g¦^À³
¤½¶}»¡©ú®Ñ³sµ²

doc.twse.com.tw/server-java/t57sb01?step=1&colorchg=1&co_id=6446&year=&seamon=&mtype=B&

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJoe10147646  µoªí®É¶¡:2018/12/29 ¤U¤È 12:49:30²Ä 5808 ½g¦^À³
½Ð°Ý¦U¦ì¤j¤j²{ª÷¼W¸ê¤½¶}»¡©ú®Ñ­n¨ì­þÃä¤U¸ü? ÁÂÁÂ
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/29 ¤U¤È 12:11:04²Ä 5807 ½g¦^À³
6446 ¤º¥~¸ê¦X­p¶R¶W¤j·§¬O5%ªÑ¥»
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/29 ¤W¤È 11:59:59²Ä 5806 ½g¦^À³
¥»©P³Ì·sªºªÑÅv¤À´²ªí¥X¨Ó¤F

¤d±i¤jªÑªF¼W¥[ 0.02%

400±i~999±i¤jªÑªF¼W¥[¤F 0.02%

¦^ÅU12/22 vs 12/14 ¤d±i¤jªÑªF´î¤Ö 0.03%

·í®É¤j®a¦b½×¾Â¤S¦A¾á¤ß¥D¤O/¤jªÑªF¶X°ª¥X³f

§Ú¤@ª½½Ð¤j®a§NÀR§PÂ_

¨ä¹ê³oÀɪѲ¼

¬Ýªº¥X¨Ó¦³«H¤ßªº¤H¤@ª½ hold ªÑ²¼

±q¸gÅç¨Ó¬Ý

³æ¯Â´N¬O·Q½ä©M¤£·Q½äªº¤H¦bª±µu½u

³o¨Ç¯uªº¤£¬O©Ò¿×ªº¥D¤O/¤½¥q¬£­Ë³f

¦ýªø½u hold ªº¤H, ¥u·|§C¶R, ¤£·|°l°ª

¤p§Ì¥u§Æ±æ«ÈÆ[ªº¼Æ¾Ú¥i¥HÅý¤j®a«ÈÆ[§NÀRªº§PÂ_

¤£¯à§â¨C¦¸¤U¶^³£Âk¯Ç¬°¥D¤O®`ªº

¦AªÌ¤½¥qÀ³¸Ó­n¦n¦n«ä¦Ò, ¦p¦ó§l¤Þ¥t¥~¤@ªiªø½u§ë¸ê¤H¶i³õ

¤£½×¬O¹L¤º¥~ªk¤H(¥»¤g¦ÛµM¤HÀ³¸Ó¤£·|¦³·sªº¶R½L¤F)³£¥i

Á`Æ[¤µ¦~6446¨«¶Õ, ³£¦b 180¤W¤U10%¾_Àú

¦¨¥æ­È ¦¨¥æ¶q(±i) ¦¨¥æ¶q²Ö¿n ¤ñ­«(%) ²Ö¿n%

180 4365 4365 3.19 3.19

174 4356 8721 3.18 6.37

173 4018 12739 2.94 9.31

170 3895 16634 2.85 12.16

175 3566 20200 2.61 14.77

171 3549 23749 2.59 17.36

181 3502 27251 2.56 19.92

172 3463 30714 2.53 22.45

178 3353 34067 2.45 24.90

182 3262 37329 2.38 27.28

177 2976 40305 2.18 29.46

176 2945 43250 2.15 31.61

181.5 2906 46156 2.12 33.73

180.5 2797 48953 2.04 35.77

171.5 2716 51669 1.99 37.76

179 2691 54360 1.97 39.73

170.5 2654 57014 1.94 41.67

173.5 2644 59658 1.93 43.60

174.5 2563 62221 1.87 45.47

172.5 2494 64715 1.82 47.29

179.5 2432 67147 1.78 49.07

177.5 2252 69399 1.65 50.72

¥~¸ê¤µ¦~¶R8114±i

§ë«H¤µ¦~¶R1222±i

¤ÀÂI¨é°Ó¶R¶W«e10¦W¤À§O¬O

¶×Â× ¶×¥ß ²Î¤@HQ °ª²± ³¥§ø ¤j¼¯ ¤p¼¯ ·ç»È ³Í°òHQ ³Í°òªF¶Õ

¤ÀÂI¨é°Ó½æ¶W«e10¦W¤À§O¬O

¤¤«HHQ ¥ÃÂפº´ò °ê®õHQ §»»·HQ ´I¨¹¤¯·R ¦X®w¦Û±j ³Í°ò¥x¥_ ´I¨¹«Ø°ê ³Í°ò´_¿³ ¤¸¤jHQ

´I¨¹¤¯·R©M´I¨¹«Ø°êÀ³¸Ó¬O®ü­ô

¨ä¥LHQÀ³¸Ó³£¬OIPO¤§«e¿³Âdªº«ùªÑ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¸ê¤á10000187  µoªí®É¶¡:2018/12/29 ¤W¤È 10:26:43²Ä 5805 ½g¦^À³
©_©ÇÃĵئôªºÀ禬«á´X¦~¤j´T¦¨ªø,¦ý§Q¼í´£¤É¬Û¸û¤§¤U¨S¦³¨º»ò§Ö,

¬d¤F¤@¤U»¡©ú®Ñ,ÃĵرN¬ü,¤¤,¤éªº¦æ¾P¶O¥Î¦ô¬°30%~40%,

¬Ý±o¥X¨Ó¤½¥q«Ü¦³¨M¤ß­n§âÃĽæ¦n(©IÀ³¤@¤U¤§«e¦³¤Hı±o¤p¤½¥q¦Û¤v¤£®e©ö°µ¦æ¾PªººÃ¼{),

¤£ª¾¦³¨º¦ì¥ý¶i¬O§_¤F¸Ñ,3~4¦¨Àç·~ÃBªº¦æ¾P¶O¹ï©ó·sÃĨӬÝ,

¬Oªì´Áªº±À¼s¸û°ª©Ò­P,ÁÙ¬O¤@¯ëªº±À¾P¶O¥Î´N¬O³o¼Ë.

¬Ý¤F»¡©ú®Ñ,¹ï©óÃĵإ¼¨Óªºµo®i½ü¹ø§ó¦³«H¤ß¤F,

¦ý­p¹º¬O¤@¦^¨Æ,¹ê»Úªº°õ¦æ¤S¬O¤@¦^¨Æ,ÁÙ¬O¦³¥i¯à¦]¯S®í¦Ò¶q¦Ódelay,

©Ò¥H´N¬OÃ䨫Ãä¬Ý¤F.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦B«B10138946  µoªí®É¶¡:2018/12/29 ¤W¤È 09:32:00²Ä 5804 ½g¦^À³
¦^ÅU107¦~....¤j½L¶^8.6%(10642¶^¨ì9727)...Ãĵغ¦22%(143º¦¨ì174.5)....

ÁZ®Ä¥´±¾¤@²¼ÁZÀuªÑ....«Ü¥i¥H¤F.....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/29 ¤W¤È 08:16:40²Ä 5803 ½g¦^À³
¦P·N¤p¸ê¤á¥Sªº»¡ªk

¦Ó¥BRopeginterferon ªº±M§Q

¬O¦³´Á¶¡­­¨îªº

¦L¶H¤¤¬O¨ì2032¦~

¦p¦ó¦b­­©w´Á¶¡¤º¨ú±o§ó¦h±iÃÄÃÒ

§â±M§Q´Á¶¡»ù­È³Ì¤j¤Æ

¤~¬O¤½¥q¸Ó°µªº¨Æ

¦pªG¥u¬O¬°¤F¼È®ÉªºÂà¬Õ

¦Ó±N«á­±ªºÁ{§É¸ÕÅ窺©µ¿ð­Ó¤T¤­¦~

³o¼Ë¤Ï¦Ó¬Oµuµøªñ§Qªº§@ªk

¥u¥i±¤¥xÆW§ë¸ê¤H¤j¦hÁÙ°±¦b¹q¤lªÑªº§ë¸ê¤ßºA

¹ï©ó¤¤¸Î¡BÃĵسoºØ°ê»Ú¯Å·sÃÄ»âÀY¦Ï

ÁÙ¬O¬Û·íÆ[±æ¸òÂÔ·V

¤£¤@©w¯à°÷µ¹¤©¥¿½Tªºµû»ù

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¸ê¤á10000187  µoªí®É¶¡:2018/12/29 ¤W¤È 02:23:21²Ä 5802 ½g¦^À³
¤£¹L,´N¦p¤pªL¤jªº¸ê®ÆIncyte®³ÃÄÃҦܤµ¨ä¹ê¨C¦~³£¦b·l¥­¤§¶¡¦Ó¤v,

´N¬O±N¿ú³£¦A§ë¤JÁ{§É,¤~¦³¤@¨ÇpipelineªºÃÄÃÒ¥i¥HÄ~Äò²£¥Í,

Ãĵسo¼Ëªº§G§½ªø»·¨Ó¬Ý¬O¦X²zªº,­Y¬O¤@¨â¦~¤§«á³°Äò¶i¤J¥¿ªºEPS,

¦Ó¥B³°Äò¦³·sªºÃÄÃÒ²£¥Í,¤ñ°_Incyte¤@ª½¦b·l¥­¤§¶¡¨ä¹ê¤v¸g«Ü¦n,

¦Ó¹ï¤ñ©óIncyteªº¥«­È,¤j®a­ì·Nµ¹Ãĵئh¤Ö¥«­È,¥u¯à¬Ý¥«³õ¨M©w¤F.

­Y¬O®³¤F¤@±iÃÄÃÒ¤§«á¥ý°±º¢¤£«e,­nµ¥¨ì¥ýÀò§Q¦AÄ~Äò¨ä¥LÃÄÃÒ¶}µo,

ÁöµMEPS¤ñ¸û§Ö³tÂॿ,¦ý»·´º¤£¨Î,¬Û«H§ë¸ê¤Hµ¹ªºµû»ù¤]¤£·|¤Ó°ª.

¥u¯à»¡ÃĵجOí¥¾Ã­¥´,¦³ªø»·³W¹º,¦A¤@¨â¦~´N·|Ãzµo¤F.

¦ý§ë¸ê¤H­Yµu´Á·|¥Î¨ìªº¸êª÷,¥i¯à¤£¾A¦X³£À£¦b³o¸Ì.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¸ê¤á10000187  µoªí®É¶¡:2018/12/29 ¤W¤È 02:05:38²Ä 5801 ½g¦^À³
109¦~³°Äò¨ú±oÃÄÃÒ,¤½¥qÀ³¸Ó¦³«H¤ßP1101 for PV in

USA¥i¥H¦b108´£¥X¥Ó½Ð, 109¨ú±oÃÄÃҨö}½æ,

¼Ú¬w³¡¤À,ÄÝ©óAOPªº¾P°â½d³ò, Ãĵإi¯à¤£¾A¦X°µ¾P°â¹w´ú.

AOP¦b¼Ú¬w¤ñÃĵإ¼¨Ó¦b¬ü°ê´£¦­¤@¦~¶}½æ,

¤]³\¥i¥H§âÃĵئb¬ü°ê109~111¦~ªº¹w¦ôÀ禬¥´­Ó§éµø¬°AOP¦b¼Ú¬w108~110ªºÀ禬,

µM«á­¼¥HÅv§Qª÷ªº%§@¬°Ãĵتº§Q¼í. ³o¼Ë¦b110¦~¥[¤WAOPªºÅv§Qª÷,¥þ¦~À³¸Ó¥iÀò§Q.

¦¹«e,¦]Á{§Éµ¥¶O¥Îªº¤ä¥X,ÁÙ­nµ¥«Ý¤@¨â¦~ªºÁ«·l.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/29 ¤W¤È 02:03:35²Ä 5800 ½g¦^À³
¨Ì·Ó¥H¤U¤j¤jªº»¡ªkªº¸Ü ...³o¼Ë¬Ý°_¨ÓÁÈ¿ú¤]¬O ­nµ¥¨ì 2020¦~©Î³\¤ñ¸û©úÅã

¤]Ãø©Ç ªÑ»ù³£¨SÔ£°Ê.....³o¼Ë¦n¹³³Q¦X²z¤Æ¤F .... ¤@­ÓÁÙ­nµ¥¤@¨â¦~ªº¤~ÁÈ¿úªº

¦ó¥²²{¦b´N¶R µ¥©ú¦~¤¤«á¹L¦A¶R¤]¤£¿ð ³o¬O§Ú­Ó¤H·Qªk

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/12/29 ¤W¤È 01:11:00²Ä 5799 ½g¦^À³
¦A©¹«á­±¬Ý¡A¦p°e³ø¤j©Ò­z...

P.92

(3)¦^¦¬¦~­­¤§¦X²z©Ê

¥»¤½¥q¥»¦¸¶Ò¶°¸êª÷¹w­p©ó108¦~²Ä¥|©u§ë¤J¨Ï¥Î¡A¨Ã©ó111¦~²Ä¤G©u°õ¦æ§¹²¦¡A¥»¦¸·sÃĶ}µo¶µ¥Ø¡A³¡¥÷¹w­p©ó109¦~°_³°Äò¨ú±o¦U¦a°Ï¤§ÃÄÃҥӽФW¥«¡A¨Ã«ö¦U¦a°Ï¯f¤H¼Æ¤Î­q»ùµ¦²¤¦ô­pÀ禬¡C±©109~110¦~«×¡A¥»¤½¥q«ö¨ä¬ãµo­pµe¡A¤´»Ý§ë¤JÃe¤jªº¬ãµo¶O¥Î¡A¥H­P¥»¦¸¼W¸ê®Ä益²£¥Í¤§Àç·~§Q益¤´¬°­t¼Æ¡C¥»¤½¥q¹w¦ô¦Û111¦~°_¡A¦]PV¤W¥«¾P°â²Ä¤T¦~À禬í©w¦¨ªø¡A¥[¤WET¤Î¨xª¢¥ÎÃħ¡¤W¥«¾P°â¡A¤½¥q²£«~½u§óÁͧ¹³Æ¡A¨ÏÀç·~¦¬¤J¤j´T¤W¤É¡A¹w­p¥»¦¸¸êª÷¥Î¥H¶}µo·sÃĤ§¦¨¥»§ë¤J±N©ó112¦~¦^¦¬¡A©|ÄݦX²z¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2018/12/29 ¤W¤È 12:58:04²Ä 5798 ½g¦^À³
¥»¦¸¤½»¡.­n¥æ¥N¿úªá¨ì­þ.¦³¦h¤Ö¦¬¯q.

¼Ú¬w³¡¤À¨Sªá¿ú.©Ò¥H¤£­p¼Ú¬w...

²qªº..

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/12/29 ¤W¤È 12:49:46²Ä 5797 ½g¦^À³
107Q4¤ä¥X¡÷2.14E (107¥þ¦~¹w­p¤ä¥X¡÷ 7.73E)

108Q1¤ä¥X¡÷4.64E

108Q2¤ä¥X¡÷6.04E

108Q3¤ä¥X¡÷3.18E

108Q4¤ä¥X¡÷3.61E (108¥þ¦~¹w­p¤ä¥X¡÷17.47E)

109Q1¤ä¥X¡÷3.99E

109Q2¤ä¥X¡÷4.14E

109Q3¤ä¥X¡÷4.30E

109Q4¤ä¥X¡÷4.58E (109¥þ¦~¹w­p¤ä¥X¡÷17.01E)

110Q1¤ä¥X¡÷3.70E

110Q2¤ä¥X¡÷3.64E

110Q3¤ä¥X¡÷3.59E

110Q4¤ä¥X¡÷3.65E (110¥þ¦~¹w­p¤ä¥X¡÷14.58E)

111Q1¤ä¥X¡÷2.38E

111Q2¤ä¥X¡÷2.42E (111¤W¥b¹w­p¤ä¥X¡÷ 4.80E)

109¦~¦¬¤J¡÷ 4.21E Àç§Q¡÷-19.06E

110¦~¦¬¤J¡÷ 27.22E Àç§Q¡÷ -1.19E

111¦~¦¬¤J¡÷ 95.22E Àç§Q¡÷+25.54E (Âà¬Õ)

112¦~¦¬¤J¡÷197.81E Àç§Q¡÷+46.66E

µù:¤£§tPV©ó¼Ú¬w¦a°Ï¤§¾P³f¦¬¤J¤ÎÅv§Qª÷¦¬¤J

¨Ì¤½¥q©Ò´£¨Ñ¸ê®Æ¡A±µ¤U¨Ó¤T¦~±Nªá±¼50E¡A110¦~¬ù²ö·l¯q¨â¥­¡A111¦~¶}©lÂà¬Õ

¼Ú¬w¨S¹w¦ô¡A¤£ª¾¹D¬O§_»PAOP¥òµô®×¦³Ãö?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/29 ¤W¤È 12:25:58²Ä 5796 ½g¦^À³
lee-sen¥S¡G

±z»¡ªº¨S¿ù¡A¦b¤U¦Ñ²´©üªá

¦b¦¹¦V¦U¦ì½ß¤£¬O¡C

¦ýµL½×¦p¦ó¡A2020¦~¦³¼Ú¬w¥H¥~4.2»õªºÀ禬

·Q¥²2019¦~¯à¦³FDAªº¦n®ø®§ªº¾÷²vÀ³¸Ó¤£§C¤~¬O

¤j¹Ù¤@°_ÀR«Ý¨Î­µ¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Glee-sen10145657  µoªí®É¶¡:2018/12/29 ¤W¤È 12:16:08²Ä 5795 ½g¦^À³
ªü½÷¥S»¡ªº¼Æ¦r¡AÀ³¸Ó¬O2021¡B2022¡B2023¦~¤~¹ï¡A2020¦~¹w¦ô¾P³f¦¬¤J¬O4.2»õ¡]¤£§t¼Ú¬w¡^¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/28 ¤U¤È 09:44:13²Ä 5794 ½g¦^À³
²{¼W¤½¶}»¡©ú®Ñ

¤½¥q¹ï2020¡B2021¡B2022¤T¦~ªºÀ禬¹w¦ô

¤À§O¬O27»õ¡B95»õ¤Î197»õ

¦Ó¥B¬O¤£§t¼Ú¬wªº¥«³õ

¬Ý¨Ó¤½¥q¹ï©ú¦~¥i¥H®³¨ìFDAªºÃÄÃÒ«D±`¦³«H¤ß

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/12/28 ¤U¤È 06:02:15²Ä 5793 ½g¦^À³
4)³Ìªñ¤­¦~¶}µo¦¨¥\¤§§Þ³N©Î²£«~

類§O ²£«~ ¾AÀ³¯g ¥Ø«e¶}µo¶¥¬q

¦å²G

P1101(·s¤@¥Nªø®Ä«¬¤z

ÂZ¯À)

¦Û¦æ¶}µo

¯u©Ê¬õ¦å²y¼W¥Í¯g

PV

•¼Ú¬w:107 ¦~ 12 ¤ëÀò±o¼Ú·ù¤HÅé¥ÎÃÄ©e­û·|

(CHMP)µ¹¤©±ÀÂˤW¥«³\¥i¤§¥¿­±·N¨£

•¬ü°ê:·Ç³Æ²Ä¤T´ÁÁ{§É¸ÕÅç(Phase III)¼Æ¾Ú¤å

¥ó¤Î¥Ó½ÐÃÄ«~¤W¥«¬dÅçµn°O(BLA)

•¥xÆW:·Ç³Æ¶i¦æ¾ô±µÁ{§É¸ÕÅç

•¤é¥»:¶i¦æ²Ä¤@´ÁÁ{§É¸ÕÅç(Phase I)

•¤¤°ê:¶i¦æ²Ä¤@´ÁÁ{§É¸ÕÅç(Phase I)

¦å¤pªO¼W¥Í¯g ET •¥þ²y:¥Ó½Ð²Ä¤T´ÁÁ{§É¸ÕÅç¼f¬d(IND)

PEG-EPO(ªø®Ä«¬¬õ¦å²y

¼Wªø¿E¯À)

¦Û¦æ¶}µo

µÇ¯f±w³h¦å¡BÀù¯g¤Æ

Àø³h¦å •«Øºc²Ó­M®è¤Î»sµ{¶}µo

PEG-GCSF(ªø®Ä«¬¥Õ¦å

²y¼Wªø¿E¯À)

¦Û¦æ¶}µo

Àù¯g¤ÆÀø¤Î·R´þ¯f

©Ò²£¥Í¤§¥Õ¦å²y§C

¤U¯g

•«Øºc²Ó­M®è¤Î»sµ{¶}µo

ºC©Ê

¨xª¢

P1101(·s¤@¥Nªø®Ä«¬¤z

ÂZ¯À)

¦Û¦æ¶}µo

B «¬¨xª¢ • ¥Ó½Ð²Ä¤T´ÁÁ{§É¸ÕÅç¼f¬d(IND)

C «¬¨xª¢ • ¶i¦æ²Ä¤T´ÁÁ{§É¸ÕÅç Phase III

B «¬¨xª¢+ C «¬¨xª¢ • ÀÀ¥Ó½Ð²Ä¤T´ÁÁ{§É¸ÕÅç¼f¬d(IND)

B «¬¨xª¢+ D «¬¨xª¢ • ÀÀ¥Ó½Ð²Ä¤G´ÁÁ{§É¸ÕÅç¼f¬d(IND)

¸~½F

¯e¯f

§Ü PD-1 §ÜÅé(§K¬ÌÀË

¬dÂI§í¨î¾¯)¦Û¦æ¶}µo Àù¯g • «Øºc²Ó­M®è¤Î»sµ{¶}µo

Oraxol® (¤fªAµµ§ü¾J)

±ÂÅv¶}µo ¨ÅÀù

• ¥xÆW:§¹¦¨¦w¥þ©Ê¾ô±µ¸ÕÅç

• «n¬ü¬w¡G¥Ñ¦X§@¹Ù¦ñ Athenex ¤½¥q©ó«n¬ü¬w

¶i¦æ¤HÅé²Ä¤T´ÁÁ{§É¸ÕÅ礤

¥Ö½§

¯e¯f

KX01(¿E酶§í¨î¾¯)

±ÂÅv¶}µo ¤û¥ÖÅ~ • ¥xÆW:¶i¦æ²Ä¤@´ÁÁ{§É¸ÕÅç Phase

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¤¤10143502  µoªí®É¶¡:2018/12/28 ¤U¤È 05:53:51²Ä 5792 ½g¦^À³
6446ªº²{ª÷¼W¸ê¤½¶}»¡©ú®Ñ(©|¥¼µ²®×ª©),

¤w¸g¥X¨Ó¼È©w160¤¸

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJoe10147646  µoªí®É¶¡:2018/12/28 ¤U¤È 01:10:26²Ä 5791 ½g¦^À³
¤µ¤Ñ¤¤¸Î¯E¹©¤Wº¦À³¸Ó¬O¦]¬°¦­¤W¤Q¤@ÂI¯Î±Ò´fÀò§PµL¸oªº½t¬G
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/28 ¤W¤È 11:52:08²Ä 5790 ½g¦^À³
¤¤¸Î ¸ò ¯E¹© ¨ì½u¦A¨â¤ä®t¤£¦h ¦Uº¦¥|¢H¥ª¥k¡@¡C¡C¡C¡C«Ü¬°¥L­Ì°ª¿³

¦ý¤]¬O·sÃĪº¼Æ¤@ÄݤGªº¡@ÃĵØÃÄ¡@«o¤@ÂI°ÊÀR³£¨S¡C¡C¡C¦n¤ï¤]¤@°_º¦¤@¨Ç§a¡@¯u©_©Ç

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2018/12/27 ¤U¤È 11:45:03²Ä 5789 ½g¦^À³
Dr Ruben Mesa: Interferons: a promising potential therapy for MPN: at video of 1¡¦30¡¦¡¦~ ¡¦¡¦...Interferon may lead the better outcome in five to ten years....¡¦¡¦

VJHemOnc ¡V Video Journal of Hematological Oncology

µo§G¤é´Á¡G2017¦~7¤ë28¤é

youtu.be/TUzSDQISwKk

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2018/12/27 ¤U¤È 10:51:44²Ä 5788 ½g¦^À³
µL²á¦æ±¡, ©Î³\¦b¨ä¥L¦a¤è¤w¸g¬Ý¹L, ­Y¬Ý¹Lªº´N·í§@¬O¨ú·x»P½Æ²ßÅo! Share.....

HU ¨Ï¥Î¦bMPN¼Æ¤Q¦~, NCCN guideline«o¦b2017¦~­º¦¸±NMPN ªvÀø¯Ç¤J....¨Ã´£¤Î¥ÌÂZ¯À...¬OÁͶծɶժº§Y®É§ó·s»P¯f¤HªºÁn­µ¶Ü?

1 NCCN guideline¬ü°ê°ê®a¼sªxÀù¯g¸ê°Tºôªº«ü¾É¤è°w§ó·s (¯Ç¤JMPN) ©óJuly/ 2017: www.nccn.org/about/news/newsinfo.aspx?NewsID=978; www.nccn.org/professionals/physician_gls/default.aspx#site

2 Clinical Advances in Hematology & Oncology (November 2017)

New Guidelines From the NCCN for Polycythemia Vera www.hematologyandoncology.net/archives/november-2017/new-guidelines-from-the-nccn-for-polycythemia-vera/

2.1 H&O: When was polycythemia vera added to the NCCN guidelines? (¦ó®É±N¬õ¦å²y¼W¥Í¨u¨£¯e¯f³Q¯Ç¤J¦bNCCN ¬ü°ê°ê®a¼sªxÀù¯g¸ê°Tºôªº«ü¾É¤è°w¸Ì­±?)

2.2 Dr. Ruben Mesa :The National Comprehensive Cancer Network (NCCN) added myeloproliferative neoplasms as a whole to the guidelines in the fall of 2016. Treatment guidelines for polycythemia vera were added in the summer of 2017. These guidelines were added to introduce greater uniformity in the diagnosis and treatment of polycythemia vera throughout the United States (2016¦~¬î¤Ñ¶}©l¯Ç¤JMPN³o¶µ¥Ø¨ìNCCN Guideline, ¦ý¬OMPNªºªvÀø¤è°w«h¬O¦b2017®L¤Ñ³Q¯Ç¤J. )

2.3 µ²½×: °£¤Fªì©l¥i¯à·|±Ä¥Î§C¾¯¶qªü¥q¤ÇªL©M©ñ¦å¤â³N, ¥H«O«ù§C©ó45% ªº¦å¤ñ®e­È¡K..

2.3.1 Cytoreductive therapy²Ó­MÁÙ­ìªvÀø¤§¤@½uªvÀø [ Interferon & HU]

[ Interferon & HU]: °ª­·ÀI±Ú¸s¥H¤Î§C­·ÀI±Ú¸s (¦³¦å²y¼Æ¤W¤É²{¶H¡B¹ïÀR¯ß¤Á¶}³N(©ñ¦å)¤£­@¨ü©Î¦³µÊ¸~¼W¥Í¶É¦V)

[ Interferon] Ãh¥¥©Î·Ç³ÆÃh°ü¤k, ¦~»´±wªÌ

Ropeginterferon §¹³ÓHU¤§«á, ±N¨Ó¤W¥««á, ·|¦³¦h¤Ö¯f±w¦]¦Ó¨ü´f? ³t«×? ¶â, ¥B¨«¥B¬Ý, ¤W¤Ñ«O¦ö¥xÆW¶¤¤§¥ú!

Note:

PV ±wªÌ:¦ô150,000 (USA):

Q3/2018 Incyte Finance ¤½§i: Jakafi ¨Ï¥Î¯f±wÁ`¤H¼Æ (Q3/2018): 4000+ (PV), 6500+ (MF)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/12/27 ¤U¤È 08:47:00²Ä 5787 ½g¦^À³
¥­¤ß¦Ó½×¡A­«¼C¤jblogªº¤å³¹¡Aºâ¬O©¾¹ê³¯­z·sÃĤ½¥q²Ä¤@­ÓÃÄÃÒ¨ú±o«á¡A©Ò»Ý­±¹ïªº¼h¼hÀËÅç¡C°Q½×¸s²Õ¸Ì¡A±`·|³´¤J¥H¤ù­±¸ê°T¶i¦æ°Q½×¦^À³¡A¦Ó°¾Â÷¤F­ì©l¤å³¹¡B³ø§iªº½×­z»P¤ÀªR¡C¥H³o­Ó¨Ò¤l¡A«h«Øij¦bµ¹¤©¦^À³«e¡A¥²¶·¥ý¬Ý¹L­«¼C¤jªº¡u§¹¾ã¡v½×­z»P§»»·§ëÅUªº¡u§¹¾ã¡v¬ã³ø¡C

µL½×¬O·sÃĪѩιq¤lªÑ¡A¥²µM³£¦³¦U¦Ûªº«e´ººÃ¼{»PÂø­µ¡A¦]¦¹¥ô¦óµû½×©Î¬ã³ø©Ò´£¥XªºÆ[¹î­±¦V¡A³£­È±o§ë¸ê¤H«ä¦Ò¡A¨Ì«ÈÆ[¸ê°T¶i¦æ¦Û§Ú½×­z»P§PÂ_¡A«ùÄò°lÂÜ»PÅçÃÒ¡C¨Ã¤£¬O·¥«×¬Ý¦nªºµû½×¡Bµ¹¤©°ª¥Ø¼Ð»ùªº¬ã³ø¡A¤~¥s°µ¡u¨S¦³°¾¨£¡v¡F¥u­n¤£±a¦³¡u¤Þ¾É¦¡´£°Ý»P³ø¾É¡vªºµû½×(¨Ò¦pGºô³¡¤À¤å³¹)¡A³£¨ã¦³¨ä°Ñ¦Ò»ù­È¡C

¦^¨ìÃĵتº°ò¥»­±¡A·í©ú¦~Q1¨ú±oEMAÃÄÃÒ«á¡A¥uºâ¬O¨ú±o¤F°ê»ÚÁɪº¡u¤W³õ¸ê®æ¡v¡A³õ¤Wªºªí²{»Ý­n¤@¨B¨B¾a·~ÁZ¨ÓÅçÃÒ¡C2019¦~¤W¥«­º¦~«×ªºÀ禬¶Õ¥²¤£¦h¡A¥BÀHµÛET»PB¨x¥þ²y¤T´ÁÁ{§Éªº±Ò°Ê¡A2019¦~«×ªº¡uÁ«·l¡vÀ³¸Ó·|ÂX¤j(¬Æ¦Ü¬O¾ú¥v³Ì¤j)¡A³o¬O²ßºD¥H¹q¤l·~¦¨¼ô´ÁEPS«äºûªº§ë¸ê¤H©Ò»Ý­n¥ý»{ª¾ªº¡A¤]¬O¬°¦ó·sÃĪѶ·­n¥H§é²{²{ª÷¬y(DCF)¨Ó¶i¦æµû»ù¡C¬Ý¨é°Ó¹ï·sÃĪѪº¬ã¨s³ø§i¡A¥Ø¼Ð»ù»Pµûµ¥¤Ï¦Ó³Ì¤£­«­n¡A³Ì¦³»ù­È¤§³B¦b©óÁA¸Ñ¤ÀªR®vªº°²³]»Pµû»ù¤èªk¡A±q¦Ó«Ø¥ß¦Û¤vªºµû»ù¨Ì¾Ú¡C

Incyte±q2013¦~¨ú±oJakafi²Ä¤@±iÃÄÃҦܤµ¡A¨C¦~«×ªºEPS³£¥u¦b·l¯q¨â¥­¤§¶¡¡A­ì¦]¬OIncyte±NJakafi³Ð³yªº¤jµ§À禬¡A¶W¹L¤»¦¨¦A§ë¤JJakafiÂX¥R¾AÀ³ÃÒÁ{§É»P¨ä¥L­Ô¿ïÃĪ«ªº¶}µo¡A³y´N²{¦bIncyte¤w¸g¬Opipeline¥þ¤è¦ìªº·sÃĤ½¥q¡AJakafiªº¾AÀ³¯g¤w±qMF,PV¨ì§Y±N®Ö­ãªºGVHD¡A»P¶i¤Jpivotalªº¯SÀ³©Ê¥Ö½§ª¢¡C

§Ú¤£´±»¡Ãĵدà¨B¤WIncyteªº¦¨´N¡A¥xÆWªº§ë¸ê¤H¤j·§µLªk§Ô¨üÁȤF¤jµ§¿ú¡A¤j³¡¤À¦A§ë¤J¬ãµo¦Ó¤£°t®§¡CÃĵØPV¼Ú¬w¦¨¥\¨úÃÒ«á¡A±µ¤U¨Ó­«ÂIÆ[¹î°£¤F¬ü°ê¨ó°Ó¶i«×¡A´N¬O¦p¦óµ½¥Î²Ä¤@±íª÷(ªì´ÁÁÙ¬O»Ý­n²{¼W)¨ÓÂX®i¾AÀ³¯g¡A¦bÃĪ«±M§Q´Á¤º¶}µo¥X³Ì¤jªº»ù­È¡A³o¹Lµ{°£¤F¾a¸gÀç¹Î¶¤ºë·Çªºµ¦²¤»P°õ¦æ¤O¡A¤]±oµøÃĵتºªÑªF­Ì¦³¦h°ªªº²´¬É¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/27 ¤U¤È 07:50:49²Ä 5786 ½g¦^À³
¤§«e¤j®a¾á¤ßªº²Ä¤@ª÷°ª¶¯

§Ú°O±o§Ú¦³¸ÑÄÀ¹L,

½Ð¤j®a¤£¥Î¾á¤ß

¥»¤ë¥L¶R¤F371±i

ºâ¬O¦³±¡¦³¸qªº

¨ä¹ê¹ï©óIPO¤§«e´N«ùªÑªº­ì©lªÑªF¨Ó»¡

«O«ù«ùªÑ³¡¦ìªº 10%~20% °ª½æ§C¶R

¨Ã¨S¦³Ô£¤£¹ï

²¦³º¤S¤£¬O¸gÀç¹Î¶¤

¤§«e¶^®É,¤j®a¤Ñ¤Ñ¨n³o®a¬Ý

»¡¬O¥D¤O½æªÑ²¼

²{¦b¥L¶R¤F¤@­Ó¤ë

¤]¨S¤H´£¨ì¥D¤O¶}©l¶RªÑ²¼

³o´N¬O§Ú¬Q¤Ñ´£¨ìªº

³o¨Ç¸ê°T¦³¦h¦³ªÅ

¤d¸U¤£­n

º¦®É¥u¬Ý§Q¦h

¶^®É¥u¬Ý§QªÅ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/27 ¤U¤È 05:42:54²Ä 5785 ½g¦^À³
®¥³ß°ê²¼-³Õ·R¬Q¤Ñ¶R¤µ¤Ñ½æÁÈ¿ú¡A¬Ý¬Ý§a³s³oºØ¤£¯à·í¨Rªº¤]¬O¤£¤Ö¤H¹j¤é¨R...
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/27 ¤U¤È 02:30:32²Ä 5784 ½g¦^À³
§ó¥¿¡G

À³¬° ¡uoff label use¡v

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/27 ¤U¤È 02:23:33²Ä 5783 ½g¦^À³
HU, Pegasys ¹ï©óPV ¬O ¡u¥é³æ¾AÀ³¯g¥~¥ÎÃÄ¡v

¤]´N¬O³q±`»¡ªºoff leabl use

¯uªº­n²ºÙªº¸Ü¡A¦Ü¤Ö¨Ï¥Î¡u¥é³æ¥~¥ÎÃÄ¡v³o¼Ëªº»¡ªk

¤ñ¸û¤£·|²V²c

¤@ÂI¤p¤p«Øij¤j®a°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/27 ¤U¤È 02:05:17²Ä 5782 ½g¦^À³
§Ú¦Û¤vªºÆ[ÂI»{¬°¦b¬ü°ê©Î¼Ú¬w¨ì®É­ÔÂå®v¤@¼Ë¤@¶}©lªì´Á¯gª¬´N¥ý¥Î©ñ¦å©ÎHUÀ£¤@À£¬Ý¬Ý¬O§_´N¨S¨Æ¤F¡C

¦pªG¤[¤F,À£¤£¦í¤F¦pªG¨S¦³µÊŦ¸~¤j¤~¶}©l¨Ï¥ÎBesremi¡C

¦³¤@¨Ç¬O²{¦b¥¿À£¤£¦íªº´N¬O²Ä¤@§å¨Ï¥Îªº±w¡C

¥H¬ü°ê¨ÓÁ¿,jakafi¨Ï¥ÎªÌ3000¤H±À¦ô,¤]³\¥¿»Ý­nBesremiªº¯f±w¤]¬O³o­Ó¼Æ¦r,¤]´N¬O3000¤H,¼Ú¬w¤]®t¤£¦h¡C

¥H¦¹±À¦ô¼Ú¬w¤@¦~ÁÈ4»õ,¬ü°ê¤@¦~¤]ÁÈ4»õ,¦Ó¥B³o¤]³\¬O2020©Î2021¤~¯à¹F¨ìªº¼Æ¦r¡C

³o¸Ì­±¦s¦b¤@­ÓÅܼƤ]¬O§Æ±æ,´N¬O·í«OÀI¥Ó½Ð³£µ¹¥I¤F«á,¬O§_Âå®v§¹¥þ¤£¦A¨Ï¥Î¥é³æÃĤF?¦pªG¯uªº¤£¦A¨Ï¥Î¥é³æÃĦӧï¥Î¨ãÃÄÃÒªº,¨º»ò³o¼Æ¦r¥i¥H¦A¥[¤Q­¿¡C

·íµM·Q¹³ªÅ¶¡ÁÙ¦³ET.MF,ÁÙ¦³¤é¥»¿D¬wÁú°ê¤j³°µ¥µ¥....ÁÙ¦³¬ü°ê¬O§_¦Û¤v¦æ¾P§Q¼í²v§ó°ª,¬O§_¶¶§Q¡C

§Ú²{¦b¬O­W¯ºªº,¨S¦³¥Í®ðªº»¡¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GChang252810146909  µoªí®É¶¡:2018/12/27 ¤U¤È 12:50:36²Ä 5781 ½g¦^À³
·PÁ­«¼C¤j¡A¤£¹L¨Ì§Ú¬Ý«Ü¦h¤å¨ä¹ê¤£¬O°w¹ï§A¡A¦ý´Á¦³ªÅ¦h¨Ó«ü±Ð!
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¨}¥²«L10147410  µoªí®É¶¡:2018/12/27 ¤U¤È 12:47:16²Ä 5780 ½g¦^À³
µo²{ªñ¨Ó¥xªÑ°µµu½uªº¤H¶V¨Ó¶V¦h¡A

¥H³oªiÃĵإX³õ¤£¤Ö¡A¤]¦³¶i³õ¤p¶q§C¶Rªº

¦³®É­ÔªÑ²¼¥u­n«e´º¬O¬Ý¦nªº¡A¦ó¥²°õµÛµu´Áªº°_¥ñ

ÃĵحӤH¤]ªø´Á«ù¦³«Ü¦h¦~¤F¡A

ÃĵطsÃĶ}µo¤]¶W¹L¤Q¦~¤F¡A¥¿­nÁÚ¦V¶}ªáµ²ªG¤§®É

´N¦n¹³¥q°¨Åt¡u¤Q¦~¿i¤@¼C¡A¤@¼C©w¦¿¤s¡v

¥q°¨Åt¦b¡§ªÅ«°­p¡¨¤¤¦³´X¥y¡G

1¡B¤£¨D³Ì¦n¡A¦ý¨Dº¡·N;

2¡BµL®¬ªº¿ï¾Ü¬O¦nªº¿ï¾Ü;

3¡Bµ´¤£±¼¤J§O¤H·Ç³Æ¦nªº¿ï¶µùØ¡C

¤H³o¤@½ú¤l¡A¶¶­·¶¶¤ôªº®É­Ô°ªºq²r¶i¡A¨º³£¤£ºâ¥»¨Æ¡A

°f­·°f¤ô¡A¨«­I¦rªº®É­Ô¡A¯à¤ßºA¥¿±`¡A§ä·Ç¥X¸ô¡A

Á{¦M¤£¶Ã¡A³o¤~¥s¥»¨Æ¡C

¤°»ò§ëÅU¥~¸ê¥Ø¼Ð»ù©Î³ø§i¤§Ãþªº©ÎªÌºô¸ô½×¾Â

¡A¥u­n°Ñ¦Ò´N¦n¡A³Ì¥D­nÁÙ¬O¦Û¤v¦h°µ¥\½Ò

¤£­n¤H¤ª¥ç¤ª¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/27 ¤U¤È 12:30:52²Ä 5779 ½g¦^À³
§¡½u¤S¶}©lªÈµ²¤F¡A·Pı­n½Ä¤F¡A¤w¬Y­Ó§Þ³N½×ÂI¨Ó»¡
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/27 ¤U¤È 12:17:52²Ä 5778 ½g¦^À³
¤w¤µ¤Ñ³o¼Ëªº¶q·Pı´N¥u¬O´²¤á¦b¶i¥X¡Aªk¤H¶i³õ¤£¤Ó¥i¯à¥u¦³¨â¦Ê¦h±i
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Glee-sen10145657  µoªí®É¶¡:2018/12/27 ¤U¤È 12:13:12²Ä 5777 ½g¦^À³
·PÁ­«¼C¥S¥x»¡©ú¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/27 ¤U¤È 12:09:06²Ä 5776 ½g¦^À³
¤jº¦µL¶q¡A¬Ý¬Ý´N¦n¡A¦Ó¥B¬Ýªº¥X¦³¨Ç§ë¾÷ªÌ¡Aµu½uªÌ¡AºCºC¦bÂ÷³õ¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­«¼CµL¾W10030199  µoªí®É¶¡:2018/12/27 ¤W¤È 11:23:32²Ä 5775 ½g¦^À³
2018.12.27

§Ú´N¦A¯}¨Ò¦^ÂФ@¨Ç§a¡A¥»·N¬Oµ½©À¡AµL©`Å¥ªÌ°õ©À«Ü²`¡C

§Ú¤£·|¤@ª½¦^ÂСA§_«h¥´µ§¾Ô¡A¨S§¹¨S¤F¡C

³o¤]¬Owhy §Ú¤£µo¤å ¡A¤£­ãcopy±i¶K ©ó ¥²´Iºô¡A ¦]¬°·| §n½¤Ñ¡C

(1) Russell ¥S¥x¡A ¡§¤@°ï§Ì§Ì³£¦ô¤£·Çªº¤H¡¨

¡÷ §Ú¤£­n¹ï¸¹¤J®y¡A©Î³\¤£¬O»¡§Ú§a¡C ¦ý¤¤¸Î7¤ë ¡÷ 11¤ëªºÀ禬¡A§Ú½T¹ê¬O ¡§´£«e¤@©u¡¨ ´N¦ôº¡·Çªº¡A ¨C¤ë¬Û®t¡A¤£¨ì200¸UNTD¡C ©Ò¥H§Ú«üªº ¡§boomingºC¡¨ ¤£¬O¥u°w¹ï ÃĵØÃÄ¡A ¨ä¥¦ªº ¤¤¸Î¡B´¼Àº¡B¡B¡B ³£¤@¼Ëªº¡C

¡§¤@¸s¤H©é©R·Q§âÃĵؽò¦b¸}©³¡¨

¡÷ ¤@©w¤£¬O»¡§Ú°Õ¡A §Ú¦b Blog ©ú¤å»¡¡A§Æ±æÃĵدà 400¤¸¡A600¤¸¡C

«h¥i¥H±a°Ê¥Í§Þ¸s¡C (¸Ó¤£·|¤S»{¬°¬O ¡§»¡¤Ï¸Ü¡¨ §a ? )

(2)lee-sen ¥S¥x : ¡§¨Ó­ÓÅÞ¿èÃD¡G¤@ÁûÃĦpªG¦ô­p¥u¯à½æ10»õ¥x¹ô¤£¨ì¡¨

¡÷ «D¤]¡A10»õ¥x¹ô¤~¥u¦³ 0.34»õ¬üª÷¡A Besremi ªº¾P°âÃB¡Aµ´¹ï»·»·»·»·°ª©ó 0.33»õ¼Æ­¿¡A10­¿ªº¡C

(3)°±¤î©I§l¥S¥x : Gºô ©M ­«¼C¤j ³£¥Î³ÌÄY®æ§âÃö

¡÷ «D¤]¡AGºô §Ú¤£µû½×¡C ¦Ü©óÂI¦W¨ì ­«¼C¡A

§Ú­«¥Ó100¦¸ºô¤Í¤]Å¥¤£¶i¥h : ¬O½×­z¤@­Ó ¥xÆW·sÃÄÃþªÑ³£¾A¥Î¡A·|¹J¨ìªº¡C

¤¤¸Î¡B´¼Àº¡B¡B¡B¬ÒµM¡C ÃĵØÃĤ] Ãø¥HÁקK¡C

³o¼Ëºâ¬O ­«¼C¤j³£¥Î ¡§³ÌÄY®æ§âÃö¡¨ ? «D¤] «D¤]

(4) °e³øªº ¥S¥x : ¡§³o®Ú¥»´N¬OµÛ±a°¾¨£ªº·¥¥ª³ø§i¡¨

¡÷ ©Ò¥H¦P¤@¥÷³ø§i¡A¤£¦P¤H¬Ý¡A·P·Q ¤Ñ®t¦a»· ­C !

¥H§Ú¬Ý¨ìªº¡A³o¥÷³ø§i¹ï ÃĵØÃÄ¡A¬O ¡§¥¿­±¡¨ ¥B ¡§µ½·N¡¨ ªº¡Aµûµ¥¤]¬O ¡§¶R¶i¡¨

Besremi ¾P°âÃB¬O¦ô 10»õ¬üª÷ ! (300»õ¥x¹ô! )

(¦ô±o¤ñ¤¤¸Î¡A°ª«Ü¦h )

«ç»òÅܦ¨ : ¡§·¥¥ª³ø§i¡¨ ?

¤@¤Áªº ¡§ª§½×¡¨ ¥i¯à¥u¦b : 2019¦~¡A§Ú­Ì»{¬° booming³t«×¨S¨º»ò§Ö¡A

¤@¨ÇÃĵؤä«ùªÌ¡A»{¬° 2019¦~´N¥i¥H¤j¤j¤j¤j booming §a !

(5)§Ú¦A±j½Õ¡AÁ¿¬O boomingªº³t«× : ¡§¥xÆW¡¨ ·sÃÄÃþªÑ¬Ò¾A¥Î¤]¡C

§Ú±q¨Ó¨S¦³ ¤£¦Û¶q¤Oªº¥h§åµû : ÃĪ«¤£¦n¨SÄvª§¤O or peak sale §C¸¨¡C

ÃÄµØ : ±q¼Ú¬w µÛ¤â ¡÷ ªñ30­Ó°ê®a¡A¥BEMAºÞ²zÃÄ»ù ¡÷ ¥»¨Óbooming ´N¸û¬ü°ê¥«³õºC¡C (¦³ºô¤Í­n¤Ï»é³o¤@ÂI¶Ü? )

¬ü°ê ¡÷ ¥Ø«eÃĵØÀÀ¦Û¦æ¾P°â(???) ¡÷ ¥xÆW¤p¤½¥q¡A­Y­n¦Û¦æ¥´¬ü°ê¥«³õ¡A¥»¨Ó´N¬O§xÃø¡C ¤£³æ·sÃÄ¡A¬Æ¦Ü¹q¤lACER ¡BHTC¡B¡B¡B³£¬O§xÃøªº¡C (¦³ºô¤Í­n¤Ï»é³o¤@ÂI¶Ü ? )

¹ï©Ò¦³·sÃĪѬҾA¥Î¡A«ç»ò¤@ª½­n¾É¦V ¡§¹ïÃĵØÃÄ ¤£¤Íµ½¡¨ ?

®Æ¼Ä±qÄY ¿m¼Ä±q¼e

¯E¹©¡B¤¤¸Î¡BÃĵءB¡B¡B¡Bµ¥²³¦h¥Í§ÞªÑ¬ÒµM¤]¡C §Ú¨S¦³¿W«p¤¤¸Î(??)¡A¦Ü¤Ö§Ú¦Û¤vªº¬ã¨s¡A¤@ª½¦b¬D¤¤¸Îªº¤ò¯f¤]¡C

¯E¹© : ·í®Éªº¤@±ì¶i¬}¨úÃĵý¡A§Ú¤]¤£¥H¬°µM¡C

¤¤¸Î : ·í®ÉªºBTDª½®³ÃÄ¥¿¡A§Ú¤]¤£¥H¬°µM¡C ÃÄ»ù¥¼¤½§i«e¡A§Ú¤]¥u±Ä 5¸UÁâ¥h¦ô¡C

¤Ñ©Rºô¤Í¦b§j±·¨C­Ó¤ë¦h500¤H®É¡A§Ú¤]¤£¥H¬°µM¡C (©Ò¥H°k¹L¤@§T)

§Ú¤]¨S¦³¤@´[±¡Ä@»{¬° ¤¤¸Îªº¾P°â¤@©w¦n¡C

¥h¬Ýn ½gªº¤å³¹¡A§Ú¤@ª½±j½Õ : ¤£¤U©w½×¡A­nµ¥2019¦~1Q 2Q 3Q ªºÀ禬¥X¨Ó¡C

®Æ¼Ä±qÄY ¿m¼Ä±q¼e

¤ß¥­®ð©Mªº¥h¬Ý ³ø§ior½×­z

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2018/12/27 ¤W¤È 09:45:49²Ä 5774 ½g¦^À³
¦pªG¯uªº³o»ò¨S»ù­È,¨ºªá¤j¿ú¤w±Ò¥Îªº°w¾¯¼t¬Ý¨ÓÀ³¸Ó¥ý¥Î¨Ó¥Í²£¶¼®Æ¥R¤@¤UÀ禬¤F...
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°±¤î©I§l10142179  µoªí®É¶¡:2018/12/27 ¤W¤È 09:43:52²Ä 5773 ½g¦^À³
´«­Ó¨¤«×·Q

ÃĵØÃļڬwÃÄÃÒ¶V±ß¹L¶V¦n¡I¦n¦n¾Q³¯¹D¸ô~

¤Ï¥¿³£¹LÃö¤F~¶X¦¹®É¥´³q³q¸ô¡A¬ü°êÃÄÃÒ~´NÅý¼Ú¬w¥ÎÃĤ@¬q®É¶¡~¦n¦n¥´ÅT¦W®ð~¤Ï¥¿ÃĵطQ¿W½æ~´NÅý¬ü°ê¤Hµ¥§a~¤j®a«æµÛ·Q¥ÎÃÄ¡A¦ÛµM´N¶¶§Q¥´³q¸ô~~¹LÃö«á¤S¦³®É¶¡¤W«OÅ@~Ãĵتºµ¦²¤À³¸Ó¬O³o»ò·Qªº§a¡I­Ó¤Hı±o¤ñ¤¤¸Î¤@¤U¥u¬ü°ê¡B¼Ú¬wµuµu®É¶¡¤@°_¹L~ÁÙ¨Ó¤£¤Î¥´³q³q¸ô~®ö¶O«OÅ@¿W½æªº®É¶¡¡AÃĵؤ@½u¥ÎÃÄ~¤S°ß¤@¥ÎÃÄ¡A¤pªL¤j»¡ªº«Ü¹ï~´«°µ§A¬OÂå°|§A§Æ±æ¦Û¤vÂå¥Í¿ï¾Ü«K©yªºÃÄÁÙ¬OÀ~¦º¤H°ª¤ò§Q¡BÃĮĤS¦n°Æ§@¥Î¤S¤ÖªºÃÄ~¦Û¤v®a¤Hªá¤@¦Ê¦h¸U±Ï¦Û¤v¿Ë¤H¡Aªp¥B¤S¦³«OÀI¤v¥I~§A±Ï¤£±Ï¡AGºô©M­«¼C¤j³£¥Î³ÌÄY®æ§âÃö¡A¨ä¹ê¤]¤£¿ù~¦n¦nÅý¨S«H¤ßªº¤H¤U¨®¡A¥~°ê¹LÃö³£¤jº¦~§Ú­Ì¹LÃö³£¤j¶^~¬O¬G·NÅý¤j¼t¨Ó¦¬Áʤ½¥q¶Ü?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Glee-sen10145657  µoªí®É¶¡:2018/12/27 ¤W¤È 09:25:06²Ä 5772 ½g¦^À³
¨Ó­ÓÅÞ¿èÃD¡G¤@ÁûÃĦpªG¦ô­p¥u¯à½æ10»õ¥x¹ô¤£¨ì¡I

AOP¡BÃĵØÃÄ·|¤j¶O©P³¹¡Aªá¿úªá®É¶¡¥h°ê»Ú¥òµô¡I

¥hª§¨ú2%ªº§Q¯q¡I10»õNTªº2%,¤~2000¸UNT¡I

¦³¥²­n¶Ü¡H¦³¥²­n¶Ü¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/12/27 ¤W¤È 08:22:37²Ä 5771 ½g¦^À³
¤@°ï¦ô§Ì§Ì³£¦ô¤£·Çªº¤H

Á¿¤°»ò¡A«Ü­«­n¶Ü¡H

§Ì§Ì¤W¥««e§â¥¦±·¤W¤F¤Ñ¡Aµ²ªG«¨¡I

Á`ı±o¦³¤@¸s¤H¡A©é©Rªº·Q§âÃĵؽò¦b¸}©³

¨s³º¬O¬°¤F¤°»ò©O¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gª£¦Ì¯»10146792  µoªí®É¶¡:2018/12/27 ¤W¤È 05:11:07²Ä 5770 ½g¦^À³
¦Û²Ä¤T´ÁÃĮijQ¥¿­±ªÖ©w¥H¨Ó¬ü°ê¥Í§Þ«ü¼Æ¤@ª½©¹¤U³e±þ¡A¤µ¤Ñ¤jº¦¤§«á¡A·sÃĪÑÀ³¸Ó·|¦A¦¸¨üÆf¥Ø¡A¦¬¬B³o´X¤Ñ¤U¶^ªº´e®ð¡A´Á«Ý¨C­Ó©ú¤Ñ§a
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2018/12/27 ¤W¤È 01:34:13²Ä 5769 ½g¦^À³
³o®Ú¥»´N¬OµÛ±a°¾¨£ªº·¥¥ª³ø§i.AOP¤£¬O«Xù´µªº¤½¥q­n¨ì¼Ú¬w½æÃÄ.¬O·í¦a§G§½¤w¤[ªº¦ÑµP¤½¥q..

2Q19´Nºâ¤F.¨ì4Q19 º¯³z²v¤£¨ì1%(¥Ø¼Ð¯f±w80000¤H­p)..

¹ï©ó¤@­Ó°ß¤@³\¥iªº¤@½u¥ÎÃÄ..

±z¦Ñı±o³o¼Ëªº³ø§i¥i«H¶Ü??

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gmtalps200110147181  µoªí®É¶¡:2018/12/27 ¤W¤È 12:35:51²Ä 5768 ½g¦^À³
­Y¥H10%ªº¤À¦¨¤Ï±À¦^¥h¡C

¨ºAOPªº¹w¦ôÀç·~ÃB¬°¦h¤Ö¡H¬O§_©MÃҨ餽¥qªº¹w¦ô¨«¶Õ¬Ûªñ¡H

AOP¬O±M·~©t¨àÃĪº¼t°Ó¡A©Ò¥H¤@©w¤ñ§Ú­Ì³o¨Ç´²¤á§ó²M·¡³o¤äÃĪºÀò§Q¦±½u¡C

¦pªG¬O¤@­Ó¥¢±Ñªº¥«³õ©Î¬OÀò§Q¦±½u½wºC¡AAOPÀ³¸Ó·|¤ñ§Ú­Ì§ó¼f·V¤~¬O¡C

´dÆ[°²³]¡G©Ò¥HAOP¤~»Ý­n¼Ú¬w¥H¥~ªº¥«³õ¨Ó¤À¾á­·ÀI??

¼ÖÆ[°²³]¡GAOP·Q§â¤J¤fªºªÎ¦×¡A¾ã¸J±·¨«¡H¡H

­l¥Í¥t¥~ªº°ÝÃD¡H

¬°¤°»ò»Ý­nµo®iÀu¤Æªº»sµ{¡H¬O­ì¥ý»sµ{ªº¦¨¥»¹L°ªµLªkÀò§Q¡H

ÁÙ¬O§Þ³Nºt¶i§ä¨ì§ó¦nªº¥Í²£¤è¦¡¡H

¦hªÅ¨«¦V³£¦³¤H¦bÃöª`¡C´N¬Ý¦Û¤vªº¨M©w¡C

¬Ý¦hªº¥i¥H§ä¾÷·|¥[½X¡A¬ÝªÅªº¤]¥i¥H§ä¾÷·|¤U¨®¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/27 ¤W¤È 12:00:13²Ä 5767 ½g¦^À³
µLµß®ñ¤j³Á«è¹ÄÅo,

¦bP1101Á{§ÉÀø®Ä§¹³ÓHU«á,¬Æ¦Ü¦³ªv¡±wªÌªº¥i¯à,

¨º¨Ç¥u·|¥H²Ä4½u³Ì¥½½uÃĪ«ªº¯U¹i²´¬É¨Ó¬Ý«Ý²Ä¤@½uÃĪ«,¤£³×¬O¥HºÞ¿s¤Ñ.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/26 ¤U¤È 11:59:36²Ä 5766 ½g¦^À³
www.mobile01.com/topicdetail.php?f=291&t=4919602&p=12

¹ïPV¯f±w¦Ó¨¥¡BÁöµMHU«K©y¡A¦ý¦]§ÜÃĩʸò°Æ§@¥Î¡AHU³s¤G½u¥ÎÃij£¤£ºâ¡A¥u¯à§@¥é³æ¥ÎÃÄ¡C

¦ý¤@¨Ó®e©ö¦³ªÈ¯É....¤G¨ÓÅܦ¨MF...­n¦Y§ó¶QªºJakafi¡C

=======================================================================

¦pªG±Ë±ó¥¿³Wªº¦nÃĤ£¥Î¦Ó¹ç¨Ï¥Î¥é³æ¥ÎÃÄ,¨º¯u¬OFDAªº´d«s!

¦pªG¦U¦ì¬Ý­¾¦³PV¯g,¤@©w­n°O±o­n¨DÂå®v¨Ï¥Î¦nªºÃÄ,¦]¬°¥Î¦nªºÃĤ~¦³¾÷·|®Úªv¡C

¤£­n³à¥¢¦Û¤vªºÅv¯q,¦P®É¤]­n­n¨D°·«O§½¯Ç¤Jµ¹¥I¡C

°²¦p¦U¦ì¬Ý­¾¦³¦å²G¬ìªºÂå®v,¦³¤@½uÃÄ´N¤£­n¨Ï¥Î¥é³æÃÄ¥H§K¦³ÂåÀøªÈ¯É¤~¬O¡C

§Ú²{¦b¬O­W¯ºªº,¨S¦³¥Í®ðªº¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/26 ¤U¤È 11:39:15²Ä 5765 ½g¦^À³
www.chinatimes.com/realtimenews/20180109003490-260410

¦b¬ü°ê¡A¨Ï¥Î²Ä¤G½u¥ÎÃÄ Jakafi ªº PV ¯f±w¬ù¦³ªñ3,000¤H¡A¦~¾P°â¤w¹F4»õ¬ü¤¸¡C

®Ú¾ÚÃĵظu¥Î¬ü°êÅU°Ý¤½¥q©Ò°µªº¥«³õ¬ã½Õ¡A¥H Ropeg ¥Ø«eªºÁ{§É³]­p¡A¥iÀ³¥Î©ó²Ä¤@½u¥ÎÃĪºPV¯f±w¡A¥Ø«e¦³±µ¨üªvÀøªº¯f±w¤wªñ8¸U¤H¡A¨ä¤¤¥]¬A¦³¬ù 1 ¸U¦h¤H¨Ï¥Î¶Ç²Î¤zÂZ¯À©Î Pegasys¡A¤Î¶W¹L5¸U¤H¨Ï¥ÎHU¡C

================================================================================

®z¤ô¤T¤d¡A¥u¨ú¤@¿]¶¼¤]¦nÃø³á........

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/26 ¤U¤È 11:32:38²Ä 5764 ½g¦^À³
www.tfrd.org.tw/tfrd/library_d/content/id/1356

PV¦b¬ü°ê¯f¤H¼Æ¦ô­p¬ù¦³15¸U¤H¡B¼Ú¬w¯f¤H¼Æªñ¹F20¸U¤H,

«ç»ò¦ô¨£¤H¨£´¼,®t²§·|¬Û·í¤j¡C¥u¯àµ¥®É¶¡¨ÓÃÒ©ú¤F¡C

°²¦p¨â¦~¤º¼Ú¬ü¥¼¹F5%ªº¤H¨Ï¥Î,¨º¯uªº¬O¥¢±Ñªº§@«~¡C

¼Ú¬w´NÄ~Äò©ñ¥L­Ìªº¦å,¬ü°ê´NÄ~Äò¥ÎHU¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/26 ¤U¤È 11:19:14²Ä 5763 ½g¦^À³
§Ú­W¯ºªº¡A¨S¦³¥Í®ðªºÂ½Ä¶¤@¤U:·q½Ð«ü¥¿¡C

2019¦~2Q:84¤H,

3Q:312¤H,

4Q:484¤H¡C

¤]¬O¦³¥i¯à°Õ!¥u¬O³o¼Ë¼Ú¬w­n¨ì20000¤H¨Ï¥Î­n¦n¤[§r!

¬°¤°»ò»¡20000¤H?¦]¬°³o¼Ë¤~¯àÁȨì¤ñ¸û¹³¼Ëªº¼Æ¦r¡C

¦pªG¯à¥[¤J¬ü°ê´N¦n¤F¡C

¤@¤Á­nµ¥¨ì¨ú±oÃÄÃÒ,¶i¤J¦U°ê,ñ§¹«OÀI¤~¯à¶}©lÃÒ©ú¡C

ºÝ¬Ý¼Ú¬wªºÂå®vÄ~Äò¹ê¬I©ñ¦å©Î§ï¥Î³o­ÓÃÄ¡C

©ñ¦å©ñ¨ì«á¨Ó©O?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/26 ¤U¤È 11:02:14²Ä 5762 ½g¦^À³
¤£¦n·N«ä,¬O¯u¨S¬Ý¨ì±zªºBLOG¦³©ú¤å[¤£¥i¥H±N¤å³¹¶K©ó¥²´Iºô],

¦³¿³½ìªÌ§»»·ªºÃĵجã¨s³ø§i½Ð¦Û¦æ¨ì­«¼CBLOGÂI¾\!

¸Ñ¹aÁÙ»Ýô¹a¤H,³Ò½Ðª©¥D±N¤U¤å§R°£¤F,ÁÂÁÂ~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G­«¼CµL¾W10030199  µoªí®É¶¡:2018/12/26 ¤U¤È 10:46:55²Ä 5761 ½g¦^À³
<§i¥Ü¤å >

§Ú­W¯ºªº¡A¨S¦³¥Í®ðªº¡A·Ð½Ð ¥²´Iºôª©¥D¡AROGER5889¡A §R°£ :

(1)¦¹§i¥Ü¤å

(2)ROGER5889ªº COPY ¶K¤å¡C

ROGER5889¥S¥xÀ³¸Ó¬O²¨©¿¨S¦³¬Ý¨ì¡A§Ú¤£©Ç¸o¡C §ÚªºBLOG¦³©ú¤å¡A¤£¥i¥H±N¤å³¹¶K©ó ¥²´Iºô ¡A¤£¬O¦]¬°¤£°ª¿³¡A³æ¯Â¤£·Q®{¼W ¯ÉÂZ¤]¡C ª´ºÀ¡B¦Ê¦X¡B­[²ú¡B¡B¡B¡A¦U¦³°õµÛ³ß·R¤§¤H¡C §Ú¥u¦b¦Û¤vªº BLOG §çµo¡A¤«¤ô¤£¥Çªe¤ô¤]¡C

¤S¡A¤W­zªº ÃĵØÃÄ À禬¡A¨Ã«D§Úªº¹w¦ô­È¡A ¤£­n»~¸Ñ¡C

¦Ü¤µ§Ú§¹¥þ¨S¦³¦ô­p ÃĵتºÀ禬¡C

§Ú©Ò¿×ªº Ãþ¦ü ¡A¶È¤î©ó : ÃĵØÃÄ ( EX: Àò¨úÃĵý²Ä¤@¦~ 2019 )¡AÀ禬 ·|¤ñ¤¤¸ÎºC¡C

§Ú¨Ã¨S¦³¦ôºâ¥ô¦ó¼Æ¦r¡C ¤£­n»~¸Ñ¡C

¤é«á¡A½Ð¤£­n±N§Úªº¤å³¹¡ACOPY Âà¶K©ó ¥²´Iºô¡A ¥H§K®{¼W¯ÉÂZ¡C

­Y¶KÁpµ²¡Aºô¤Í¦Û¦æ¥h BLOG Æ[¬Ý¡A §Ú¨S¦³·N¨£¡C

( §Ú¥u¦b¦Û¤vªº BLOG §çµo¡A¤«¤ô¤£¥Çªe¤ô¤] )

§Ú­W¯ºªº¡A¨S¦³¥Í®ðªº¡A·Ð½Ð ¥²´Iºôª©¥D¡AROGER5889¡A §R°£ :

(1)¦¹§i¥Ü¤å

(2)ROGER5889ªº COPY ¶K¤å¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/12/26 ¤U¤È 08:53:15²Ä 5760 ½g¦^À³
¥þ²y¥D­nªÑ¥«³£¦b±YÃaªº¸`«µ¡A¤W¤£¥h¤]¥¿±`¡A¥¼¨Ó¯uªº¥u¯à¦b160-180¾ã²z´N¤£¿ù¤F¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/26 ¤U¤È 01:17:35²Ä 5759 ½g¦^À³
¤£ºÞ¬O¤j½LÁÙ¬O­ÓªÑ...§Ú·Pıªº¥X¨Ó¤j¦h§ë¸ê¤H³£¨S«H¤ß¡A°£¤F¦³¨ÇÁÙ¦bª£§@ªºªÑÁ٫ܬ¡µ¸¡A¨ä¥L¸ò¥»³£µL¶q
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/12/26 ¤U¤È 01:04:10²Ä 5758 ½g¦^À³
ªñ´Á´N¬O¤j°Ï¶¡¤º¾_Àú

Ãi±o¶}Äw½XK¡A²Ê§ì¤@¤U»ù®æ¡A160~200

²{¼W®×ªñ§ÀÁn¤ÎFDA½T»{PV§K°µ¤T´Á¤§«á¡A¤~¤ñ¸û·|¦³©¹¤W¬ð¯}¨ì200¥H¤Wªº°Ï¶¡

ÁöµM­Ó¤H¨Ì¾Ú¤½¥q·s»D½Z¤Îª©¤W¦U±M·~¤j¤j©Ò¤À¨Éªº¸ê°T¡A»{¬°¬O§K°µ¤T´Á

¦ý¦]¥«³õ¤W»{¬°ÅܼƤ´¦b¡A©Ò¥H¦¨¥æ¶q«Ü¤p¡A¦ý¶q¤p¾A¦XªÑ»ù¾ã²z¡A¨S¤°»ò¤£¦n

«¬ºA¤W¡A²{¦b¦]¬°¶q¤p¡A¥i¤ÀªR¸ê°T¸û¤£¨¬¡A¬Ý¨ì¬ð¯}§¡½uªº¬õ¶ÂK¡A¨ä¹ê³£ªñµu½uÂà§é

2018/6/25¬ð¯}3/13«e°ª¡AÀH«á¤]¬OÀ£¦^

2018/8/22±a¶q¤¤ªø¬õ¡A¹j¤Ñ¦¬ªø¤W¼v½u«á¤]¬O¶i¤J¾ã²z

2018/10/11±a¶q¤j¶ÂK¯}½u¡A¶^¯}8­Ó¤ëªº¾ã²z°Ï¶¡¡A¦ü¥G¦³ÀY³¡¸ñ¶H¡Aµ²ªG¹j¤Ñ´N¨£³Ì§C

¤£¨ì¤@­Ó¤ë¤S¯¸¤W160¥H¤W°Ï¶¡¡A¦Ó¥B¬O¦b¶q«Ü¤pªº±¡ªp¤U¯¸¤W

¥H¤W³£¬O¬Ý¹Ï»¡¬G¨Æ¡A¨þ¨þ

­Ó¤H¬Oªø§ë¡A©Ò¥H¤£¦b·N³o¨Çµu½uº¦¶^

¤Ï­Ë¬O¦³¶^¸¨­Ó¤H³]©wªº°Ï¶¡¤º¡A·|¦A¦ø¾÷¥[½X

¥H¤W°Ñ¦Ò~~

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gmtalps200110147181  µoªí®É¶¡:2018/12/26 ¤U¤È 12:01:23²Ä 5757 ½g¦^À³
³¥¤HÄmÃn¤@¤U¡G

1. Äw½X¥æ´«¼Æ¥Nªí¨C±iªÑ²¼ªº»ù®æ¡A¬OÄw½X¶°¤¤«×ªº¦nÀ°¤â¡A¦ý¬O¤]¦³§½­­©Ê¡C

2. ¹L¥h¤@¦~¨«°Ï¶¡¾_Àú¡A­Ó¤H°²³]«ù¦³¶W¹L¤@¦~ªºÄw½X¬O¦w©wÄw½X¡A©Ò¥H¨ú¹L¥h¤@¦~ªº¥æ´«¶q¡C

3. ¥æ´«¶q¤j¡A¥Nªí³o­Ó¦¨¥»»ù¦ì±aªº±i¼Æ¦h¡A¤]¬O»ù®æªº¤ä¼µ©ÎÀ£¤O»ù¦ì©Ò¦b¡C

4. ±q¥æ´«¶q¨Ó¬Ý¡A¥h¦~©³¶}©l©¹¤W©Ôªº¹Lµ{¡A³Ì¤jªº´«¤â¶q¦b168.¦Ó¹L¥h¤@¦~¤]¶È10¤ë©³¤j¶^®Éµu¼È¶^¯}¡C©Ò¥H³o­Ó¤ä¼µªº¤O¹D«Ü±j¤j¡C­Ó¤H²q·Q½äÃÄÃÒªº¤¤¹ê¤á«ù¦³¦¨¥»¤]¦b³o­Ó»ù¦ìªþªñ¡C

5. ¹L¥h¤@¦~ªº©¹¤Uªº­Ó¤ä¼µ»ù¦ì¬O162.5¡A¦ý¬O¶q¥u¦³168ªº¤@¥b¡C¤@¥¹»ù®æ§C©ó168¤¤¹ê¤á¶}©l°±·l½æ¥X¡A»ù®æ´N·|¤@¸ô©¹¤U¡C¬Ý¶q¯àªºÅܤơA³ÌÁVªºª¬ªp¬O150¡C

6. ©¹¤WªºÀ£¤O°Ï¬O180.5¡A­Ó¤H¥H¬°³o°}¤l½æ¥XªºÀ³¸Ó¬O¦¨¥»¦b³o­Ó»ù¦ì±a¥ª¥kªº«ù¦³¦¨¥»¡C¥H¥Ø«eªºª¬ªp¨Ó¬Ý¡A°£¤F¾Þ½L¤â¡A»ù®æ¬O«ÜÃø¦A©Ô¤W180.

==================================================================================

¤pµ²¡G

1. ·|¬Ý¤£¥Nªí·|¶R¡A¤p§ÌÁÙ®M¦b¤µ¦~6¤ë©³ªº°ªÂI¡AÀqÀqµ¥«Ý¾Þ½L¤âªº±Ï´©¡C

2. ³o´X¤Ñªº¨«¶Õ¡A·Pı¾Þ½L¤â¬O¥ð°²©ÎªÌ´«¤â¤F¡H ¦pªG¬O«áªÌ¡A¨º·|¤£·|¶}±Ò¶³¾]­¸¨®¼Ò¦¡¡A´Nµ¥®É¶¡ÃÒ©ú¤F¡C

3. ¤p§Ì¤£¤ÓÀ´³o®É­Ô¼W¸êªº¼vÅT¡A¦³«ÝªO¤W¦U¦ì¥ý¶iªº¤À¨É¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/26 ¤W¤È 11:23:12²Ä 5756 ½g¦^À³
¼F®`¼F®`¡A11ÂI15¤À³æµ§16±i½æ¡A¹ï¥Ø«e³o¼Ëªº¶q¡A¥u·|À~¤H¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/26 ¤W¤È 08:47:58²Ä 5755 ½g¦^À³
ªÑÅv¤À´²ªºÄw½X³¡¤À½Ð¤j®a¥i¥H°Ñ¦Ò

norway.twsthr.info/StockHolders.aspx?stock=6446

§Ú«ÈÆ[ªº»¡

³o¨Ç¸ê°T¦³¦h¦³ªÅ

¤d¸U¤£­n

º¦®É¥u¬Ý§Q¦h

¶^®É¥u¬Ý§QªÅ

¤ÏªÌ¬Ý¤Ï¦Ó¤~¬O§ó¥¿½Tªº¬Ýªk

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¶Â10145930  µoªí®É¶¡:2018/12/26 ¤W¤È 08:21:49²Ä 5754 ½g¦^À³
½Ð±Ð¤@¤Umtalps¤j

1/©Ò¿×¦¬½L»ù©M¦¨¥æ±i¼Æªº³o¨Ç¼Æ­È.¦³¬Æ»ò¼ËªºÃöÁp©Ê¥i¨Ñ¾Þ§@§PÂ_?

2/¬°¤°»ò¬O¶^¯}168±¡ªp·|´c¤Æ.¦Ó¤£¬O¨ä¥¦»ù¦ì?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/12/26 ¤W¤È 08:05:53²Ä 5753 ½g¦^À³
¤½¥qÀ³¸Ó¤£·|ÅýªÑ»ù¶^¯}¼W¸ê°Ï¶¡©³»ù160¡A¤£µM·|µ¹¦Û¤v¥´¤Ú´x¡A«ÜÃø¬Ý¡A¥u¯à»¡¤½¥q«Ü·|¬D®É¶¡¤½§i¼W¸ê¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GJoe10147646  µoªí®É¶¡:2018/12/26 ¤W¤È 12:54:27²Ä 5752 ½g¦^À³
±q¤W¬P´ÁªºÄw½X¨Ó¬Ý¡Aªº½T¬O¤j¤á´î¡A´²¤á¼W¡A ¤j¤á¶X§Q¦h¸¨¶]¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gmtalps200110147181  µoªí®É¶¡:2018/12/26 ¤W¤È 12:28:08²Ä 5751 ½g¦^À³
¹L¥h¤@¦~¤º¡AªÑ»ù©M¥æ´«±i¼Æ«e10¤jªºÂ²³æ¹ï·Ó¡G

¤]»¡©ú¤F¤j³¡¤Àªº¤H¥Ø«eªº«ùªÑ¦¨¥»²{ªp¡A

¥u­n¥¼¨Ó¤j½L¤£©ú¡A·|¦³§ó¦hªº¤H¦b¤p½ß©Î¤£·\ªº±¡ªp¤U¥X²M²{¦³«ùªÑ¡C

­Y¬O¶^¯}168ªº¸Ü¡A¤p§Ì¥H¬°¡Aª¬ªp´N·|§ó¥[´c¤Æ¡C·|¦³§ó¦h¤H»{½ß¥X²M¡C

FYI,

¦¬½L»ù Á`©M - ¦¨¥æ¸ê®Æ(±i¼Æ)

174 9931

173 6687

180.5 5568

182 4951

189 3939

168 3770

171 3745

178 3694

177 3521

201.5 3342

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/25 ¤U¤È 04:34:04²Ä 5750 ½g¦^À³
§ó¥¿»ù¦ì173...³æµ§40±i
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/25 ¤U¤È 04:25:31²Ä 5749 ½g¦^À³
¤µ¤Ñ¦³¤@­Ó173±i³æµ§¦¨¥æ¡A¼w«HÃÒ¨é¡A¥ú³o­Ó´N§â¤@°ï´²¤áÀ~ªº©È¦º¡A¤£´±©¹¤W°l¶R¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/25 ¤U¤È 03:34:56²Ä 5748 ½g¦^À³
µ²ªG¤µ¤Ñªº¤U±þ¡A¸ò§Ú»¡ªº¨SÔ£¨â¼Ëªü¥~¸êªk¤H³£¨S°Ê§@¡A´N¥u¬O´²¤á¦Û¤v¦bÀ~¦Û¤v½}¤F¡I
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¥Åb10143507  µoªí®É¶¡:2018/12/25 ¤U¤È 03:18:00²Ä 5747 ½g¦^À³
­n¤½§G¼W¸ê»ù¤Îú´ÚºI¤î®É¶¡¡A¦ó®É¬O¤ñ¸û¹ïªº®É¶¡¡H²×»Ý­±¹ï¡A¤j®a¦³¦ó°ª¨£¡H
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G±i±M­û10145380  µoªí®É¶¡:2018/12/25 ¤U¤È 03:15:55²Ä 5746 ½g¦^À³
¤Ñ§@Ä^¡AµS¥i¹H¡F¦Û§@Ä^¡A¤£¥i¬¡¡C¼õ¤F¨º»ò¤[¦n¤£®e©ö¬ß¨ìÃÄÃÒ´X¥GÅK©w¨ì¤âªº¦n®ø®§ §¹¥þ¨S¦³¼y¯¬¦æ±¡¤]´N½}¤F ³ºµM¬O°_¶^ÂIªº¶}©l ¤~´X¤Ñ´N§â³o´X­Ó¤ëªºº¦´T³£¦Y±¼ [§ó§O°ø±æ®³¨ìÃÄÃҪѻù·|¼Q¥X] ¡C ¤jÀô¹Ò¤£¦n¥~¥[¤p¥ÉªºÀ禬½ÄÀ»µw¥Í¥Í§âªÑ»ù¥´¦^­ì§Î ³o¨Ç©|ÄݤѷNµLªkÁקK ¦ý¦¹®É¦¹¨è³º¤½§i¼W¸ê©ó160~180¤¸ ¥u¯à©Ç¤½¥qªº·MÄø©Î§O¦³¥Î¤ß ¤]Ãø¬°¤@¸ô¬Û®¼ÀqÀq¤ä«ùªºµØ¤Í­Ì
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/25 ¤U¤È 02:12:54²Ä 5745 ½g¦^À³

¤G­Ó¤ë©³®³¨ìÃÄÃÒ¡I

Ãĵط|¦b®³¨ìÃÄÃÒ«e«á

¤½§i¼W¸ê»ù¦ì ?

¤ð´ö®@ !

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G³¥Åb10143507  µoªí®É¶¡:2018/12/25 ¤U¤È 01:55:01²Ä 5744 ½g¦^À³
ÅÞ¿è¤WÃÄÃÒ®³¨ì¬O½T©w¤F¡I©Ò¥H¤U­Ócheck point for ªÑ»ù¡AÅÞ¿è¤W«ÜÃø»¡¬Oµ¥¤G­Ó¤ë«á®³¨ìÃÄÃÒ¡I

¦ó®É¶}½æ¡H¤ë¥­¿Å¡H©u¥­¿Å¡H¨ìÀò§Q¡H

³o¤è­±¦³¨S¦³«e½ú¥i¥H¤ÀªR¤@¤U¡H¡I

AOPªº¥òµô¡A¦æ¾P¥«³õº¯³z²v¡A¹ï·sÃĹê¦b¨S·§©À¡I©Ò¥H¦]¬°¤¤¸Îªº¸gÅç¤j®a¥u¦nÆ[±æ¡H¡I·~ÁZªí²{¤£·|³o»ò§Ö¡H¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GG94010145720  µoªí®É¶¡:2018/12/25 ¤U¤È 01:53:02²Ä 5743 ½g¦^À³
¤£±`¹ïÃĵصoªí¬Ýªk¡A¥uı±o¬Ý¨ì¨«¶Õµoı¥«³õ¦]¬°¨S«H¤ß

¥[¤W°ê»Ú±¡¶Õ²V¶Ã¡A¤£ºÞ§A¤°»ò©Ò¿×¼W¸êµÛ²´ªø´Á¡A´î¸ê¿ú°hÁ٪ѪF´£°ªEPS¡A¥¿¤Ï­±¸ÑŪ±`±`³£¨S¥Î

¨S¦³¹ï¿ù¡A¥þ²y¥¦´N¬O¤@­Ó¤£½T©w©ÊÃb¸n¡A¥þ³¡³£¬Oµu½u¤ßºA¥D¾ÉµÛ¥«³õ...

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/25 ¤U¤È 01:46:19²Ä 5742 ½g¦^À³
¤º¸ê¯uªº¹ïÃĵؤ£¤Íµ½ ?

À³¬OÃĵعï¦Û¤v¤£¤Íµ½

§â¦n®ø®§CHMP ¥¿­±®ø®§

¸ò¼W¸ê®ø®§ (160-180)

²V¦b¤@°_¤½§i,Åý¥¿­±®ø®§³Q©è®ø

ªÑ¥Á¤£·|°µ¥\¼w¶R»ù¦ì¶W¥X (160-180)

±q°ªÂI 200 ­°¦Ü¤µ¤Ñ 173 ( 2018, 1¤ëªì»ù¦ì)

2018 ¾ã¦~¥´¦^­ì«¬

«Ü¥i±¤ ³o»ò¦³«e´ºªº·sÃÄ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/25 ¤U¤È 12:53:12²Ä 5741 ½g¦^À³
¥~¸ê¥ð°²¤¤µ¥Âk¶¤Åo¡I¦]¬°¤º¸ê¯uªº¹ïÃĵؤ£¤Íµ½
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GDarren10146466  µoªí®É¶¡:2018/12/25 ¤U¤È 12:20:57²Ä 5740 ½g¦^À³
¶q¤Ö¡A¦b¥[¤W¥D°Ê¶Rªº¤Ö¡A¤j¦h³£±¾¦b¥ªÃäµ¥¤H½æ¡A¦Ó´N¤W¶g¨ì²{¦b¡A¤j¦h³£¬O´²¤á¥X°â©~¦h...¦Ó°ê»Ú½L¤£¦n¤]¬O¼vÅT¤§¤@
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/25 ¤W¤È 11:46:11²Ä 5739 ½g¦^À³
³Ìªñªº½L¶Õ¯uªº«Ü®z

¬Û¹ï¨ä¥L·sÃÄÃþªÑ

6446©¹©¹¬O¶^³Ì¦hªº

©ú©ú¨S´X±i½æ³æ±¾µÛ

»ù¿úÁÙ¬O¤@¸ô¦V¤U

¤£ª¾¹D¥¿¦¡ÃÄÃÒ®³¨ì¤§«á

¯à¤£¯àÂà¤@Âà®ð

°ò¥»¤W±qCHMP¥¿­±·N¨£¨ú±o¤§«á

ªk¤H³£ÁÙ¨S¤°»ò¯u¥¿ªº¤j°Ê§@

§Æ±æ¬O¦bµ¥¥¿¦¡ÃÄÃÒÅo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAlan Liu10136094  µoªí®É¶¡:2018/12/24 ¤U¤È 06:36:28²Ä 5738 ½g¦^À³
ÁÂÁ°e³ø¤j¤À¨É, ¼v¤ù¥þ¤å½Ķ¦p¤U¨Ñ¦U¦ì§ë¸ê¥ý¶i­Ì°Ñ¦Ò¡C

Dr. J.J. Kiladjian ASH 2018 Headline Research Studies

Ropeg 3 Year Follow-Up vs. Hydroxyurea, MPNs in Patients Under the Age of 25 at Diagnosis, Targeting the JAK2 Mutation with Interferon and Arsenic

J.J. Kiladjian Âå¥Í¦bASH 2018 ­«ÂI¬ã¨s¡FÃĵØÃÄ·s¤@¥Nªø®Ä«¬¤zÂZ¯À P1101 ¹ï¤ñ HU ªº¤T¦~´Á°lÂÜ¡F¥H¤Î°w¹ï25·³¥H¤Uªº°©Åè¼W¥Í©Ê¸~½F(MPNs)¯f±w¶EÂ_¡F¥H¤Î¤zÂZ¯À©M¯~(Arsenic)¹ï©óJAK2 ¬ðÅܼйv¬ã¨s¡C

www.pvreporter.com/dr-j-j-kiladjian-ash-2018-headline-research-studies/

by David Wallace

David Wallace

(ªþµù¡GDavid Wallace ¥»¨­¬°PV ¯f±w, ³Ð¥ßPV Reporter¥­¥x¡C)

Dr Jean Jacques Kiladjian, Professor of Clinical Hematology, Hopital Saint-Louis, Paris, France interviews with David Wallace, PV Reporter at ASH 2018. Discussing Ropeg 3 year follow up vs. Hydroxyurea, MPNs in patients under the age of 25 at diagnosis, targeting the JAK2 mutation with Interferon and Arsenic.

ªk°ê¤Ú¾¤Saint-Louis Âå°|Á{§É¦å²G¾Ç±Ð±Â Jean Jacques Kiladjian Âå¥Í©ó ASH 2018 ±µ¨ü PV reporterr ªº David Wallace ±Ä³X¡C°Q½×·s¤@¥Nªø®Ä«¬¤zÂZ¯À P1101 ¹ï¤ñHU ªº¤T¦~´Á°lÂÜ¡F°w¹ï25·³¥H¤Uªº°©Åè¼W¥Í©Ê¸~½F(MPNs)¯f±w¶EÂ_¡F¤zÂZ¯À©M¯~¹ï©óJAK2 ¬ðÅܼйv¬ã¨s¡C

David Wallace¡G

¤U¤@¶¥¬q§Ú­Ì­n¨Ó°Q½×¹L¥h´X¤Ñ³Q§å­ã¥Î©ó®¦·OÀøªkªºÃĵØÃÄ·s¤@¥Nªø®Ä«¬¤zÂZ¯À P1101, ¥i¥H½Ð±z¸ÑÄÀ³o¨ÇªvÀø¾A¦X¥Î©ó­þ¨Ç¾AÀ³¯g¥H¤Î®¦·OÀøªk«üªº¬O¡H

Dr Jean Jacques Kiladjian¡G

³o¥D­n¬O¬ü°êªºµ{§Ç, ªk°ê¨Ã¨S¦³, §Ú­Ì¦³¥t¥~¤@¶µ¦bÃĪ«³Q§å­ã«eªºµ{§Ç, ºÙ¬°¯f±wÃĪ«¨Ï¥Î­p¹º(Patient Named Program), ³o±µªñ©ó®¦·OÀøªk¡C

¦ý¹ï©ó·s¤@¥Nªø®Ä«¬¤zÂZ¯À P1101 ¦Ó¨¥, ¦Ü¤Ö¦b¼Ú¬w¥¦±µªñ³Q§å­ã¥Î©óPV¾AÀ³¯gªºªvÀø, ¥B·¥¦³¥i¯à¬O¤@½u¥ÎÃĪvÀø¦] PROUD-PV ³]­p¯f±w¸s´X¥G³£¬°¤@½u¥ÎÃÄ¡C§Ú­Ì¦b©P¤@¦­¤WªºASH ·|ij¤W¤]·|²³ø¤T¦~´Á¬Û¸û©óHUªº°lÂÜÁ{§É¦¨ªG, Á{§Éµ²ªGÃÒ¹êÀH¾÷¤À°t¨ì P1101 ©M HU ²Õ PV¯f±w¦b¤T¦~ªºÁ{§Éµ²ªG¤¤, ¤£½×¬O¦å²G¾Ç¤ÏÀ³¥H¤Î¤À¤l¤ÏÀ³¤W, P1101²Õ§¡¦³µÛ¸û¦nªºªí²{¡C

®Ú¾Ú¤W­zµ²ªG, §Ú­Ì´Á¬ß¥i¥H¦b2019¦~ªì¨ú±o EMA §å­ã¤W¥«³\¥i, Åý§Ú­Ìªº¯f±w¥i¥H¨ú±o¨Ï¥Î¡C©Ò¥H¦b¬ü°ê¦³³o­ÓºÞ¹D¥i¥H¨ú±o³o¶µÃĪ«¬O«Ü¦nªº, ¦b¼Ú¬w¦a°Ï©|¥¼¦³³o¼Ëªº¨ú±o¤è¦¡¡C¨Ì·Ó§Ú­Ìªº¸gÅç¨Ó¬Ý, ±qÁ{§É¸ÕÅç¨Ó¬Ý, ¯f¤H­@¨ü«×«Ü¦n, ¨C¨â©PªvÀø¤@°w, ¥H¤Î§Úªº¤j¦h¼Æ¯f±w¦Ü¥Ø«e¶È»Ý­n¨C¤ë¤@°w, ³o¯uªº¬O¤Q¤À«K§Qªº¡C

David Wallace¡G

¬Oªº, ¥Ø«e§Ú¦Û¤v´N¬O¨C¤ë¤@°wªº¾¯¶q, ³o¯uªº«Ü´Î¡I

Dr Jean Jacques Kiladjian¡G

³o¯uªº¬O¹ï¯f±wªº¤@¤j§ïµ½¡I§Ú­Ì´¿¦b¤T¦~«e¶i¦æ FedratinibÁ{§É, ¦ý FDA °±¤î¤FÁ{§É¸ÕÅç­ì¦]¬OºÃ¦ü¯f±w²£¥Í¤F¯«¸g¬r©Ê, «á¨Ó¦b°w¹ï¨C­Ó¯f¤H¤@¹ï¤@¤ñ¹ï«á, »¡©ú¦¹°Æ§@¥Î«D¸ÓÃĤް_, ©Ò¥H³o¶µÃĪ«°_¦º¦^¥Í, §Ú­Ì¦³¤@¶µÁ{§É¥i¥H´£¨Ñ§ó¦hªº¦w¥þ©Ê¼Æ¾Ú, ¥i¥H¹ï¸Ó¯«¸g¬r©Ê¦³§ó²M·¡ªº¤F¸Ñ¡C

·íµM, ³o¶µÃĪ«¥D­n¬O¥Î¦bMF, Åý¯f¤H¦³µÛJAKAFi¥H¥~ªºÃĪ«¿ï¾Ü, ¦Ó³o¤]¥i¥H¥Î¦b¦­´Á¦pPV¡BET¯f±w, ¦ý²{¶¥¬q¥D­n¥HMF¯f±wªvÀø¬°¥D¡C

µù¡GFDAÀ³©ó2013¦~­n¨DÁɿյᤤ¤î¸ÕÅç¡C

David Wallace¡G

§Ú­Ìª¾¹D«Ü¦hMPN¯f±w­Ì¥¿¦b´M¨D§ó¦hªºªvÀø¤è¦¡, ©Ò¥H§Ú­Ì«Ü¼Ö¨£³o­Ó±¡ªpµo¥Í¡C

Dr Jean Jacques Kiladjian¡G

¬Oªº, §Ú­Ì»Ý­n§ó¦h¥h¤F¸Ñ³o¼ËªºÃĪ«­I´º¡B¥i¦æ©Ê¥H¤ÎÀø®Ä¡BÃĪ«¬r©ÊªºÄÝ©Ê, §Ú­Ì»Ý­n¤F¸ÑÃĪ«ªº­­¨î, ²¦³º¤£¬O¨C­Ó¤H³£¥i¥H§Ô¨ü¤zÂZ¯À, ´N¹³¬Y¨Ç¤H¦³µÛ¦ÛÅé§K¬Ì¯e¯f­Y¬I¥´¤zÂZ¯À, ¥i¯à·|¾É­P¯e¯f´c¤Æªº­·ÀI, ©Ò¥H§Ú­Ì»Ý­n¨ä¥LªºÃĪ«¨Ó¶i¦æªvÀø¤Wªº¿ï¾Ü¡C

David Wallace¡G

§Ú­Ìª¾¹D±z¦³¤@¶µ¬ã¨s¬O°w¹ï25·³¥H¤Uªº°©Åè¼W¥Í©Ê¸~½F(MPNs)¯f±w, ¯à§_»¡©ú¤@¤U¡H

Dr Jean Jacques Kiladjian¡G

°w¹ï¦~»´¯f±w§Ú­Ì±`¿Ô¸ß§Ú­Ì§Ú­Ìªº¨à¬ì¦P¤¯Âå¥Í, ¥D­n¬OET¯f±w, ¥D­n¬O§Ú­Ì¨S¦³¤Ó¦hªº¼Æ¾Ú, ¦]¬°³oÃþ¯f±w¸s·¥¤Ö¡C¨à¬ìÂå¥Í¦P¤¯¥L­Ì¦³¦Û¤vªº¬ã¨s¦ý¤£·|°lÂܨì16¡B18·³¯f±w, ©Ò¥H§Ú­ÌµLªkª¾¹D«áÄò±¡ªp¡C¥t¤@¤è­±, «Ü¤Ö¯f±w¬O¦b«Äµ£®É´Á³Q¶EÂ_¥X¨Ó, ¨ì§Ú­Ì°lÂܮɤw¬O20·³¤F, ©Ò¥H§Ú­Ì¦³¤@­Ó·Qªk¬O»`¶°³o¨Ç¦~»´¯f±wªº¼Æ¾Ú, ³o¨Ç¦~»´¯f±w§¡¦b25·³¥H¤U, ¨Ã¬Ý¬Ý¬O§_©M¨ä¥L¯f±w¸s¦³©Ò®t²§, ³q±`¯f±w¸s³£¦b50-60·³¤W¤U¡C

³o¬O¼Ú¬w¦a°Ï«Ü¤jªº¤@­Ó¨ó¦P¦X§@, ¥D­n¦b¼Ú¬w¦å²G¨ó·|¦b°©Åè¼W¥Í©Ê¸~½F(MPNs)ªº¤u§@¸s²Õ, §Ú­ÌÁ`¦@·|¦¬¶°335¦W¦b25·³¥H¤Uªº°©Åè¼W¥Í©Ê¸~½F(MPNs)¯f±w, Æ[¹î¨Öµo¯gªºª¬ªp¡B¬Ý¬O§_¦³§ó¦h©Î§ó¤Öªº¦åºÞ¤ÏÀ³¯gª¬¡B¬ðÅܪºª¬ªp¬O§_¦³¤£¦P, ¬O§_¦³¤£¦Pªº¬ðÅÜ, §Ú­Ì¥¿¦b«Ø¥ß³o¸ê®Æ®w¡C

¨ä¤¤¤@­Óµ²ªG«Ü¦³½ì, §Ú­Ì¦b¦~»´±Ú¸s¤¤µo²{¸û¦hªºET¯f±w¡Bµo²{§ó¦hªº¤T³±©Ê¯e¯f¡A¦ý§Ú­Ì¹ï©ó¤ß¦åºÞ¨Æ¥óªº¸ê®Æ¸û¤Ö¡AÁöµM§Ú·Q¬O¦]¬°¦~»´¯f±w½t¬G¡A¦ý¦]¬°³o¼Ë´N»¡¤£¥hªvÀø§Ú·Q¬O¤£¹ïªº, ¦]¬°¦å®ê¤]¬O¤@ºØ¦åºÞ¯gª¬¡A¤]³\¥L­Ì·|¦b³o¨Ç¦~®É¶¡ÃnÅS¦b­·ÀI¤§¤¤¡A¤]³\¦³¤F§¹¾ãªº¸ê®Æ®w«á·|²z¸Ñ¨ì¶È¦b¦~»´¯f±w¤¤¨Ï¥Îªü´µ¤ÇÆF¬O¿ù»~ªº¡C

David Wallace¡G

§Ú·Q³oÅý¯f±wÅ¥¨ì¥i¥H²z¸ÑªvÀø¤è¦¡¬O«ùÄò¦b¶i¨Bªº, ¨ÃÅý¤j®a²z¸Ñ§Ú­Ì¥¿³v¨BÁÚ¦Vªv¡¥H¤Î§ó¦nªºªvÀø¡C³Ì«á§Ú¬Ý¨ì¦³¤@­Ó¯~©M¤zÂZ¯ÀªvÀø¼Ð¹vªvÀøJAK2 ¬ðÅܪº¦X¨ÖÀøªk, «ÜÃø·Q¹³¯~(Arsenic, «UºÙÏìÁ÷) ¥i¥H¥Î¨ÓªvÀø, ¬Y¨Ç¤H»{¬°³o·|±þ¤H¡C

Dr Jean Jacques Kiladjian¡G

¦U¦ì¯f±w¤£­nºò±i, ÁöµM§Ú­Ì¹L¥h³£¦³³o­Ó»{ª¾, ¦ý³o­ÓÃĪ«¥Ø«e¦b¦å²G¯e¯f¤W¦³µÛ«D±`¦nªºÀø®Ä, ¹³¬OªvÀø«æ©Ê«e°©Åè©Ê¥Õ¦å¯f(APL), ¥¦¥i¥H©µªø¯f±wªº¦s¬¡´Á, ¥¦¬O¤@ºØ«æ©Ê¥Õ¦å¯fªº¨u¨£¯gª¬, ¥ý«e³QÂkÃþ¦b³ÌÁVªº¤@Ãþ¯e¯f, ¦ý²{¦b¥Î¯~¶i¦æªvÀø«á, ¦³µÛ«Ü¦nªº¦å²G¾Ç¤ÏÀ³¨Ã¹F¨ìªv¡ªº¦¨®Ä, ©Ò¥H§Ú­Ì¦b¥ÎÃĤW¦³µÛªø´Á¸gÅç¦b¨ä¥Lªº¾AÀ³¯g, §Ú­Ì¹ï¥¦ªº¬r©Ê¤Q¤À¦³¸gÅç, ³o¬O¬Û·í¦w¥þªº¡C·|¦³¦X¨ÖÀøªkªº·§©À¦b©ó, §Ú­Ì©M³o­Ó¬ã¨s±N¯~¥Î©ó«æ©Ê«e°©Åè©Ê¥Õ¦å¯f(APL)ªº¹Î¶¤ºò±K¦X§@, ¥L­Ì²z¸Ñ¨ì³o¦³¨âºØ³~®|, ¤@¶µ¥Ñ¤zÂZ¯À¡B¤@¶µ¥Ñ¯~(Arsenic)¦P®É·|«ü¦V§Ú­ÌºÙ§@¦­¥®²É²Ó­M¥Õ¦å¯f®ÖÅé (PML nuclear bodies)¤@ºØ³J¥Õ½è, ¦s¦b©ó²Ó­M²Õ´¤¤¡A³o¥i¥H»¤¾É²Ó­M°I¤`¡C

¦b³o¼Ëªº¾÷¨î¤U, §Ú­Ìµo²{¤zÂZ¯À¥i¥H»¤¾É³o­Ó¾÷¨î¦Ó¯~(Arsenic)¥ç¦P¡C¦b°©Åè¼W¥Í©Ê¸~½F(MPNs) ªº´c©Ê²Ó­M¤¤, ¥¦­Ì°k²æ¤F³o­Ó°I¤`(senescence)µ{§Ç, ¾É­P³o¨Ç´c©Ê¸~½F²Ó­M¥i¥H«ùÄò¦s¬¡, ¦ÓÃöÁä´N¦b©ó³o¨Ç²Ó­M¬O´c©Êªº¡C¦]¦¹­Y¥i¥H±N³o­Ó°I¤`µ{§Ç­«·s±Ò°Ê, «h³o¨Ç´c©Ê²Ó­M´N·|¦Û¦æ°I¤`¡C¦b³o¼Ëªº°²³]«e´£¤U, §Ú­Ì¯uªº³ê¿ô°I¤`(senescence)µ{§Ç, §Ú­ÌÅý¥¦¦¨¥\¹B§@¡C

David Wallace¡G

¥Ø«e¦b­þ¤@­ÓÁ{§É¶¥¬q¡H

Dr Jean Jacques Kiladjian¡G

¥Ø«e¤´¦bÁ{§É«e¬ã¨s, §Ú­Ì­º¥ý¦b¦³JAK2¬ðÅܩΨS¦³JAK2¬ðÅܤUªº²Ó­M®è¶i¦æ¬ã¨s, ¦Ó§Ú­Ìµo²{¦X¨ÖÀøªk¥Î¦b¦³JAK2¬ðÅܪº±¡ªp¤U§ó¦³®ÄªG¡C¨ä¦¸§Ú­Ì¥Î¦b¦³JAK2¬ðÅܯf±w¨ú¥Xªº²Ó­M¤¤, µ²ªG¤]Ãҹ꦳®ÄªG¡C±µµÛ¦b¦Ñ¹«°Êª«¼Ò«¬¤¤, §Ú­Ì½T»{¦b»¤µo°©Åè¼W¥Í©Ê¸~½F(MPNs)ªºJAK2 ¬ðÅÜ°ò¦]¤¤, ¨Ï¥Î¦X¨ÖÀøªk«á, ¯e¯f¤]®ø¥¢¤F¡C§Ú­Ì¶i¦æ³æ¤@¤zÂZ¯ÀªvÀø¥H¤Î¦X¨ÖÀøªkªº¬ã¨s¤¤µo²{, ¦X¨ÖÀøªk«áªº¦Ñ¹«´_µo¾÷²v¬°40%, ¬Û¤ñ©ó³æ¤@¤zÂZ¯À´_µo¾÷²v70%¬°§C¡C

§ó­«­nªº¬O, §Ú­Ì±N¨Ï¥Î¦X¨ÖÀøªkªº¦Ñ¹«, ¦¬¶°¨ä°©Åè²Ó­M«á²¾´Ó¨ì¨ä¥L¦Ñ¹«¨­¤W, ­Y²¾´Ó«áªº¦Ñ¹«¤£·|¦A²£¥Í³o¶µ¯e¯f, «h¥Nªí°©Åè·F²Ó­M¦^¨ì¥¿±`ª¬ºA¡C¦Ó³o¨Ç¦X¨Ö¥ÎÃī᪺¦Ñ¹«, ¨ä²¾´Ó«á¨Ã¥¼µo®i¦¨¯e¯f, ³o¥Nªí§Ú­Ì®Ú°£¤F¸Ó¯e¯f¡C©Ò¥H§Ú­Ì«Ü¥i¯à·|¶}©l¶i¦æÁ{§É¤@´Á¸ÕÅç, ³o¤]¬O¦]¬°³o¶µ¦X¨ÖÀøªk¤w¥Î©ó¨ä¥¦¦å²G¯e¯f¤¤¹³²O¤Ú½F¤§Ãþªº¯e¯f, ©Ò¥H§Ú­Ìª¾¹D³o¥i¦æ©Ê¡B¬r©Ê¸ê®Æ¡C§Ú­Ì¦³2~3ºØÁ{§É¬ã¨s±Ä¥Î¦X¨ÖÀøªk¨Ã¶i¦æµoªí¡C¦pªG°Êª«¹êÅ禨ªG¬°¯u, «hÀ³¸Ó·|¦³­ÓÅåÆAªº¦¨ªG¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/24 ¤W¤È 10:05:15²Ä 5737 ½g¦^À³
¦¨¥æ¶q¯uªº¦³ÂI¸Ø±iªº¤Ö
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/12/23 ¤W¤È 08:20:58²Ä 5736 ½g¦^À³
·PÁ°e³ø¤j´£¨Ñ¸ê°T

Ropeg 3 Year Follow-Up vs. Hydroxyurea, MPNs in Patients Under the Age of 25 at Diagnosis, Targeting the JAK2 Mutation with Interferon and Arsenic

­^¤å¦r¹õ

www.youtube.com/watch?v=8MiSvSfP5oQ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gªü¹Å10138576  µoªí®É¶¡:2018/12/22 ¤U¤È 12:00:06²Ä 5735 ½g¦^À³
FDA¸ò¨ä¥¦¬ü°ê¬F©²ÃöªùµLÃö¡A¥H«e§Ú­Ó¤H¤â¤Wªº¬Y«ùªÑ¤]¹J¨ì¬Û¦üºÃ°Ý¡Aµ²ªG¬O¸ò¬ü°ê¨ä¥¦¬F©²¾÷ºcªºÃö¤£ÃöªùµLÃö³s¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/22 ¤W¤È 11:34:36²Ä 5734 ½g¦^À³
¤t´¶·d¨ì¬ü°ê¬F©²Ãöªù

FDA ·|¤£·|¤]Ãöªù

«¢

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G°e³øªº10135990  µoªí®É¶¡:2018/12/22 ¤W¤È 10:40:33²Ä 5733 ½g¦^À³
¨S¦r¹õ¥i½Ķ..À°¬Ý¤@¤U§a..

Interesting interview with Dr. Kiladjian at ASH 2018, Ropeg 3 Year Follow-Up vs. Hydroxyurea, MPNs in Patients Under the Age of 25 at Diagnosis, Targeting the JAK2 Mutation with Interferon and Arsenic -

www.pvreporter.com/dr-j-j-kiladjian-ash-2018-headline-research-studies/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GRussell10140734  µoªí®É¶¡:2018/12/22 ¤W¤È 09:43:07²Ä 5732 ½g¦^À³
¤§«e¬O2/15¶}·|

2/21¤½§iµ²ªG

3/21¤½§i·|ij°O¿ý

µ¥¤½§iÅo

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/22 ¤W¤È 08:34:41²Ä 5731 ½g¦^À³

´CÅé¥D­n¤]¬O·QÁÈ¿ú

¤S¤£¬O·Oµ½¨Æ·~

¬ÝªÅ6446¥LµLªk¿Ä¨é­É¨é

¥ô¦ó©ñªÅªº¤â¬q³£¨S¦³

®Ú¥»µLªkÀò§Q

¯uªº¦³³o»ò¦n¤ßªº´CÅé

§Ú¤£¤Ó¬Û«H

´CÅé¥i¥H¤½¥¿«ÈÆ[ªº´y­z¨Æ¹ê

¦pªG¥[¤W´CÅé¦Û¤vªº¬Ýªk

³Ì¦n¬O¦³«ùÄò©Ê

©Ò¥H¤£ºÞ6446¤§«á¦p¦óµo®i

Gºô³£¥Î³ÌÄY®æªº©ñ¤jÃè¼Ð·Ç¨ÓÀ˵ø

³o¼Ë¤]¬O¤@ºØ°í«ù¤Ï¦Ó¦n

¦ý¦pªGGºô³Ì«á½ªÅ¬°¦h,¤Ï¦ÓÀ³¸Ó¥i¥H¥h½Ð½Õ¬d§½©Î¬Oª÷ºÞ·|¬d¤@¤U

§Ú¤£¤Ó¬Û«H¦³Ô£¤½¥­¥¿¸qªº°¶¤j¨Æ±¡

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GµLµß®ñ10021927  µoªí®É¶¡:2018/12/22 ¤W¤È 12:28:45²Ä 5730 ½g¦^À³
°Q½×°Ï¡u§Ú²q⋯⋯À³¸Ó¬O⋯¡v,«Ü¥¿±`§a?

¦pªG«ÜªÖ©wªº,¨º¤£¬O¦­´Nµo¥¬ªº,¤£µM´N¬O°ê¥~¥ý¬Ý¨ìªº,¦A¤£µM´N¤º½uÅo!

©Ò¥H,¦b°Q½×°Ï¡u§Ú²q⋯⋯À³¸Ó¬O⋯¡v«D±`¥¿±`¡C

§Ú§ï¥Î­Óµü,§Úı±o:¥H¤U¬O§Úı±o.....«Ü¦Û¥Ñ,ºÉ¶q¥Î!

FDAªºET¤T´ÁÁ{§É¸ÕÅç¨S®ø®§´N¬O¦n®ø®§,

¦]¬°¨S®ø®§´N¬O¥i¥H¡u¦Û°Ê¶}©l¡v¤F,´N¬O®Ö­ã°µ¤F,§Ú°O±o¬O³o¼Ë¡C

¦Ü©óFDAªºPV¬O§_»Ý­n¸É°µ?À³¬O¨ú±oEMAÃÄÃÒ¤§«áªº¨Æ,³£ÁÙ¨S¨ú±o¦b½aºò±i?2/20¤§«áªº¨Æ¡C

Âûºô¤]§O²´¬õ³Â,¤@ª½°Û°I¤]¤£´¿±¼¨ì¦Ê¤¸¥H¤U,°Û¥\¦³«Ý¥[±j®@!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦V¿ú¨«10137837  µoªí®É¶¡:2018/12/21 ¤U¤È 11:21:10²Ä 5729 ½g¦^À³
§Ú²q⋯⋯?

À³¸Ó¬O⋯⋯?

¹É¹É¡A¯u¬O¨¥½×¦Û¥Ñ°Ú¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/21 ¤U¤È 10:37:23²Ä 5728 ½g¦^À³
¤@®É¨S·Q¨ì¦bºô­¶P1101§ï¥ÎAOP2014·j´M,´N¥Xºl¤F¡A¯u¬O©êºp!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/12/21 ¤U¤È 10:30:14²Ä 5727 ½g¦^À³
·Pı¦U¦ìªºÁr´ú¤w¸g·U¨Ó·U°¾Â÷¡A«Øij¥i¥H¥´¦í¤F¡C

Conti-PV¦b¦¹:

clinicaltrials.gov/ct2/show/NCT02218047?term=AOP2014&rank=3

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2018/12/21 ¤U¤È 09:51:52²Ä 5726 ½g¦^À³
1.·s»D¸ÑŪ§PÂ_»P¤½§i: ¥ô¤@·s»D°Ñ¦Ò¥i,¦ý§^¤H§¡ª¾´CÅé¥R¥¸¤Ó¦h¦³¤ß¤HÄÀ©ñªº°²®ø®§©Î¬O¥Dµ§³ø¾ÉªºÂÕ»~,¤p¤ß¤Þ¥Î»P¨DÃÒ·s»D! ¦pªG¥ô¦ó¤WÂd¥«¤½¥q¦b·s»Dµo§Gªº·í¤U¦³°w¹ï´CÅé¶i¤@¨B¤½§i¸ÑÄÀ©Î¼á²M,«h¥»¥H¤½§i¬°¨ÌÂk,­Õ­Y·í®É¤½¥qµL¶i¤@¨B¸ÑÄÀ©Î¼á²M,©Î³\¥i¥H±À´ú·s»D¨Ó·½¥i¯à¥i«H«×°ª¤@ÂI,¦ý¤£½×¦p¦ó,¥¿¦¡¤½§i·íµM¬O³Ì¨Î¸ÑÄÀ! §ë¸êªÌ¹ï¨Æ¥óªº§PÂ_»P¦æ¬°/³ø¹S©Î·l¥¢§¹¥þ¨ú¨M¦Û¤vªº­·ÀI©Ó¾á¯à¤O»P¨Æ¥óªº¡u´¦¾å»Pµ²ªG¡v!

2.©IÀ³¤p¥øÃZ5713½g¤À¨ÉªºÀô²y¥Í­p¤ë¥Z:¡u¼Ú·ù¡B¬ü°ê ¬d¼t¤@¦¸·d©w! EMA©MFDA¨óij¥þ­±¤À¨É¬d¼t³ø§i¡v,¬ÛÃö­ì¤å³sµ²»P­«ÂI½Ķ¦p¤Uªþ¥ó# A/B/C³sµ² ¡C

3.¦¹¬G,°ò©ó¼Ú·ù»P¬ü°êªºMRA¨óij, Ãļt¦b¤@¤è§¹¦¨EMA©Î/FDAÃÄÃÒ»P¬d¼t¼f®Öµ¥µû¦ôµ{§Ç¤§«á,¤j­P¤W¥Î¤@¤è¤w¥Ó½Ð®Ö­ãªº¸ê®Æ¦V¥t¤@¤è¥Ó½Ð,µ{§Ç¤W¦ü¥G¤£»Ý¤ÓÃhºÃ§a! ¬ÆªÌ, ±q¤½¥qºô¯¸¬ÛÃö³ø¾É ¤º®e¤¤, (2018.03.21ÃĵØÃÄ»PFDA¨ú±o¦@ÃÑÃÄÃҥӽФjÁÚ¶i), ¨ä¹ê¤T­Ó°Q½×ijÃD­«ÂI´N¬O¤½¥q¨Æ¥ý»PFDA·¾³q¥¼¨Ó±N¦p¦ó¾ã²z¼Ú·ù°e¼f³q¹Lªº¤T´ÁÁ{§É¯Ç¤J±Æ¥X±ø¥ó»P¸ê®Æµ²ªG¨Ó°µ¿n¤U¨ÓªºFDAÃÄÃÒ°e¥ó¡K

4.¦¹¬G,ºî¦XMRA»PÃĵØ3/21¤½¥¬ªº·|ijµ²½×Æ[¤§,­Ó¤H¸ÑŪ¶É¦V¬O¤£»Ý°µ¬ü°ê¤T´Á¸ÕÅç. Áö¦p¦¹,°e¥óFDA¥i¯à»Ý­nµ¥Ãĵئ¬¨ì¼Ú·ù§¹¾ãªº³Ì«á¼f®Ö¤§«á,ÃÄ°Órequester¤~§ó¦³¨Ì¾Ú±o¥H¥¿¦¡¦V¬ü°êFDA»¼¥XÃÄÃÒ¼f®Ö,¦b¦¹¤§«e³Ì¦h³£¬O¹q¸Ü·|ij/¤fÀY·¾³q©Îµ{§Ç¤Wªº¤F¸Ñ.

5.¦Ü©óFDAµû¦ôªº®É¶¡ªøµu«h§¹¥þ¨ú¨M©óÃĵش£¨Ñªº¤º®e¶µ¥Ø»P­n¨D¬O§_¥i¯à²Å¦X¯à§_a)Àu¥ý¼f¬d‎/‎©Îb)¬ð¯}©ÊªºªvÀø/‎©Îc)¥[³t¼f§å/©Î‎d)§Ö³t³q¹D (¦Ü©ó¬Oa/b/c/©Îd«h¦U¦³»Ý­n²Å¦Xªº±M·~­n¥ó»PFDAªº»{¥i),¥H´Á¥[³tÃÄÃÒ¼f§å. ­Y¥HPV1101 Conti-PV³Ì²×ªí²{Àu©óHU¤S¬OÄÝ©óÀù¯g¦å²G¯e¯f, ©Î³\¦³¾÷·|³QFDAµû¦ô¬yµ{¥[§Ö¤@ÂIÂI [³o¬O¨ú¨M©óÃĵؽШD»P²Å¦X­þ¤@ºØ¥[§Ö¼f§åªº±ø¥ó¤]³QFDA©Ò±µ¨ü]

A.Mutual Recognition Agreement (MRA)

www.fda.gov/internationalprograms/agreements/ucm598735.htm

‎FDA»P¼Ú·ù¤§¶¡ªº¬Û¤¬©Ó»{¨ó©w¤¹³\ÃĪ«Àˬd­û¨Ì©¼¦¹¹Ò¤º¶i¦æªºÃĪ«Àˬd©Ò´£¨Ñªº¸ê°T¡C®Ú¾Ú2012¦~¹{§Gªº¡m­¹«~©MÃĪ«ºÞ²z§½¦w¥þ©M³Ð·sªk¡n, ¦pªG­¹«~©MÃĪ«ºÞ²z§½(FDA)½T©w¥~°êºÊºÞ¾÷ºc¦³¯à¤O¶i¦æÃĪ«Àˬd, FDA¦³Åvñ¸p©Ó»{³o¨Ç¾÷ºc¶i¦æªºÃĪ«Àˬdªº¨ó©w¡C¶i¦æ²Å¦X¬ü°ê­n¨DªºÀˬd¡C¦Û2014¦~5¤ë¥H¨Ó, FDA»P¼Ú·ù¦X§@, µû¦ô¦U¦ÛÀˬdÃÄ«~»s³y°Óªº¤è¦¡, ¨Ãµû¦ô¬Û¤¬©Ó»{ÃĪ«Àˬdªº­·ÀI©M¦n³B¡C‎

MRA¦n³B:

ƒÞ~ ‎³q¹LÁקK­«½ÆÀˬd, ´£°ª¬ü°ê©M¼Ú·ùºÊºÞÅé¨tªº®Ä²v‎

ƒÞ~ ¯à°÷­«·s¤À°t¸ê·½, ¹ï¥þ²y¥i¯à­±Á{§ó°ª¤½¦@½Ã¥Í­·ÀIªºÃÄ«~»s³y³]¬I¶i¦æÀˬd‎

B.Mutual Recognition promises new framework for pharmaceutical inspections for United States and European Union

www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm544357.htm

C.Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review

www.fda.gov/ForPatients/Approvals/Fast/ucm20041766.htm

‎¥[§ÖªvÀøÄY­«¯e¯fªºÃĪ«ªº¨ÑÀ³²Å¦X¨C­Ó¤Hªº§Q¯q, ¯S§O¬O·íÃĪ«¬O²Ä¤@­Ó¥i¥ÎªºªvÀø¤èªk©ÎÃĪ«¤ñ²{¦³ªvÀø¦³Àu¶Õªº®É­Ô¡C­¹«~©MÃĪ«ºÞ²z§½¨î©w¤F¥|ºØ¤£¦P©M¦¨¥\ªº¿ìªk, ¥H«K¾¨§Ö´£¨Ñ³oÃþÃĪ«:‎

‎Àu¥ý¼f¬d‎

‎¬ð¯}©ÊªºªvÀø‎

‎¥[³t¼f§å‎

‎§Ö³t³q¹D‎

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/21 ¤U¤È 09:39:09²Ä 5725 ½g¦^À³
¦³¤@¯«¶¤¤Í¨S¿ù,´N©ÈÃĵئۮa¥X¯Äº|!

¬dFDAºô­¶¬Ý¤£¨ì«áÄòCONTI-PV?

2016.11.28 P3

[Completed] Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

clinicaltrials.gov/ct2/results?cond=&term=P1101&cntry=&state=&city=&dist=

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/21 ¤U¤È 09:38:54²Ä 5724 ½g¦^À³
Pround PV¤T´ÁÁ{§É¶O¥Î³£¬OAOP¥Xªº

Conti PV ¤Î²Ä¤T¦~ ,¤T´ÁÁ{§É¶O¥Î ©Î³\AOP­n¨DÃĵإX

·íªì¦X¬ùÀ³¥u½Í¨ì,Pround PV¤T´ÁÁ{§É¶O¥Î

¨S·Q¨ì Pround PV¤T´ÁÁ{§É,µ²ªG¤£¦H©óHU (­è¶}©lp1101 ¾¯¶q«Ü¤p¤ÏÀ³«ÜºC)

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/21 ¤U¤È 09:27:50²Ä 5723 ½g¦^À³
¨ä¹êAOP¯uªº«Ü±M·~

Á{®É§ï¼Ð·Ç

¥B¥L¤]«Ü¼ô±x¼Ú·ùªº¬yµ{

©Ò¥H¤j®a­n¬Û«H6446¿ïªº¹Ù¦ñ

À³¸Ó¬O°ª¤â

¦Ü©ó¥òµô¡A§ÚÁÙ¬O¼ÖÆ[¬Ý

²¦³º»s³y©M±M§Q¦b6446¤W

¦ý¾ã­Ó¤T´ÁÁ{§É¶O¥Î³£¬OAOP¥Xªº

¦ý¥Ó½ÐFDA¼Æ¾Ú¤S¦bAOP¨ºÃä

¨âÃä©Ô¿÷¤@©w·|½Í¥X­Óµ²½×

¤@©w¬O win-win ªº

¤j®a¤£¥Î¾á¤ß

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/21 ¤U¤È 09:26:45²Ä 5722 ½g¦^À³
EMA ÃÄÃÒ³£¤w¸g§Ö¹L¤F

FDA /CFDA,PMDA ÃÄÃÒ

¨S¦³¹L©Î¤£¹Lªº°ÝÃD

¥u¦³®É¶¡ªøµuªº°ÝÃD

¥H¤WÃĵذõ¦æªøªL°êÄÁ,¦bªÑªF·|»¡¹Lªº¸Ü

«HµM!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/21 ¤U¤È 09:12:08²Ä 5721 ½g¦^À³
«¥»P¤p¥øÃZ¤j·Q¨ì¦P¤@¥ó¨Æ¤W¤F.

¬Ý103/07/21¤½§i[FDA±µ¨üÃĵإH¼Ú¬w¶i¦æ¤§PROUD-PV trail¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C]

À£®Ú¨S¼g¨ìFDA±µ¨üCONTI-PV¼Æ¾Ú§_?

«á¨ÓPROUD-PV¼Æ¾Ú¶È¬O¤£¦H©ó,Ãĵاï«ÝCONTI-PVÁ{§Éµ²ªG¦A°e¥ó,¦]¦¹FDA±µ¤£±µ¨üCONTI-PV¼Æ¾Ú´N¬O¦³«Ý°Óºe¤§³B?

¤Ï¥¿¤@¤ÁºÃ°Ý¦b¤½¥q°ª¼hªñ¤éªð¥x«á·|©ú®Ô¤Æ.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/21 ¤U¤È 08:43:26²Ä 5720 ½g¦^À³
§Úªº¤ù­±²q´ú

¦]¬°¤G´Áªº¼Æ¾Ú«Ü¦n(¨â¦~)

©Ò¥HFDA¦P·N¥ÎEMAªº¤T´Á¼Æ¾Ú¨Ó¥Ó½Ð(¦pªG¤T´Á¦³¹LÃö)

¦ý

2016 ASH¤½§iªº¤T´Á¤@¦~¼Æ¾Ú¥u¦³§CªÅ­¸¹L(ÁÙ¦nAOPÁ{®É§ó§ï¬°¤£¦H©ó, §_«h«Ü¥i¯à·|Åܦ¨¤T´Á¥¢±Ñ)

2017 ASH¤½§iªº¤T´Á¤G¦~¼Æ¾Ú¤j³Ó(¦¹¼Æ¾Ú©M¤§«e¤G´ÁÁ{§É¨â¦~ªº¼Æ¾ÚÃþ¦ü)

¤]¦]¬°¾ã­ÓÁ{§Éµ²ªG delay ¤@¦~¤~¥X²{©úÅãÀø®Ä

©Ò¥H¾ãÅé®É¶¡¤]delay ¤@¦~¥H¤W

¥H¤W³£¬O§Úªº²q´ú

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/21 ¤U¤È 08:27:50²Ä 5719 ½g¦^À³
Roger ¤j,

2013 ¤½§i»y·N§t½k

­YP1101§K§@¤T´Á,¤µ¦~¤G¤ë´N·|¸òFDA¶}Pre-BLA meeting

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/21 ¤U¤È 08:18:07²Ä 5718 ½g¦^À³
»Ý¤£»ÝP3½Ð¥HÃĵؤ½§i°T®§¬°·Ç.

©³¤U¬O2013/07/21¸ê®Æ.

¤½§i¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡A¤wÀòFDA®Ö­ã¡C

1.¨Æ¹êµo¥Í¤é:103/07/21 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q4.¬Û¤¬«ùªÑ¤ñ¨Ò(­Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î5.µo¥Í½t¥Ñ:¥»¤½¥q¦V¬ü°êFDA¥Ó½ÐP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(Polycythemia Vera)¤§²Ä¤T´ÁÁ{§É¸ÕÅç(IND½s¸¹119047)¡A¤wÀòFDA¥¿¦¡³qª¾¥i«ö­pµe¶i¦æ(¥ç§Y¬ü°êFDA®Ö­ã±µ¨ü¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç­pµe)¡C6.¦]À³±¹¬I:¶i¦æ¤½§i¡C7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:(1)¥»¤½¥q«e©ó102¦~9¤ë26¤é»P¬ü°êFDA¶i¦æPre-IND meeting¡A·|¤¤FDA©x­û«Øij¥»¤½¥q¥i¿ï¾Ü¶È¥H¦b¼Ú¬w¶i¦æ¤§PROUD-PV trail(§YP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅç)¼Æ¾Úµ²ªG¡A³w°e¬ü°êFDA¥Ó½ÐÃÄÃÒ¡C(2)PROUD-PV trail«Y¥»¤½¥q±ÂÅv(Out-Licensing)¹Ù¦ñAOP¤½¥q¦b¼Ú¬w¶i¦æ¤§²Ä¤T´ÁÁ{§É¸ÕÅç¡F¸g»PAOP¤½¥q¨ó°Ó«áij©w¡A¥Ñ¥»¤½¥q©e°UAOP¤½¥q¾á¥ôCROÅU°Ý¡A¨ó§U¬ü°êIND¥Ó½Ð°e¥ó¨Æ©y¡C<ºK¿ý¤½¶}¸ê°TÆ[´ú¯¸>

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/21 ¤U¤È 07:00:59²Ä 5717 ½g¦^À³
Ãĵإ¼´¿¥¿¦¡¤½§i P1001,FDA¤£¶·°µÁ{§É¤T´Á.

¤fÀY»¡©ú,·s»D³ø¾É

¯uªº¶È°Ñ¦Ò

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/21 ¤U¤È 06:56:25²Ä 5716 ½g¦^À³
¥»®×¤H¨Æª«¦³§ïÅÜ?

2013-10-19Ãĵةt¨àÃÄ ±N´£«e¦b¬ü¤W¥« (¨Ó·½¡G¸gÀÙ¤é³ø)

¥Í§Þ¤½¥qÃĵغX¤U§Ü¯u©Ê¬õ¦å²y¼W¥Í©t¨à·sÃÄP1101¡Aªñ´Á¯}¤Ñ¯îÀò¬ü°ê­¹«~ÃĪ«ºÞ²z§½¡]FDA¡^¨ç¤å±N¡u§KÁ{§É¤T´Á¸ÕÅç¡v¡A³Ð¥xÆW­º¨Ò¡A¸ÓÃĪ«¥i±æ´£«e¦b¬ü°ê¤W¥«¡A·m§ð¤W¦Ê»õ¬ü¤¸¥«³õ¡C

Ãĵج°®È¬ü¥Í§Þ±M®aªL°êÄÁ³Ð¿ì¡Aªñ¤@¦¸¼W¸ê¦³Áp¹qºaÅA¸³¨Æªø±ä¿³¸Û¡B§»¹F¹q¸³¨Æªø¤ý³·¬õ­Ó¤HºX¤Uªº§ë¸ê°òª÷¡B³»·s¶°¹ÎÃQ®aµ¥¡A¬ì§Þ¡B¶Ç²£¤j©@³£¬ÛÄ~·m¶i¡A­ìªÑªF«h¥]¬A°êµo°òª÷¡B¸gÀÙ³¡Ä£µØ¬Á¼þ¡B¶£®õ§ë¸ê¡B§»¨È­¹«~µ¥¡C

ÃĵةM¼Ú¬w©t¨àÃĤ½¥qAOP¦X§@ªº·sÃÄP1101Á{§É¤T´Á¸ÕÅç¤w±Ò°Ê¡Aªñ´Á¬ü°êFDA¨Ó¨ç«ü¥X¡A¦pªG¼Ú·ùÁ{§É¤T´Á¼Æ¾Ú¥¿­±¡A°ò©ó°ê»ÚÁ{§ÉICHªº­ì«h¡A¬ü°êFDA±N¦Ò¶q¦@¥Î¼Ú·ù¼Æ¾Ú¡AÅýÃĵءuª½±µ³q¹L¡v¤T´ÁÁ{§É¡C

¤]´N¬O»¡¡AP1101¦b¬ü°ê±N§K°µ¤T´ÁÁ{§É¡A¥Ó½Ð¨Ã¨ú±o¤HÅéÁ{§É¸ÕÅç³\¥i«á¡A¥iª½±µ¥Ó½ÐÃÄÃÒ¡F·~¬É«ü¥X¡A³o¬O°ê¤º¥Í§Þ¤½¥q­º¨Ò¥Hºñ¦â³q¹D¦b¬ü¥Ó½ÐÃÄÃÒ¡C

ÃĵØÁ`¸g²zªL°êÄÁªí¥Ü¡AICH¬O¥H°ê»ÚÂåÃĪk³W¨ó©M·|©Ò³W©wªº¡uÀu¨}ÂåÃÄÁ{§É¸ÕÅç³W½d¡v¬°¼Ð·Ç¡A¬ü°ê¡B¼Ú·ù¥Ø«e¦@¥Î¦¹Á{§É¼Ð·Ç¡A¥Ñ©óÃĵغX¤U·sÃÄÁ{§É¸ÕÅç¥þ¨ÌICH³W½d¶i¦æ¡Aªñ´Á¤wÀòFDAªì¨B»{¥i¡C

¬Ý¦nÃĵصo®i¡Aªñ´Á¿n·¥±´´M¥xÆW¥Í§Þ§ë¸ê¾÷·|ªº¼¯®Ú¤h¤¦§Q¡A¨ä¥xÆW°Ï¸³¨ÆÁ`¸g²z¬_¤§µ`¿Ë¦Û«ô³XªL°êÄÁ¡Aªí¹F¿n·¥¤JªÑ·NÄ@¡C

ªL°êÄÁ»¡¡A¤j¼¯¦³·N§ë¸ê¡A­Y¶¶§Qªº¸Ü¡A¤Uªi¶Ò¸ê¾÷·|Âù¤è¥i±æÄâ¤â¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/21 ¤U¤È 06:43:34²Ä 5715 ½g¦^À³
±q¥j¦Ü¤µªº°T®§,©ú©ú¥Õ¥Õ´¦ÅS¬ü°ê¤£¶·°µÁ{§É¤T´Á,·s»D¶È°Ñ¦Ò½Ð¥HÃĵؤ½§i°T®§¬°·Ç.

1.2014-07-18 CEO±M³X ³¯©É´@¢x²z°]©P¥Z725´Á¢x

www.moneyweekly.com.tw/Journal/article.aspx?UIDX=16588779220

...........ÃĵØÁ`¸g²zªL°êÄÁ«ü¥X¡A¥Ñ©óP1101¤w¨ú±o¬ü°êFDAªº©t¨àÃĸê®æ»{©w¡A¥BFDA¤]¶É¦V¦P·N³z¹L¹ê¦a¼f¬d¼Ú¬wªº¤HÅé¸ÕÅç¸ê®Æ»P¥¼¨Ó»¼¥æµ¹¼Ú¬wÃĪ«ºÞ²z§½¡]EMA¡^ªº¤T´Á¤HÅé¸ÕÅçµ²ªG¡Aª½±µ¦VFDA¥Ó½Ð·sÃĤW¥«³\¥i¡C

²¦Ó¨¥¤§¡AÃĵتºP1101­Y¬O¦b¼Ú¬wÁ{§É¹êÅç¤T´Á³q¹L¡A¬ü°êFDA¥iª½±µ¦P·N¥Ó½Ð·sÃĤW¥«¡A¹w®Æ¦¹Á|±N¤j´T¸`¬Ù¤½¥q¦b¬ü°êªº¤T´ÁÁ{§É¸ÕÅ禨¥»¡A¨Ã¦³§U¥[³tP1101·sÃĦb¼Ú¬w¡B¬ü°ê¤G¦aªº¦P¨B¤W¥«¡C........

2. 2017.12.20 (ªk»¡Q&A)ÃĵØÃĪL°êÄÁ¦^µª12­Ó°ÝÃD-

www.genetinfo.com/investment/featured/item/13472.html

«¥«D·|­û¤]¨Sµù¥U µLªk¬Ý¸Ô¤å!¬O§_»P²z°]©P¥ZCEO±M³X¤@­P?±æª©¤W¦³¤H¯à¤À¨É.

3. 2018-03-23 01:25¸gÀÙ¤é³ø °OªÌ¶À¤å©_/¥x¥_³ø¾ÉÃĵطsÃÄ©é©ú¦~¦b¬ü¤W¥«

money.udn.com/money/story/10162/3046990

............¥~¶ÇÃĵØP1101¥i¯à­n¸É°µ¬ü°êÁ{§É¤T´Á¡A¹ï¦¹¡A¸â«C¬h¡BªL°êÄÁ³£§_»{¦¹¶µ¶Ç»D¡A¨â¤H¨Ãªí¥Ü¡A¥Ø«eP1101¦b¼Ú¬w§¹¦¨ªºÁ{§É¤T´Á¡BPROUD/CONTI-PV¸ÕÅ窺Á{§É¼Æ¾Ú¡A§¡²Å¦X¬ü°êFDAªº­n¨D¡A»¼¥ó«á±N»PFDA©x­û¦A¶i¦æ°Q½×¡C¥Ø«e¹F¦¨ªº¦@ÃѬO¡A¤£¶·°µÁ{§É¤T´Á¡A

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/21 ¤U¤È 06:12:16²Ä 5714 ½g¦^À³
¤j®a¤ßºA°¾¦h,¨º«Ü¦h¨Æ±¡³£¥u·|¬Ý¦h

¤j®a¤ßºA°¾ªÅ,¨º«Ü¦h¨Æ±¡³£¥u·|¬ÝªÅ

¦ý¥ø·~¸gÀ祻¨Ó´N¬O¦hªÅ¥æ¿ù

§Ú¤W¦¸¤]»¡¤F

¹L¤F¤@Ãö, ¤j®a³£¾á¤ß¤U¤@Ãö

¤@¤U¤lFDAÃÄÃÒ. ¤@¤U¤l©w»ù, ¤@¤U¤l¥«¥e²v, ¤@¤U¤l©MAOPªº¥òµô

¨S¦³¤H¯à«OÃÒ

6446 ¥þ³¡¹F¨ì¤j®aªº­n¨D¤§«á

¥»¯q¤ñ¥i¥H¦³10­¿

¤]´N¬O¤@¦~20¤¸, ¤~¯à¤ä¼µ200¤¸ªºªÑ»ù

³o´N¬O¥«³õ¦³½ì¤§³B

½¶}¥xªÑªº­ÓªÑ

³o¼ËªºªÑ²¼¤ñ¤ñ¬Ò¬O

§Ú¬Û«H·|¬Ý½×¾Âªº¤j¤j

¤j¦h¬O¤w¸g«ùªÑªÌ

¨S¦³«ùªÑ·Q¶R¶iªº¤H

´Nºâ¹L¤F¤@Ãö,¤S·|¾á¤ß¤U¤@Ãö

ÁÙ¬O¤£·|¶R

¦³®É­Ô¦A·Q

¦pªG§Ú¬OÃĵتº¦ÑÁó

°®¯Ü½æ¤@½æ, µM«áÀ£¤O¤p¤@ÂI

Á¿¥yÃøÅ¥ªº

ªÑ²¼º¦, §Q¦h§QªÅ¤j®a³£¤£¦b·N, ¦]¬°¤ß±¡¦n

¤Ï¤§¥çµM

¦pªG¤Ó¦h´Á±æ,´N¥i¯à²£¥Í¥¢±æ©Ê½æÀ£

§Ú²{¦bÁÙ¤£²M·¡¥Ø«e³o­Ó»ù¦ì

¨ì©³¹ï©ó³\¦hÃö¥dªº¹w´ú©M§PÂ_

©Î³\¥i¥H½Ð¤j®a§ë²¼¨Ó¬Ý¬Ý

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/12/21 ¤U¤È 05:35:06²Ä 5713 ½g¦^À³
·PÁÂLibad¤j´£¨Ñ¥¿½T°T®§¡C

­Y¬O12¤ë20¤é»PFDA°Q½×PV¡A¤£ª¾·|ijµ²ªG¡A¬O§_¤wª¾¥i±o½T©w§K§@¤p¤T´Á¡C¦ó®É¥iª½±µ¥Ó½ÐÃÄÃÒ¡C

²¦³º¡Aªñ¤éºô¸ô·s»D¤´½èºÃ¶·§@¤p¤T´Á¤§°ÝÃD¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/21 ¤U¤È 04:48:37²Ä 5712 ½g¦^À³
³o¼Ë¬O¤£¬O¬d¼t¥i¥H§Ö¤@ÂI??

www.gbimonthly.com/2017/08/12221/

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/21 ¤U¤È 04:30:49²Ä 5711 ½g¦^À³
¤p¥¿¥¿¤j

§õªü½÷¤jÁ¿ªºÀ³¸Ó¥¿½Tªº

12/20 - FDA ¬O§_§K¤T´Á,

Pre-BLA meeting

BLA ¥Ó½ÐÃÄÃÒ

FDA ¬d¥x¤¤¼t¤Î°w¾¯¼t

¢±¢¯¢±¢¯¡A¢ß¢±¡Ð¢ß¢²¡@®³¢Ô¢Ò¢ÏÃÄÃÒ

¡@

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/12/21 ¤U¤È 04:03:31²Ä 5710 ½g¦^À³
¤@¡B·PÁ§õªü½÷¤j¡A´£¨Ñ¸ê°T¡C

¤G¡B12¤ë20¤é»PFDA°Q½×¬°¦ó¡H

(¤@)°Q½×ET¡G

Âø»x³ø¾É¡G¤Q¤G¤ë¤G¤Q¤é±N»P¬ü°ê¢Ô¢Ò¢Ï¶i¦æ¢Ó¢â(¦å¤pªO¼W¥Í¯g)¤§¤T´ÁÁ{§É¸ÕÅç°Q½×¡A¦pªG¶¶§Q¡A¦³¾÷·|¦b©ú¦~²Ä¤@©u®i¶}

(¤G)°Q½×PV¡G

ºô¸ô·s»D¡GÃĵØÃÄ«ü¥X¡A¦b®³¨ìÃÄÃÒ«á¡A©¡®É P1101 ±N¥¿¦¡¦¨¬° EMA ®Ö­ã³J¥Õ½è·sÃÄ¡A¤]¬O¥þ²y­º³ÐªvÀø PV ªº³æ¤@ÃĪ«¡A¥¼¨Ó¤]±N¦b¬ü°ê FDA ¤è­±¿n·¥ª§¨úÃÄÃÒ¡AÃĵØÃijzÅS¡A20 ¸¹±N»P¬ü°ê FDA ¦A«×¨ó½ÕÃÄÃÒ¶i«×¡A¬Û«H«Ü§Ö´N·|¦³¦n®ø®§¡C(¹d¦ëºô)

(¤T)¤pµ²¡GÀ³«DPV, ²z¥Ñ¦p¤U¡G

(1)¤j³¡ºô¸ô·s»D³ø¾ÉÃĵØÃĪí¥Ü¡A¨ú±o¼Ú¬wÃÄÃÒ«á¡A©ú¦~°_±N¥[³t»PFDA·¾³q¥Ó½Ð¬ü°êÃÄÃÒ(®É³ø)¡C©ú¦~±N¶}©l¦V¬ü°êFDA°e¥ó¥Ó½ÐÃÄÃÒ(°]°T)¡C

(2)Ãĵةxºô¡G©ú¦~°_¤½¥qÀç¹B±N¤j¨B¦V«eÁÚ¶i¡A¥]¬A¥[³t»PFDA·¾³q¥Ó½Ð¬ü°êÃÄÃÒ¡C

(¥|)©Î³\±À½×¦³»~¡A¤@¤Á¥HÃĵإ¿¦¡¤½§i¬°¥D¡A©Î½Ð±Ð¤½¥qµo¨¥¤H¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/21 ¤U¤È 03:52:13²Ä 5709 ½g¦^À³
¤p¥øÃZ¤j¡G

­YFDA PV§K°µ¤T´Á

¤U¤@¨B¦ÛµM´N¬OBLA¥Ó½Ð¤F

¥u¬O±qBLA¥Ó½Ð¨ì¨ú±oÃÄÃÒ

ÁÙ­nªñ¤@¦~ªº®É¶¡

¤¤¶¡»Ý­nÀ˵ø©Ò¦³Á{§É¡B«DÁ{§Éªº¼Æ¾Ú

¥H¤Î¥²¶·³q¹LFDAªº¬d¼t

¤]¬O¤@³õµw¥M­n¥´

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/21 ¤U¤È 03:42:15²Ä 5708 ½g¦^À³
12/20 À³¸Ó¤£¬Opre-BLA Meeting

¥H¤U¬O§Úªº²q´ú,ÁٽбM·~¤H¤h¸Ñµª

pre-BLA Meeting ´N¤w¸g¬Oµ¥©ó·Ç³Æ­n®³ÃÄÃÒªº«e¸m·|ij

¦pªG¬O³o¼Ë

¤j®aÁÙ¾á¤ß¬Æ»ò?

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/21 ¤W¤È 11:36:01²Ä 5707 ½g¦^À³
¥ý±´Âø»x©Ò´£¨ì

12/20¬O»P¬ü°êFDA¶i¦æET¤T´Á¤§°Q½×¡H

¤§«e©ÒÄÀ©ñ¥Xªº®ø®§

¸Ó¤é¤£¬O¶i¦æPVªºpre-BLA Meeting¶Ü¡H

¦AªÌÀ³¸Ó¤]¤w¸g¶}§¹·|¤F

³£¨S¦³¥ô¦ó®ø®§¶Ç¥X⋯

²{¦b¯uªº«Ü»Ý­nFDA¥Ó½ÐBLA§K¤T´Áªº®ø®§

¬°¥«³õª`¤J¤@¤ä±j¤ß°w°Ú¡I

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/21 ¤W¤È 11:27:56²Ä 5706 ½g¦^À³
§@ªÌ¡G®}¥É§g ¤å³¹¥X³B¡G¥ý±´Âø»x 2018´Á ¥X¥Z°Ï¶¡¡G2018/12/21~2018/12/27

®}¥É§g

¾ú®Éªñ¤G¡³¦~¡AÃĵØÃĪºP1101¡]Ropeg¡^²×Àò¼Ú·ùCHMP¥¿­±·N¨£¡A¦pªG¶¶§Q¡A©ú¦~²Ä¤@©u§Y¥i¥¿¦¡¨ú±oÃÄÃҨäW¥«¡A¦b¦¹¤§«eÁÙ¦³´XÂIºÃ¼{«ÝÂç²M¡C

¤S¤@®a·sÃĬãµo¤½¥q§Y±N¨ú±oÃÄÃÒ¡IÃĵØÃÄ(6446)¦Û¦æ¬ãµo¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(¢Þ¢ä)ªºP1101(Ropeg¡F°Ó«~¦WBesremi)¡A¤Q¤G¤ë¤Q¥|¤éÀò¼Ú·ù¤H¥ÎÃÄ«~©e­û·|(CHMP)¥H¥¿­±·N¨£¡u«Øij·í§½±Â¤©BesremiÃÄ«~¤W¥«³\¥i¡v¡A³Qµø¬°¨ú±o¼Ú·ùÃÄÃÒªº«e­ï¡A©ú¦~±N¥¿¦¡¨úÃҨäW¥«¡C

¤W¥«¾P°â³W¹º¬O­«ÂI

¥u¤£¹L¡A¨úÃÒ¤§«á¨Ã«D´N¦¹¥­¨B«C¶³¡A¦]¬°¼Ú¬ü¥«³õªºÃÄ«~¤W¥«¾P°â¡A¨Ã«D§Ú°ê·sÃĬãµo¤½¥q±M¶µ¡A«D±o¸g¹L±ÂÅv¨Ó§¹¦¨ªì´Áªº¾P°â¥¬§½¡FÃĵØÃĦ۵M¤]¤£¨Ò¥~¡A¦bP1101¶i¤J¤T´ÁÁ{§É¸ÕÅ礧«á¡A§Y»P¼Ú¬wAOP Orphan Pharmaceuticals AG¤½¥qñ¸p¦X§@«´¬ù¡A³W¹ºP1101ªºÁ{§É¡BÃÄÃҥӽСB¤W¥«¾P°âµ¥¨Æ©y¡C

¤@¤C¦~¤@«×¦]¬°ÃĵØÃIJĤG¥N¥Í²£»sµ{¸û²Ä¤@¥N»sµ{¦¨¥»§C¤­¦¨¥H¤W¡A¨Ì¾ÚÃĵØÃÄ»P¢Ï¢Ý¢Þªº¦X¬ù¡AÃÄ«~ªº»s³y¦¨¥»¥Ñ¢Ï¢Ý¢Þ»{¦C¡A¦ý¬O¥Ñ©ó»s³y¦¨¥»ªº¤U­°¡A¢Ï¢Ý¢Þ­n¨DÃĵØÃÄ¥H²Ä¤G¥N»sµ{§Þ³N¦¨¥»»{¦C¡AµM»sµ{§Þ³Nªº´£¤É¬OÃĵØÃĪº¤É¯Å¦¨¥»¡A¨S¦³¹D²z¢Ï¢Ý¢Þ¤À¤@ªMü¡A¦Ó·í®É¡AÃĵØÃĪºRopeg(Besremi)¥¿³B©ó¼Ú·ùÃÄÃÒªº¥Ó½Ð¶¥¬q¡A»ÝÀ˪þ¢Ñ¢Û¢Ñ»sµ{¤å¥ó¡A¢Ï¢Ý¢Þ¥HÃĵØÃÄ¥¼¯à´£¨Ñ¢Ñ¢Û¢Ñ¼Æ¾Ú¬°¥Ñ¡A´£¥XÃĵØÃÄ¥i¯à¦]¦¹©µ»~ÃÄÃҥӽЮɵ{¡A¦Ó¥Ó½Ð°ê»Ú¥òµô¡C

¦p¤µ¡A¼Ú·ùÃÄÃҶȮt³¡¤À¦æ¬F¬yµ{«Ý§¹¦¨¡A§Y¥i¨ú±oÃÄÃÒ¡F´«¥y¸Ü»¡¡A·í®Éªº¥òµô¨Æ¥ó¥D¦]À³¸Ó¤w¸g¤£¦s¦b¡C¥u¬O¡ARopeg(Besremi)ªºÁ{§É¸ÕÅç¡B¼Ú·ùÃÄÃÒªº¥Ó½Ð¡A­ì¥»´N¬O¥H²Ä¤@¥Nªº»sµ{§Þ³N¥Ó½Ð¡A¥B¤w¸g¹L¬d¼t¡A§Y«K¢Ï¢Ý¢Þ­n¨DÃĵØÃÄ¥H²Ä¤G¥N»sµ{§Þ³N¨Ó¥Ó½ÐÃÄÃÒ(¤£¦X²z)¡A¤]Áٻݭn¥¿±`¬yµ{­«·s¥Ó½Ð¬dÅç¡A³o­ÓºÃ¼{ÃĵØÃĭˬO¨S¦³¯S§O»¡©ú¡C

¦Ü©óÃÄÃÒ¨ú±o«á¡A¦]°ê»Ú¥òµô©|¥¼¦³µ²ªG¡A¸Ó­n¦p¦ó¾P°â¡HÃĵØÃÄ«ü¥X¡A¦b¢Ï¢Ý¢Þ´£¥X°ê»Ú¥òµô«á¡AÃĵØÃħY»P¢Ï¢Ý¢Þñ­q¡uÁ{®É¦X¬ù¡v¡A¤~¦³¿ìªkÅýÃÄÃҥӽШ«¨ì¤µ¤Ñ³o¤@¨B¡A¦Ü©ó¦X¬ù¤º®e¡AÃĵØÃĶȪí¥Ü¡A¦]¬°»P¢Ï¢Ý¢Þñ¤F«O±K±ø´Ú¡A¤£«K³zÅS¡C¥uªí¥Ü¡AÃÄÃÒ¨ú±o«á¡AÃĵØÃıN·|¶}©l¥Í²£¨ÑÀ³¢Ï¢Ý¢Þ¾P°â©Ò»Ýªº­ìÃĮơA¨Ã¥B¨É¦³¢Ï¢Ý¢Þ©ó¼Ú¬w¥«³õ¾P°âªº¤À¼íѺª`¡C

¬ü°êÃÄÃÒ¤~¬OÃöÁä

ÁöµM¡uÁ{®É¦X¬ù¡v¤¤¡A¢Ï¢Ý¢Þ¥ç¦³°w¹ï©ú¦~¨ú±oÃÄÃÒ¤§«áªº¾P°â¹w¦ô­È¡A¥H¤Î¾P°â¤è¦¡¡A¤£¹L¡AÃĵØÃħ¡¥H«O±K¨ó©wªí¥Ü¡A²{¶¥¬qµLªk§iª¾¡C³o¹ï§ë¸ê¤H¦Ó¨¥¡A¾P°â¹w¦ô¬O«Ü­«­nªº°ò¦¦Ò¶q¡A§Y«K°T®§³z©ú«×·¥°ªªº¤¤¸Î(4147)¡A®Ú¾Ú¦X§@¹Ù¦ñTheratªº¹w¦ô­È¡A³£¦³·¥¤jªº®t¶Z¡AÁÙ¦]¦¹¾É­PªÑ»ù¸y±Ù¡C

¦AªÌ¡AÃĵØÃÄ©ó·s»D½Z¤¤«ü¥X¡A¦³Ãö§¹¾ãªº¾AÀ³¯g¬O¡G¡uBesremi¬O¾A¥Î©ó¤£¨ãµÊŦ¸~¤j¯gª¬ªº¯u©Ê¬õ¦å²y¼W¥Í¯g(¢Þ¢ä)¦¨¤H¯f±w³æ¤èÃĪ«¤§ªvÀø¡v¡F«Øij¶·¥Ñ¹ï¦¹¯e¯f¦³ªvÀø¸gÅ窺Âå®v¶}¥ß³B¤è¡C®Ú¾ÚÃĵØÃĪº»¡ªk¡A¤@¯ë¢Þ¢ä¯f±wªºµÊŦ¸~¤j¤À¦³¼xª¬©MµL¼xª¬¡A¤j¦h¼ÆÄÝ©óµL¼xª¬ªº¥¿±`ª¬ºA¡A¦³¼xª¬ªºµÊŦ¸~¤j¤@¯ë´N·|±Ä¥Î¤G½u¥ÎÃÄJakafi¡F¦Ó®Ú¾ÚÃĵØÃÄÁ{§É¤T´Á¸ÕÅ禬®×¸gÅç¬Ý¤ñ¨Ò¡A¬ù¦³¤K¡D¤­¢Hªº¯f±w¦³µÊŦ¸~¤jªº¼xª¬¡F´«¥y¸Ü»¡¡A¤ñ¨Ò§C©ó¤Q¢H¡C

¾Ú²Î­p¡A¥Ø«e¼Ú¬ü¬ù¦U¦³¤Q¾l¸U¢Þ¢ä¯f±w¡A¤j¦h¼Æ¶È¯à¥H©w´Á©ñ¦å¡A©Î¨C¤éªA¥Î¦³Àù¯g¥ÎÃÄHydroxyurea(HU)©Î¶Ç²Î¤zÂZ¯Àµ¥¨Ó±±¨î¯e¯f¯gª¬¡AµLªk§¹¥þ®Úªv¡A¦ý¬O¢Ö¢ã»ù®æ¬Û·í«K©y(¤@Áû§é¦X¥x¹ô¬ù¤Q¤K¤¸)¡AµMÃĵØÃĪº°w¾¯¨C¨â©P¥´¤@°w(¤@°w¬ù¤»¸U¥x¹ô¡A»ù®æ¤£µá)¡A¦p¦ó»¡ªA¯f±w©ÎÂå¥Í³B¤è±Ä¥Î¡A¥H¤Î¼Ú¬ü«OÀIµ¹¥I±µ¨ü«×¡A³£»Ý­n¦æ¾P¥\¤O¡C

¦Ü©ó¬ü°êÃÄÃҥӽжi«×¡AÃĵØÃĪí¥Ü¡A¤Q¤G¤ë¤G¤Q¤é±N»P¬ü°ê¢Ô¢Ò¢Ï¶i¦æ¢Ó¢â(¦å¤pªO¼W¥Í¯g)¤§¤T´ÁÁ{§É¸ÕÅç°Q½×¡A¦pªG¶¶§Q¡A¦³¾÷·|¦b©ú¦~²Ä¤@©u®i¶}¡G¦Ü©ó¢Þ¢äÃÄÃÒ¡A·í®ÉÃĵØÃĪí¥Ü¡A¼Ú·ùÃÄÃÒ¨ú±o«á¡A¦A¦V¬ü¢Ô¢Ò¢Ï´£¥X¥Ó½Ð¡A¦Ü©ó¦p¦ó¥Ó½Ð¡AºÝµø¢Ô¢Ò¢Ï¦p¦óµô©w¡A¬O¥H¼Ú·ù¤@¡Ï¤G¦~Á{§É¸ÕÅ窺¼Æ¾Ú¥Ó½Ð¡H©Î»Ý¦A¶i¦æ¤p«¬¤T´ÁÁ{§É¡H³£ÁÙ¬O¥¼©w¤§¼Æ¡C

¾¨ºÞ©|¦³³\¦h¤´«ÝÂç²Mªº²Ó¸`¡A¤£¹LÃĵØÃĤâ¤WÁÙ¦³¤£¤Ö·sÃĶi«×¤w¶i¤JÁ{§É¤G´Á¡B¤T´Á(¸Ô¨£ªþ¹Ï)¡F´«¥y¸Ü»¡¡A®w©Ðªº¼uÃÄÁÙ«Ü¥R¸Î¡A¦ýÁÙ¶·Æ[¹î¤â¤¤²{ª÷°÷¤£°÷¤äÀ³Á{§É©Ò»Ý(¸³¨Æ·|¤é«e¨Mij¿ì²z²{¼W¡A¨CªÑµo¦æ»ù®æ¼È©w¤@¤»¡³¡ã¤@¤K¡³¤¸¶¡)¡F¦Ó¢Ñ¢Ö¢Û¢Þªº·N¨£ÁöµMÅýÃĵØÃĪºªÑ»ù¤@«×µn¤W¤G¡³¡³¤¸¾ã¼ÆÃö¥d¡A¥u¬O§ë¸ê¤H¤w¸g¤F¸Ñ¨ì¥Í§Þ·sÃĪº§ë¸ê¡A¤£¬O®³¨ìÃÄÃÒ´N¯à¦¨¬°ªÑ»ùµL°Ã¤ý¡A«Ü¦h²Ó¸`¤´­n¤@¤@Âç²M¡A¤~¯à©ú½T§PÂ_«áÄòªº§ë¸ê¤è¦V¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2018/12/21 ¤W¤È 12:07:24²Ä 5705 ½g¦^À³
¦^ÅU°lÂܤ@¤UP1101¦bHBV B¨x¤G´ÁÁ{§É¼Æ¾Úµ²ªG»P¨ä¥L¤zÂZ¯À¤ñ¸û

1.¤u°Ó®É³ø2017/10/24: ÃĵØÃÄB¨x·sÃĵoªíI/II´ÁÁ{§É¸ÕÅç¡Aµ²ªG¥¿­±m.ctee.com.tw/focus/sjce/164993

2.­ì¤åµoªí¥Ñ°ê®õÂå°| ¶À«³¤å Huang Yi-Wen (¥t¥x¤jPei-Jer, Chen³¯­õ°ö, °ªÂåMing-Long, Yu §E©ú¶©¡Kµ¥°ê¤º¨x¯f»â°ìÅv«ÂÂå¥Í¤]³£°Ñ»P¦bÁ{§É¹êÅ礤) ¦bAASLD ¬ü°ê¨xŦ¨ó·| ½Ð°Ñ¾\ pdf page29 ³Ì«á¤@­¶: (µ²½×«h¦p¤¤¤åºK­n©Ò­z) aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep.29634

3.¥t¦³§ó²M·¡ªº¹Ïªí¬Ý¥XP1101¤£¦P¾¯¶q(350ug vs 450ug)»Ppeginterferon alpha-a ªºB¨x§Ü­ì¦å²MÂà´«²v³t«×¤ñ¸û (¥´¶}¤U­±³s±µ¨Ã°õ¦æ ¨Ó¦Ûprogram.m-anage.com ´£¨ÑªºPDFÀÉ, ¥i¥H¬Ý¨ì)

www.google.com.tw/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwix9sDe3q7fAhVQQLwKHfjNBa4QFjAAegQIAhAC&url=https%3A%2F%2Fprogram.m-anage.com%2Filc2018%2Fen-GB%2FProgramSearch%2FDownloadAbstractOfPresentation%2F328942&usg=AOvVaw3xNp9Yl8mieo4BEhE5uN5U

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2018/12/20 ¤U¤È 11:31:35²Ä 5704 ½g¦^À³
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

tw.news.yahoo.com/b¨xµLªk-§¹¥þªv¡-¬°¤°»ò­nªvÀø-¬ã¨sµo²{¥i­°§C6¦¨¿©Àù²v-015832182.html

B¨xµLªk¡u§¹¥þªv¡¡v¬°¤°»ò­nªvÀø¡H ¬ã¨sµo²{¥i­°§C6¦¨¿©Àù²v

¥þ¥Á°·±d°òª÷·|

2018¦~6¤ë6¤é ¤U¤È 05:31

C¨x¥þ¤fªA·sÃÄ°Ý¥@«á¡A°ª¹F99%ªºªv¡²vÅý³\¦h¯f¤Í±q¦¹Â\²æC¨x¯f¬rªºªÈÄñ¡A¬°¼Æ§ó¦hªºB¨x¯f¤Í¤]¦b´Á¬ß¡G¡u¦ó®É¤~¦³ªv¡ªº¤@¤Ñ¡H¡vB¨x¥Ø«e¤´µLªk¦p¦PC¨x¯ë®Ú°£¡A¥u¯à°h¦Ó¨D¨ä¦¸´M¨D¡u¥\¯à©Êªv¡¡v¡]functional cure¡^¡A§Y«K¦p¦¹¡A­n¹F¨ì¦¹¤@¥Ø¼Ð¤´Â¤£®e©ö¡A¬°¤°»ò¡H

»O¤jÂå°|®ø¤Æ¤º¬ì¥DªvÂå®v¡B»O¤jÂå¾Ç°|·L¥Íª«¾Ç¬ì°Æ±Ð±Â·¨§»§Ó¡A±µ¨ü¡m¦n¤ß¨x¡nÂø»x¿Ô¸ß®É«ü¥X¡A»P¤@¯ë¯e¯f¤£¦P¡AB«¬¨xª¢¦]¨ä¯f¬r¯S©Ê¡A¤£¯à¥H²³æªº¡uªv¡¡v©Î¡u¥¼ªv¡¡v³o¼Ëªº¤G¤Àªk¨Ó°Ï§O¡CB«¬¨xª¢ªºªvÀø¥i¥Îµu´Á¡B¤¤´Á¡Bªø´Á¥Ø¼Ð¨Ó¬Ý¡C

¨x¯f¨¾ªv¾Ç³N°òª÷·|¸³¨Æªø¡B¥x¤jÂå¾Ç°|¦WÅA±Ð±Â³\ª÷¤t«ü¥X¡A¥Ø«eB«¬¨xª¢ªvÀø¥i¤À¬°¨âºØ¡A¤@ºØ¬O¤zÂZ¯ÀªvÀø¡A¥t¤@ºØ«h¬OB¨x¤fªA§Ü¯f¬rÃĪ«¡C¥Ñ©ó¤zÂZ¯À°Æ§@¥Î¤j¡AÅý³\¦h¯f¤Í¬°¤§«o¨B¡A©Ò¥H±µ¨üªvÀøªº¤H¤£¦h¡C¦ý¦bB¨x¤fªA§Ü¯f¬rÃĪ«°Ý¥@«á¡A¦]¨S¤°»ò°Æ§@¥Î¡AÅý¯f¤Í±µ¨üªvÀøªº·NÄ@¤j¼W¡C¦ý¬OB¨x¤fªA§Ü¯f¬rÃĪ«¥u¯à§í¨îB¨x¯f¬rÁc´Þ¡AµLªk¹³C¨x¥þ¤fªAÃĪºÀø®Ä¤@¼Ë¡A©Ò¥H®É±`¦³B¨x¯f¤Í°±ÃÄ«á¡A¯f¬r¦A«×¤Ï¼³¡A³o®É°±ÃĪº®É¾÷´NÅã±o¬Û·í­«­n¡C

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

So.......

¥u­nÀø®Ä©M¤fªA¬Û·í, ¯f¤H¥i¥H±µ¨ü¨â¶g©Î§óªø¥´¤@°w°Æ§@¥Î¤p, ­q»ù¤S¤ñ¤fªAÃĨãÄvª§¤O, ¦p¦PÃĵØÀò¤¤°ê°ê®aÃÄ«~ºÊ·þºÞ²z§½§åRopeginterferon alfa-2b¡]P1101¡^¦b¤¤°ê¶i¦æºC©Ê¤þ«¬¨xª¢°ò¦]2«¬ªº°ê»Ú¦h¤¤¤ß¤HÅéÁ{§É¸ÕÅç

ªº¤½§i¤º®e©³ºÝ, ¤½¥q¤wªí¥Ü¤F¥Ø¼Ð¥«³õ¤F:

¥«³õ: °w¹ïµo®i P1101 ¬°ªvÀø¨xª¢¥ÎÃĪºµ¦²¤¡A·|µÛ­«¦b¤½¦@½Ã¥ÍÁٻݥ[±jªº°ê®a¡F ¦p¤¤°ê¤Î¨ä¥L·s¿³°ê®a¡C

(¼ç¦b)§Q°ò:

¦ý¦]¤zÂZ¯ÀÃÄ«~¤£¨}°Æ§@¥Î¡A¨Ï¥Î¤§¾¯¶q¨ü­­¡A P1101 ¬°³Ì·s«¬ªø®Ä¥B°Æ§@¥Î§C¤§¤zÂZ¯ÀÃĪ«¡A©w¯à¼W¥[¤zÂZ¯ÀÃĪ«¦bªvÀø¨xª¢ªº¥Î³~¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2018/12/20 ¤U¤È 11:14:39²Ä 5703 ½g¦^À³
www.liver.org.tw/knowledgeView.php?cat=5&sid=22

¨x¯f¨¾ªv¾Ç³N°òª÷·|

B¨xª¾ÃÑ:

ºC©Ê¢Ð«¬¨xª¢ªºªvÀø¤èªk

°w¹ï¢Ð«¬¨xª¢¯f¬rªº¯S©Ê¡A¥Ø«eÂå¬É¹ï©óºC©Ê¢Ð«¬¨xª¢ªºªvÀø¦h±Ä¤TºØ¤è¦¡¡G

• ¤fªA§Ü¯f¬rÃĪ«¡GªvÀø­ì²z¬O¡A±Ä¥Î§Ü¯f¬rªºÃĪ«ª½±µ§í¨î¤HÅ餤¢Ð«¬¨xª¢¯f¬rªº½Æ»s¡A¥]¬A¤z¦w¯à¡]Lamivudine¡^¡B¤z¾A¯à¡]Adefovir¡^¡B¨©¼Ö§J¡]Entecavir¡^¡B³ß¥²ºÖ¡]Telbivudine¡^¥H¤Î´f¥ß§´¡]Viread¡^¡C

• ª`®gÃĪ«¡G­Ý¨ã§Ü¯f¬r©M§K¬Ì½Õ¸`¨âºØ§@¥Î¤§ÃĪ«¡A¦p¡G£\¤zÂZ¯À¡C

• ¨ä¥L¡G§Q¥ÎÃĪ«ªº§K¬Ì½Õ¸`§@¥Î¨Ó§ïµ½¯f±¡¡A¥Ø«e¶È¦³£\¯Ý¸¢¯À (Thymosin£\)¦ü¥G¨ã¦³¦¹µ¥®Ä¥Î¡A¦ý¤´»Ý¶i¤@¨BÃÒ¹ê¡C

¦Ü©ó¥H¤W¤TºØªvÀø¤è¦¡­þ¤@ºØ¤ñ¸û¦n¡H¨Ã¤£¤@©w¡A¥HªvÀø®ÄªG¨Ó»¡¡A¤zÂZ¯À»P¤fªAÃĪ«¬Û®t¦³­­¡F¬é­n¨Ì·ÓÂå®vªº«ü¥Ü±µ¨üªvÀø¡A¤j¬ù¦³¤T¤À¤§¤@¥ª¥kºC©ÊB«¬¨xª¢±wªÌ¯f±¡¥i¥H±o¨ì±±¨î¡C

­È±oª`·Nªº¬O¡A¨Ã«D¨C¤@¦ìºC©ÊB«¬¨xª¢±a­ìªÌ³£»Ý­nªvÀø¡A¥²¶·¥ÑÂå®v¨Ì¾Ú¯f±¡¤£¦P¨Ó¨M©w¡C¤@¯ë¨Ó»¡¡A·íºC©ÊB«¬¨xª¢±wªÌ¦å¤¤GOT¡BGPT­È¶W¹L¥¿±`­È¤W­­ªº2­¿¥H¤W¡A´N¥i¥H¦Ò¼{±µ¨üªvÀø¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G£~£~10134649  µoªí®É¶¡:2018/12/20 ¤U¤È 10:06:56²Ä 5702 ½g¦^À³
Âûºô»¡ªºÂû¤O±o¬O¥i¥H§â¯f¬r²M°®²b,«oµLªk­°§C¤§«áªº¨xÀù­P¯f²v¡C

¥u¬O,³o­PÀù²v¤]³\¥u¯à·í°Ñ¦Ò,¤£¯à·íÀø®Ä«ü¼Ð§a?

Besremi«o¥i¥H´î¤Ö­PÀù,¤]¬O°Ñ¦Ò¦Ó¤w§a?

¦Ü©ó¬°¦óÁÙ­n¸Õ¤j³°ªº»æ°®?À³¸Ó¦³¥¦ªº¹D²z,§Ú°O±o«Ü¤[¤§«e¦³¤j¤j¤ÀªR¹L¡³

Âû¤O±oÃÄ»ù¤]¬O¶Q¦º¤F¡´

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/20 ¤U¤È 09:20:47²Ä 5701 ½g¦^À³
¤p¥øÃZ¤j,¯«¤]!

¤µ¤Ñ²Ä¤@ª÷·s¿³²M¥X40±i.

³o¤U¤H¤H¾á¤ß¤]³Q±z¬Ý¥ú¥ú. Orz.

[·|­û¡G¤p¥øÃZ10142872 µoªí®É¶¡:2018/12/19 ¤U¤È ²Ä 5691 ½g¦^À³

¤µ¤Ñ½æ¶W²Ä¤@¦Wªº²Ä¤@ª÷·s¿³§Úı±o¯uªº¬O«Ü¦h¤Hªº¼g·Ó ¥L¾ã­Ó¥¬§½±q2017/1/2¶}©l¶R¤¤¶¡¹Lµ{¦³¶R¦³½æ

«ùªÑ³Ì¦h´N¬O¬Q¤Ñ¤§«eªº®w¦s110±i¤µ¤Ñ½æ¥X¤§«áÁÙ¦³38±i.....]

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/20 ¤U¤È 09:10:20²Ä 5700 ½g¦^À³
ªG¤£¨äµM¤µ¤ÑGºô¬¶ÅF¤¤°ê¤þ¨xÁ{§É¸ÕÅç.

¬Ý¨Ó¬O¦³¤£¦@À¹¤Ñªº±þ¤÷¤§¤³!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥¿¥¿10141351  µoªí®É¶¡:2018/12/20 ¤U¤È 07:04:09²Ä 5699 ½g¦^À³
¥ý±´Âø»x²Ä2018´Á

2018/12/21~2018/12/27

ÃĵØÃÄ ÁÙ¦³´X¹DÃö¥d«ÝÂç²M

¦Û¥D¶}µo·sÃÄRopegÀò¼Ú·ùCHMP¥¿­±·N¨£

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/20 ¤U¤È 12:24:26²Ä 5698 ½g¦^À³
À˵ø©³¤UNo.4 ªºP3Á{§É¸ÕÅç¹w­p°õ¦æ´Á¶¡¡G2015-04-01¦Ü2017-07-31? ¤@ÀYÃú¤ôÁÙ¬O¸ß°Ý¤½¥q¬°·Ç¡C

­Ó¤HÁÙ¬O»{¬°¤zÂZ¯À¦bC¨x¤w¬OµL³½,½¼¤]¦n¡C

¯u­n¬Ý­«¨xª¢¥«³õ,[¥Ø«e]¬Ý¨Ó¬O¦bB¨x»PB+C¨x¥«³õ¸û¦³¥i¬°¡C

¥HPV3¦~Á{§Éµ²ªG§¹³ÓHU,¤ñ¹ï¤Uªí³æ¤@PV¥«³õ´N¨¬°÷¦Y¨ì¼µÃz,¦óªp«áÄòÁÙ¦³ET/MFÁ{§É¡C

¤j¼¯ 2017¦~°w¹ï PV¥«½Õ¤ÀªR...

US Polycythemia Vera 2015... 2018E

Pts on Hydroxyurea 57567 61485

Hydroxyurea Failures 23027 24594

EU Polycythemia Vera 2015... 2018E

Pts on Hydroxyurea 90201 96821

Hydroxyurea Failures 31571 33887

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/12/20 ¤W¤È 10:14:51²Ä 5697 ½g¦^À³
Roger¤j¡A

CDEªººô­¶¦³bug¡A§Ú¥ý«e§Yµo²{¨Ï¥Î¤£¦P·j´M¤è¦¡¡A¦³®ÉÅã¥Ü[¸ÕÅç¤wµ²§ô]¡A¦³®ÉÅã¥Ü[¸ÕÅç²×¤î]¡C

¹ê»Ú¤WC¨x¤G«¬P2¤w§¹¦¨¡A¹L¥h¤]¦³¤½§i¡C

P3Á{§ÉTW,KR¤w¦P·N¶i¦æ¡A´N®t²{¦bªºCN¡C

No. 2 °õ¦æª¬ºA ¡G¸ÕÅç¤wµ²§ô¡@¡@¡@ ¸ÕÅçÃÄ«~¦WºÙ / ¦¨¤À ¡G P1101 / PEG-P-IFN£\-2b

¸ÕÅç­pµe¼ÐÃD¡]¦WºÙ¡^ An Open-label, Randomized, Active Control Study to Demonstrate Non-Inferiority in Efficacy, and to Compare Safety and Tolerability of P1101 + Ribavirin to PEG-Intron + Ribavirin in Treatment-Naive Subjects with Chronic HCV Genotype 2 Infection

«ÅºÙ¾AÀ³¯g¡G Chronic Hepatitis C Infection

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/20 ¤W¤È 10:03:12²Ä 5696 ½g¦^À³
[·|­û¡GROGER588910144700 µoªí®É¶¡:2018/12/14 ¤U¤È 12:03:06 ²Ä 5515 ½g¦^À³

¥xÆWÃĪ«Á{§É¸ÕÅç¸ê°Tºô

www1.cde.org.tw/ct_taiwan/search_display_list3.php?cro=%C3%C4%B5%D8%C2%E5%C3%C4%AA%D1%A5%F7%A6%B3%AD%AD%A4%BD%A5q

..........

No. 4 °õ¦æª¬ºA ¡G¸ÕÅç²×¤î¡@¡@¡@ ¸ÕÅçÃÄ«~¦WºÙ / ¦¨¤À ¡G P1101 / PEG-P-IFN£\-2b

¸ÕÅç­pµe¼ÐÃD¡]¦WºÙ¡^An Open-label, Randomized, Active Control Study to Demonstrate Non-Inferiority in Efficacy, and to Compare Safety and Tolerability of P1101 + Ribavirin to PEG-Intron + Ribavirin in Treatment-Naive Subjects with Chronic HCV Genotype 2 Infection

«ÅºÙ¾AÀ³¯g¡GChronic Hepatitis C Infection

¥H¤W¬O­Ó¤H´©¥Îµª®×,¼Ð·Çµª®×ÁÙ¬O¸ß°Ý¤½¥q!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/12/20 ¤W¤È 09:59:26²Ä 5695 ½g¦^À³
¤¤°ê²{¦b¥Ó½ÐIND«á¡A±q¼f¬d¨ì§å­ãªº®É¶¡¤w¤j´T¤U­°¦Ü¤T­Ó¤ë¥ª¥k¡A¼eÃP¤@ÂI§ì¥b¦~¤º¦n¤F

§Ú»{¬°¬O·|°µªº¡A¤£µM¤½§i¤Sµ¥µÛ³QGºô°µ¤å³¹

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/20 ¤W¤È 09:49:23²Ä 5694 ½g¦^À³
ROGER5889¤j¤j:

¨p¥H¬°¦pªG¤½¥q¤£¥´ºâÄ~Äò°µC¨x¤T´Á

¤½§i¤º®eÀ³¸Ó¤£·|¦³¹w­p2020¦~§¹¦¨ªº¦r²´¤~¬O

¤£ª¾±z¬Ýªk¦p¦ó

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/20 ¤W¤È 09:44:21²Ä 5693 ½g¦^À³
¬ü°êFDA¦b¦UÃļt´£¥æÁ{§É¥Ó½Ð®×¡]IND¡^30¤Ñ«á¡A­Y¨S¦³¯S®í°ÝÃD¡AÃļt¥i³w¦Û±Ò°Ê¤HÅéÁ{§É¸ÕÅç¡C¦ý¦b¤¤°ê¡A¥Ó½ÐIND¸ÕÅç¡A±q¼f¬d¨ì§å­ã¸g±`¯Ó®É1~2¦~.....¡C

´©¦¹,¹ï·Ó¥xÆWC¨xÁ{§É²×¤î,­Ó¤H¥H¬°³q¹L«áÀ³¸Ó¬O¤£·|Á{§É¸ÕÅç,¤£¹L½T¤Áµª®×ÁÙ¬O¸ß°Ý¤½¥q¬°·Ç.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/20 ¤W¤È 09:40:02²Ä 5692 ½g¦^À³
¥Ø«eC¨x¤fªAÃĪ«

¤j¦h¬O°w¹ï²Ä¤@«¬°ò¦]«¬

¶È¦³Sovaldi¥iªvÀø²Ä¤G«¬

¦]¦¹6446¦b¤¤°êªºC¨x¤T´Á¤]¬O°w¹ï°ò¦]²Ä¤G«¬

ºâ¬O¦X²zªº§G§½

Sovaldi¤@¦¸Àøµ{12¶g¬ù»Ý¥x¹ô250¸U

¦]¦¹¥HP1101¥Ö¤Uª`®g³~®|

­n¬D¾Ô¤fªAªºsovaldi

¥HÀø®Ä¸ò¦w¥þ©Ê¬Û¦Pªº«e´£¤U

»ù®æ¤W¥²¶·­n¦³¬Û·íªºÀu¶Õ¤~¦æ

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/12/20 ¤W¤È 08:45:10²Ä 5691 ½g¦^À³
§Ç¸¹ 2 µo¨¥¤é´Á 107/12/20 µo¨¥®É¶¡ 00:46:42

µo¨¥¤H ªL°êÄÁ µo¨¥¤H¾ºÙ °õ¦æªø µo¨¥¤H¹q¸Ü 02-26557688

¥D¦®

¤½§i¥»¤½¥q¤wÀò¤¤°ê°ê®aÃÄ«~ºÊ·þºÞ²z§½§å­ãRopeginterferon alfa-2b¡]P1101¡^¦b¤¤°ê¶i¦æºC©Ê¤þ«¬¨xª¢°ò¦]2«¬ªº°ê»Ú¦h¤¤¤ß¤HÅéÁ{§É¸ÕÅç

²Å¦X±ø´Ú ¡@²Ä 53 ´Ú ¨Æ¹êµo¥Í¤é 107/12/19

»¡©ú

1.¨Æ¹êµo¥Í¤é:107/12/19

2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³­­¤½¥q

3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q

4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î

5.µo¥Í½t¥Ñ:

¥»¤½¥q¤wÀò¤¤°ê°ê®aÃÄ«~ºÊ·þºÞ²z§½§å­ãRopeginterferon alfa-2b¡]P1101¡^¦b¤¤°ê¶i¦æºC©Ê¤þ«¬¨xª¢°ò¦]2«¬ªº°ê»Ú¦h¤¤¤ß¤HÅé

Á{§É¸ÕÅç¡C

6.¦]À³±¹¬I:µL

7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:

(1)¬ãµo·sÃÄ¥N¸¹©Î¦WºÙ¡GRopeginterferon alfa-2b¡]P1101¡^

(2)¥Î³~: P1101 «Y³Ì·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀÃĪ«¡A¥i¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g (PV)¡B­ìµo©Ê¦å¤pªO¼W¥Í¯g¡]ET)¡B­ìµo©Ê°©ÅèÅÖºû

¤Æ¡]PMF¡^¤ÎºC©Ê¯f¬r©Ê¨xª¢¡]HBV¡BHCV¡BHDV)µ¥¡C

(3)¹w­p¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G¥»²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç©ó¥xÆW¡BÁú°ê¤Î¤¤°êµ¥¦a¦P¨B¶i¦æ¡A¹w¦ô¤T´Á¤HÅéÁ{§É¸ÕÅ秹¦¨«á¥Ó½Ð·sÃĬdÅçµn

°O¡C

(4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G

(¤@)´£¥X¥Ó½Ð/³q¹L®Ö­ã/¤£³q¹L®Ö­ã¡G

¥»¤½¥q¦Û¥D³Ð·s¬ãµo·s¥Íª«ÃÄ Ropeginterferon alfa-2b¡]P1101¡^¦V¤¤°êCFDA ´£¥X¥H¶i¤f¥Íª«ÃĥӽвĤT´Á¤HÅéÁ{§É

¸ÕÅç¡A¤w±µÀò¤¤°ê°ê®aÃÄ«~ºÊ·þºÞ²z§½§å­ã¦b¤¤°ê¶i¦æ¤HÅéÁ{§É¸ÕÅç¡C

(¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò­±Á{¤§­·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î

(¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î

(¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G¦]À³¥¼¨Ó¥«³õ¦æ¾Pµ¦²¤¡A¥H¤Î«O»Ù¤½¥q¤Î§ë¸ê¤HÅv¯q¡A¬G¤£¤©¤½¶}´¦ÅS¡C

(5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G

A.¹w­p§¹¦¨®É¶¡¡G¥»Á{§É¸ÕÅ笰¦h°ê¦h¤¤¤ß²Ä¤T´ÁÁ{§É¸ÕÅç¡A±N©ó¥xÆW¡BÁú°ê¤Î¤¤°ê¦P¨B¶i¦æ¦¬®×¡A¹w¦ô©ó2020¦~§¹¦¨Á{§É¸ÕÅç¡C

B.¹w­pÀ³­t¾á¤§¸q°È¡G¥»¤½¥q±N¤ä¥I°õ¦æÁ{§É¸ÕÅç¤Î¥Ó½Ð·sÃĬdÅçµn°O¤§¬ÛÃö¶O¥Î¡C

(6)¥«³õ²{ªp

¦b¨xª¢ªvÀø¤è­±¡A¾Ú¥@¬É½Ã¥Í²Õ´¦ô­p¡A¥þ¥@¬ÉB«¬¨xª¢±wªÌ¬ù¦³4»õ¤H¤f¡AC«¬¨xª¢±wªÌ¬ù¬°1»õ7000¸U¤H¡Cµo®i P1101 ¬°ªvÀø¨x

ª¢¥ÎÃĪºµ¦²¤¡A·|µÛ­«¦b¤½¦@½Ã¥ÍÁٻݥ[±jªº°ê®a¡F ¦p¤¤°ê¤Î¨ä¥L·s¿³°ê®a¡C¥þ²y¨xª¢¥ÎÃÄ¥«³õ¶W¹L100»õ¬üª÷¡C¦ý¦]¤zÂZ¯ÀÃÄ«~¤£

¨}°Æ§@¥Î¡A¨Ï¥Î¤§¾¯¶q¨ü­­¡A P1101 ¬°³Ì·s«¬ªø®Ä¥B°Æ§@¥Î§C¤§¤zÂZ¯ÀÃĪ«¡A©w¯à¼W¥[¤zÂZ¯ÀÃĪ«¦bªvÀø¨xª¢ªº¥Î³~¡C

(7)·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê­±Á{­·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/19 ¤U¤È 05:53:53²Ä 5690 ½g¦^À³
¤µ¤Ñ½æ¶W²Ä¤@¦Wªº

²Ä¤@ª÷·s¿³

§Úı±o¯uªº¬O«Ü¦h¤Hªº¼g·Ó

¥L¾ã­Ó¥¬§½±q2017/1/2¶}©l¶R

¤¤¶¡¹Lµ{¦³¶R¦³½æ

«ùªÑ³Ì¦h´N¬O¬Q¤Ñ¤§«eªº®w¦s110±i

¤µ¤Ñ½æ¥X¤§«áÁÙ¦³38±i

¤µ¦~11¤ë¤§«e¥­§¡«ùªÑ¬ù 60±i

11¤ë«á½ä½Lªñ¨Ó¼W¥[«ùªÑ¨ì110±i

¥­§¡¶R¶i¦¨¥» 170.58

¥­§¡½æ¥X¦¨¥» 171.66

³o¨â¦~Á`¦@¶R¤F¬ù400±i,

¦ý¤]½æ¤F360±i¥ª¥k

§Ú¤£ª¾¹D¥L¬O½Ö

¦ý³o¦ì¤¯¥S¹ï6446¤]ºâ¦³±¡¦³¸q

¥H¥xªÑªº¯S©Ê

¤@ÀɪѲ¼¨Ó¦^¾Þ§@¨â¦~

¤S¤£¬Oªi°Ê©Ê«Ü¤jªºªÑ²¼

®¼¤F¨â¦~

²×©óµ¥¨ì®³¨ìÃÄÃÒ¤F

¦ý¾ãÅé¤]¨SÁȨìÔ£¿ú

ÁÙ¬O¦^Âk¤@¥y¸Ü

¦p¦ó§l¤Þªk¤H¶R¤~¯à¦³«ùÄò©ÊªºÁͶÕ

ªÑ²¼¤W¥«ÁÙ¬O­n¹ïªÑªF­t³d

¨Ã«DÃö°_ªù¨Ó½Z¬ãµo

¦A¦nªº¤½¥q

¨S¦³¦¨¥æ¶q,¨S¦³ªk¤H¤ä«ù

¨º¥Ã»·´N¬O¤@Åu¦º¤ô

¥xªÑ«Ü¦h³o¼ËªºªÑ²¼

¥»¯q¤ñ¤£¨ì10­¿ªº¦n¤½¥q

§Æ±æ¤½¥q¦b§V¤O¬ãµo²£«~¤§¸·

¥i¥H·ÓÅU¤@¤UªÑªF

§OÅý¤¤½u§ë¸êªºªÑªF³£¥¢±æÂ÷¶}¤F

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤­¤K10147711  µoªí®É¶¡:2018/12/19 ¤U¤È 02:55:17²Ä 5689 ½g¦^À³
¦³¤@­Ó¤H¨ì¦U°Q½×ª©¡uÂy¡v¤å³¹¡A«o¤À§O³Q¨È·à±d¡B¥_·¥¬P¡BÃĵØÃĸT¨¥

ÀY«Ü¤j¤@­Ó¤£º|¡B¦³¤³¥²³ø¡A¦bgºô»Ä¨¥»Ä»y¤T®a³£¤¤ºj¡A³s¤£±µ¥L¹q¸Ü¤]¯à»Ä¤@½g¡A²q·QÃĵØÃĤ½Ãö¤]«ÜÃi±o±µ¹q¸Ü¡AÅý¥LÀ½¤å³¹À½±oÀY«Ü¤j

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAnderson10143089  µoªí®É¶¡:2018/12/19 ¤U¤È 01:12:09²Ä 5688 ½g¦^À³
´CÅé³£¦³¦Û¤vªºÁôijµ{¡A¬Ý¬Ý´N¦n¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/19 ¤U¤È 12:16:14²Ä 5687 ½g¦^À³
§õªü½÷¤j¤j»¡ªº¨S¿ù

¬D°_³o­Ó¹ï¥ßªº©l§@«MªÌ¦b¥»ª©¶Ü?À³¸Ó¬OGºô

´CÅ骺¤£¦b©ó¤½¥­¥¿¸q

¦b©ó¦³¦h¤Ö¤H¦bÃöª`©M°Q½×

©Ò¥H§Ú­Ì¤j®a¤S³´¤J¤F´CÅ骺°g¥¢

³Ì«á¤jĹ®a»¡¤£©w¤S¬OGºô

¦]¬°¦³§ó¦hªº¤H·Q¥h¬Ý¥L­Ì¦b¼gÔ£

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§ë¸ê¬ö«ß10145266  µoªí®É¶¡:2018/12/19 ¤U¤È 12:01:23²Ä 5686 ½g¦^À³
§Ú¤]»{¦P¤£¶·¹ï¥ß

¦³¨Ç¤H¬J¬OµØ¤Í¤]¬O¸Î¤Í

¬D°_³o­Ó¹ï¥ßªº©l§@«MªÌ¦b¥»ª©¶Ü?

§Ú¥uª¾¹DÀHµÛªÑ»ù¯}©³¤]¥¢Âܤ@°}¤l¤F¡A©Î³\¥¿ª±ªº¤£¥ç¼Ö¥G§a~~~XD

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2018/12/19 ¤U¤È 12:00:48²Ä 5685 ½g¦^À³
¥t­Ó­±¦V¨ÓÆ[¹î¥xÆW¥»¤g¤pµØªº¦¨´N»P«e¤!

1. ©h¥B¤£½×(¨S²`¤J¬ã¨s) Incyte °£¤FJakafi¥H¥~¨ä¥L²£«~½u«e´º»P¶i«×, ¤£¥i§_»{ªº¬O, ¦p¦PZack§ë¸ê¬ã¨s©Ò¨¥, Incyte¥Ø«eªº¥D­nÀ禬°^Äm´N¨Ó¦Û©óMF »P PV 2½u¥ÎÃÄ (°w¹ï¤@½uhydroxyurea (HU) ²£¥Í«D­@©Ê©Î¤£¾AªÌ) ¡K¡K.§^¤H¥i¹îincyte ªÑ»ù¤w±q¦~ªì$100USD ¶^¨ì10/24 ³Ì§C$60.92 ¨Ã¤Ï¼u¨ì12/3°ªÂI$68.32«á´N¤S¦^¶^¨ì¬Q¤Ñ»ù¦ì$64.26.

2. °w¹ïfirst-in-class JAK1/JAK2 inhibitor§í¨î¾¯ (Jakafi), Incyte¿W®a¾P°â¬ü°ê¥«³õªº ¤G½uPV / ¤ÎMF¾AÀ³¯g; µM¸ÓÃĦb¬ü°ê¥H¥~ªº¥«³õ«h¥ÑNovartis¿ÕµØ¾P°â(Jakavi)

3. ³o12/3 incyteªÑ»ù°T®§ªº±Ò¥Ü? 12/3? ¡¦¡¦¥©¦X¡¦¡¦ªº¬O, ¤£´N¬O¦b2018 ASH meeting´Á¶¡ (12/1~12/4), Dr. Gisslinger©ó12/2, 12/3µoªí¨º¤T½g¬ã¨s¤§«á? ªÑ»ùº¦¶^¦]¯À¦h, §Ú­Ì¤£¥i¤]¤£»Ý¹ï¤pµØ(¦Û§Ú)Áy¤W¶Kª÷©Î¬O»~¾É¤j®a³o¼ËªºÃöÁp©Ê, ¦ý¬O³oIncyteªºªÑ»ù¡uªí²{¡v«o­È±oÃö¤ßµØ¤Í­Ì°lÂÜ!

4. www.zacks.com/stock/news/285543/incyte-incy-reports-phase-iii-followup-data-for-jakafi

5. www.fairfieldcurrent.com/news/2018/12/18/incyte-incy-downgraded-to-hold-at-zacks-investment-research.html

6. www.marketwatch.com/investing/stock/incy

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G§õªü½÷10147886  µoªí®É¶¡:2018/12/19 ¤W¤È 11:46:03²Ä 5684 ½g¦^À³
¤£À´¬°¦ó­n¶ì³y6446¸ò4147¹ï¥ßªº§Î¶H¡H

¨â¶¡¤½¥q¬J¤£¬O¥«³õªºÄvª§ªÌ

ÃĪº¾AÀ³¯g¤]¤Ñ®t¦a»·

Ãø¹D§â¨ä¤¤¤@¶¡¥´À£¤U¥h

¥t¤@¶¡´N·|ÁȤj¿ú¶Ü¡H

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡Gª£¦Ì¯»10146792  µoªí®É¶¡:2018/12/19 ¤W¤È 11:40:05²Ä 5683 ½g¦^À³
§Ú­Ó¤H»{¬°·sÃÄÃþªÑ¬O¥i¥H¦@¥Í¦@ºaªº¡A¤¤¸Î¸òÃĵس£¦U¦³¤ä«ùªÌ¡A¥i¥H¤ñ¸û¦ý¤£¥²°Û°I¡A§ÚÀ£Ä_Ãĵؤ]¬OÄw½X¤ÎÀç¹B¤@±øÀs¼Ò¦¡¡A©Ò¥H§Úªø´Á§ë¸ê§ó¦³¨M¤ß¯à¾a¦Û¤v«ùÄò­_§§ªº¥Í§Þ¤½¥q
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GLibad10145748  µoªí®É¶¡:2018/12/19 ¤W¤È 11:38:55²Ä 5682 ½g¦^À³
«Ü­«­n¤£¹½¨ä·Ð¦A»¡¤@¹M

---------------------

²×¥Í¹ØÀI

¬¡¶V¤[»â¶V¦h

ÃĵتѲ¼

©ê¶V¤[º¦¶V¦h

--------------

Âûºô¥u½æÂû¤£½æÃÄ

­n¶RÂû¬ÝÂûºô

­nÁȤj¿ú¶RÃĵتѲ¼

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/19 ¤W¤È 11:24:42²Ä 5681 ½g¦^À³
¤§«e¦³¤H´£¨ì·sÃĪº°ÝÃD

´N¬Oªì´ÁÂå¥Í¤£¤Ó´±¥Î

¥H4147¨Ó»¡

¦]¬°¬O¥|½u¥ÎÃÄ

¥Nªí¤§«e123½u¥ÎÃĤw¸g¦³§ÜÃÄ©Ê

©Î³\¥Í©Rª¬ºA¤w¸g¤ñ¸û®t¤F

¦pªG§A¬OÂå¥Í§ï¥Î³o´Ú¥|½u·sÃÄ

¤@©w·|¾á¤ß¤£©¯Åý¯f±w©¹¥Í(©Î³\¥Î­þºØÃij£·|GG)

¤j®a´N·|ÃhºÃ¬O§_¬°¥ÎÃÄ°ÝÃD

©Ò¥H´«ÃĪº³t«×¥i¯à¤£·|³o»ò§Ö

¦ý6446³o¤è­±§Úı±o¦æ¾Pªº¤w¸g¤£¿ù

KOL ¤w¸g¤@­ÈÀ°¥L­ÌÁ¿¸Ü

³o¨Ç¥i¯à³£¬OÂå¥Íªº¦Ñ®v

§Ú·Q¤§«á¦A·sÃĦæ¾P¤è­±

À³¸Ó·|¤ñ¸û¶¶§Q¤@ÂI

ªp¥BÁÙ¬O¤@½u¥ÎÃÄ

¤j®a§NÀR«ä¦Ò

4147¥Ø«e¸I¨ìªº²~ÀV

6446·|¤£·|§¹¥þ½Æ»s

§Ú¤£´±¤U©w½×

¯dµ¹¦U¬°¦Û¤v§PÂ_

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/19 ¤W¤È 11:06:56²Ä 5680 ½g¦^À³
²Ä¤­¶¥¥ÎÃÄ:³æ¤@¨Ö¥Î©Î¤G·½¨Ö¥ÎªvÀø--¤fªAÃþ©T¾J(³Ì§C¾¯¶q) /§ÜIgEÃĪ«

www.nhi.gov.tw/epaper/ItemDetail.aspx?DataID=2784&IsWebData=0&ItemTypeID=7&PapersID=237&PicID=

¦ì¶¥: P1101/HU ²Ä¤@½uÃĪ« ; Xolair/¤fªAÃþ©T¾J ²Ä¤­½uÃĪ«

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GAT10147586  µoªí®É¶¡:2018/12/19 ¤W¤È 11:06:06²Ä 5679 ½g¦^À³
¿\¥É»Ý­n¾Ö©ê»PµZ¿i¤~¯àµo±¸¨ä»ù­È, µu´Á¦Û«îÁo©úªÌ¨Ó¦^¾Þ§@ªÌ©Î¬O«H¤ß¤£¨¬ªÌ,´N¯¬ºÖ¥L­Ì.

²¦³º¤H¤£¬O¯«¤]¤Å¶·¾Ò´o»P±¡ºü; ±©Ä~Äò²Ö¿n½×¾Âªº±Mª`¤~¯àµo´§¤p§L¤ÀªR®vÀ»±Ñ¾÷ºc¤ÀªR®v©Î§ëÅU¦W¼L­Ì,§ó¦óªpÂåÃÄ»â°ì¬OªùÂe°ªªº,¬Û«H¥xÆW¥»¤g°÷²`¤J¤£¦PÂåÃÄ»â°ìªº¤ÀªR®v®£©È¤£¦h§a, °£¤F§ë¾÷ªÌ¥~, µL©Ç¥G¥«³õ¤p´²ÁÙ¦bºN¯Á/¤]±`¦pÅå¤}¤§³¾!

ÁöµM¤ëªì¤~­è¹LUS ASH 2018 meeting, ¤pµØ¤]¤½§i ¹Ù¦ñAOPµoªíªº¤T½g¬Û·íÆgªº¤å³¹»P¬ã¨s, Åý§Ú­Ì¬Ý¬Ýpatient power ³X½Í¨â¦ìÂå¥Íªº¤º®e. (¨ä¤@¬O¤j®a¼ô±xªºDr.Srdan Verstovsek)

¨â¦ìÂå¥Íªº­«ÂIºK­n¦p¤Uµ¹¨SªÅ¬Ý§¹¥þ¤åªÌ...

Key summary: ¡¥¡¦Updates From ASH 2018: The Latest on Interferon Therapy in MPNs

Published on December 6, 2018

www.patientpower.info/video/updates-from-ash-the-latest-on-interferon-therapy-in-mpns

Dr. Yacoub

Interferons have a remarkable safety profile in terms of long-term use and the lack of cancer-forming risk that you can have with other drugs. So interferons can be used in young individuals who unfortunately need treatment for MPNs. They are safe during pregnancy.

interferons will be a long-term investment where you¡¦re putting a high-impact intervention early in the disease course that many years or decades later will be disease-modifying and even achieving deep responses of remission, and even beyond that there¡¦s now treatment-free remission where patients are off therapy and they have no symptoms of their disease.

Dr. Verstovsek

we believe that there¡¦s a potential for interferon to change the biology¥Íª«¾Çof the disease in terms of decreasing or eliminating cells that have mutations, perhaps improving the bone marrow function, normalizing the bone marrow.

It was a study in long-term outcome patients in the¡Xwith ropeginterferon treated that have a PV, then as you said in early-stage myelofibrosis, prefibrotic myelofibrosis°©ÅèÅÖºû¤Æ and the last study which is actually oral presentation here is comparison to Hydrea where it appears to be better than hydroxyurea in polycythemia vera.

So all these studies talk about the efficacy of this medication. Hopefully, we will have it in clinical studies, and I encourage everybody to participate, in ET and possibly in PV here in the United States.

¨Ï¥Î¤zÂZ¯Àªº¨Ò¥~±¡§Î, Âå¥Íªº¤p¤p¥mÀ{:

¦]¬°ªø®Ä¤zÂZ¯À¬O±Ò°Ê¯f¤H§K¬Ì¾÷¨î¨Ó¹ï§Ü¯e¯f, ©Ò¥H±©PV¯f±w­Õ­Y¦s¦b ¦Û¨­§K¬Ì©Ê°ÝÃDªº¯e¯f©ÎÄY­«§íÆ{¯g, «h¥i¯à­n¤£«Øij¨Ï¥Î¤§

¡K¡KSo among the very important side effects that we highlight and usually they are a reason to not use interferon would be patients with autoimmune diseases ¦Û¨­§K¬Ì©Ê¯e¯f and also patients with out-of-control depression¥¢±±§íÆ{¯g.

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/19 ¤W¤È 10:55:55²Ä 5678 ½g¦^À³
¤°»ò¬O[²Ä¤@]»P[°ß¤@]ªºÀu¶Õ!

¬Ý¬Ý±i¤l¤å³Õ¤hªºXolair®ð³ÝÃÄ,[²Ä¤@]¤W¥«ªº®ð³Ý§ÜÅéÃÄ,³Ì¥½½u[°ß¤@]ÃĪ«.

(¥i±¤TMB355¾D¤H¤¤³~¾î¤M¹Ü·R,¥H­P¤W¥«®Éµ{¤Ó±ß,¥¢¥h¥«³õ¥ý¾÷)

Ãþ©T¾J°£¤F»ù®æ«K©y°Æ§@¥Î¤£¤Ö,¦ÓXolairÃĶO¬ùUS$25000/¦~,µ²ªGXolair¾P°âÃB2017 U.S. sales: $1.83 billion.

2006 ¦~³Ì·sGINAªvÀø³W½d¹ï©ó®ð³Ý¦³¤­¶¥¥ÎÃÄ­ì«h¡A®ð³Ý¤§ªvÀøÄÝ¡u¼h¼h¥[(step up)¡v¤§·§©À¡A®ð

³Ý¯f±w±q²Ä1½u¨Ï¥Î¦Ü²Ä2½u¡B³æ¤@¨Ï¥Î¡B³æ¤@¨Ï¥Î°ª¾¯¶q¡B¦hÃĪ«¦X¨Ö¨Ï¥Î¡B¦hÃĪ«¦X¨Ö¨Ï¥Î°ª¾¯¶q¡A®ð³Ý´c¤Æ¦Ü­««×¡A¦Ó¥B¨Ï¥Î³o¨ÇÃĪ«µL®ÄªÌ¡A¤w¬O·¥¤Ö¼Æ¡C­««×®ð³Ý¬Ò¤w¦Ü²Ä¥|¶¥©Î²Ä¤­¶¥ªº³B²z¡C§ÜIgEÃĪ«(¦p¡GXolair)ÄݲĤ­¶¥¥ÎÃÄ­ì«hªº³Ì«á¤@½u¥ÎÃÄ¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pÃC10147871  µoªí®É¶¡:2018/12/19 ¤W¤È 10:16:28²Ä 5677 ½g¦^À³
§ë¸ê¤F³o»ò¦h¦~¡A°ß¤@¾á¤ßªº¬O¼Ú¬wÃÄÃÒ¨ú±o¡A¬JµM¤Q®³¤Eí¡C«á­±ªºÃÄÃÒ¨ú±o¤£¬O¤j°ÝÃD¡C­Ó¤Hı±o·íÃĵØÃĪº»ù­È³Qµo²{®É¡AªÑ»ù¶V©¹¤W¨«¡A·|¦³«Ü¦h¤H¶R¤£¤U¤â¡C­n©M¤@®a¦¨ªø´Áªº¤½¥q©ê¤@°_¡A¬OÃø¼õªº¡C¥[ªo
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/19 ¤W¤È 10:14:44²Ä 5676 ½g¦^À³
°²­Y¤¤¸ÎTMB355¬O³Ì¥½½u[°ß¤@ ]¥ÎÃÄ,«¥¤]·|§ë¤J¸êª÷,¦ý¨S¦³[°ß¤@]Àu¶Õ¥u¦³°ª¶QªºÃĶO,¤£¥uÃø»P¨ä¥L²{¦sÃĪ«Ävª§,

®É¹B¤£ÀÙ¦a¬O¤S¦³Àø®Ä§ó¨Î/»ù®æ§ó«K©y/¤fªA¬I¥´§ó¤è«Kªº·sÃĪ«±N¤W¥«,­ì¥»´Nµ°¤Ö¼¨¦hªº¥«³õ,¨ì®É®£±N³s¼xµ°¤]¨S±o³Ü!

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pªL10142678  µoªí®É¶¡:2018/12/19 ¤W¤È 10:12:29²Ä 5675 ½g¦^À³
A»PB¡A°²³]³£¬O®Ö¥iÃĪ«¡A¥B³£¦³«OÀIµ¹¥I¡C

A-ÃÄ»ù°ª¡B±M§QÃÄ

B-ÃÄ»ù§C¡B¤wµL±M§Q«OÅ@

´NÂåÀøÅé¨tªº¸gÀ٥ͺA¡AÂå®v·|±ÀÂ˦óºØÃĪ«?

Âå®v¦pªG³£¶}ÃÄ»ù§CªºB¡A¥i¯à´N³QÂå°|¸³¨Æ·|¶}°£¤F¡C

§ó¤£¥Î»¡¦pªGA¬O®Ö¥i¥ÎÃÄ¡AB¬O«D®Ö¥i¥ÎÃÄ¡C

·Q³q¤F¡A´N¥i¥H¥´¯}¦bµæ¥«³õ¶Rµæ¤ñ»ùªº°g«ä¡C

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤p¥øÃZ10142872  µoªí®É¶¡:2018/12/19 ¤W¤È 10:09:41²Ä 5674 ½g¦^À³
¤H®a¥S§Ì¬O³»µÛ¥úÀô+¥xÆW³Ì¤j¥Í§Þ°òª÷¤ä«ù

ÃĵشN¬O¾a§Ú­Ì¤@¯ë¤H¤ä«ù

¦ýªÑÅv¤À´²ªí«o§¹¥þ¬Û¤Ïªºª¬ªp

¦U¦ì¥i¥H¥h©M­ô­ô,¨ä¹ê¾ã­Ó¼Æ¦r©M§Ì§Ì®t¤£¦h

¥S§ÌªºªÑ²¼¤ñ¸û¬¡¼â

µØ¥JªºªÑ²¼¤ñ¸û·Å§]

°ÝÃD´N¬O¦b¦¨¥æ¶q(±q¤§«e´N³o¼Ë¤F)

¨S¦³½Ö¹ï½Ö¿ù½Ö¦n½ÖÃa

¤£¹L¦¨¥æ¶q¹L§C

ªº½T·|Åýªk¤H¤ñ¸û¤£´±¶R

¦p¦ó¼W¥[¦¨¥æ¶q¤]¬O«Ü­«­nªº

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GÃƪѥÁ10147162  µoªí®É¶¡:2018/12/19 ¤W¤È 10:01:05²Ä 5673 ½g¦^À³
¦pªG¯uªºµoGDR, ¥i¯à«Ü¦h¤½¥q¥]¬AINCYTE³£·|·mµÛ»{... ¦]¬°­n¨Ó¶R¥xÆWªÑ²¼¹ê¦b¦³ÂI³Â·Ð..

¸Ü»¡, Ãø©ÇÃĵسo»ò¤û¥Ö, 400±i¥H¤W¤jªÑªF¨ä¹ê«ùªÑ³£§Ö6¦¨¤F.. ©Ò¥H²{¦b­n¶R¶iªº, ¯uªº¥u¯à©ñ®ø®§À~´²¤á, ¾ß¾ß¬Ý³Ñ¤Uªº40%·|±¼¥X¨Ó¦h¤Ö¤F....

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¤pÃC10147871  µoªí®É¶¡:2018/12/19 ¤W¤È 09:59:28²Ä 5672 ½g¦^À³
¬JµM¦³«OÀI¥I¶O¡A¨S¤H·|¥h©Ó¾á¦Y¤F·|¦³­PÀù­·ÀIªº«K©yÃÄ¡AÂå¥Í¤]¨S¥²­n©Ó¾á³d¥ô¡CÂå®v¬Oªv¯f¤£¬O¨ÓÀ°«OÀI¤½¥q¬Ù¿ú¡C
¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡GROGER588910144700  µoªí®É¶¡:2018/12/19 ¤W¤È 09:53:19²Ä 5671 ½g¦^À³
BRN,°²­Y±z¬OPV±wªÌ,¬Ý¨ì©³¤UGºô³o½g:....ROPEG...Á{§Éµ²ªGÅã¥ÜPV¯e¯f¦³³Q[ªv¡]ªº¥i¯à.....

±z¦³«OÀIµ¹¥I©Î°]¤O¶¯«p¯à¦Û¶O,±z­n¦Ò¼{¥ÎP1101ÁÙ¬OHU?

ÃĵØÃıÂÅv¹Ù¦ñAOP©óASH¦~·|«Å¥¬P1101ªvÀøPV¤§¤T¦~¸ÕÅç

:www.genetinfo.com/investment/featured/item/21922.html

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
·|­û¡G¦×©@10141509  µoªí®É¶¡:2018/12/19 ¤W¤È 09:49:11²Ä 5670 ½g¦^À³
JAKAVI¬O²Ä¤G½u¥ÎÃÄ

¦­±ß¦U¤@Áû

¤@Áû¥xÆW°·«O»ù2002

¤@­Ó¤ë¤]­n12¸U

¦^ÂÐ¥»¤å ¦^¤W¥«Âd°Q½×°Ï1­¶
²Ä¤@­¶¤W¤Q­¶¤W¤@­¶181920212223242526¤U¤@­¶¤U¤Q­¶

         

¡@

§Ú¡@¡@­n¡@¡@¦^¡@¡@À³¡@¡@¥»¡@¡@¸Ü¡@¡@ÃD

·| ¡@­û¡G

  

§@ ªÌ ¡G

 

¬ÛÃöªÑ²¼¤½¥q¦WºÙ ¡G

ÃĵØÂåÃÄ

¤º¡@ ®e¡G

¡@
½Ð¥ýµn¤J ­Y±z©|µL·|­û¨­¤À¡A½Ð¥ý¥Ó½Ð±b¸¹ ¡@
¡@

°Q½×°Ï¬ÛÃö³W©w¡G
    1.­Y±b¸¹¶¢¸m¹L¤[¨t²Î·|¦Û°Êµn¥X¡A«Øij¦b¼g¦n¤å³¹¨Ã¥B©|¥¼µo°e¤§«e¥ý¦æ½Æ»s¡A¥H§Kµo°e¥¢±Ñ«á¾É­P¤º¤å®ø¥¢¡I
    2.½Ð¤Å°Q½×ªÑ²¼¶R½æ©Î´£¤Î¦¨¥æ»ù¦ìµ¥¨Æ©y¡A¤Z¬O¯d¤U¬ÛÃö¥æ©ö°T®§¡A¥»ºô±N¦Û°Ê§R°£¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    3.ÄY¸T¯d¤UÁpµ¸¤è¦¡¡A½Ñ¦pLINE¡BFB¡BE-mail¡B¹q¸Ü..µ¥¡A©Î¥H¥ô¦ó©ú¥Ü¡B·t¥Üµ¥¤âªk¶i¦æÁpµ¸¡A¹HªÌ±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    4.¬°ÁקK®ö¶Oºô¸ô¸ê·½¡A½Ð¤Å±N¬Û¦P¤º®e³sÄòµo¦b¦h­Ó¤£¦P¥DÃD¤º¡A©ÎªÌ³sÄòµo°e¦h­Ó·s¥DÃD¡A­Y¦³¦¹Ãþ¬~ª©¤§¦æ¬°±NµLªkÄ~Äò°Ñ»P°Q½×¡I
    5.ÄY¸T·N¹ÏÂǥΥ»ºô¥­¥x¤½µM´²¥¬¤å¦r©ó²³¡A¦Ó«üÂÖ¡B«V°d©Î¶Ç­z¨¬¥H·´·l¥L¤H¦WÅA¤§¨ÆªÌ¡A­Y¦]¦Ó¯A¤Îªk«ß°ÝÃD¡A·§»P¥»¤½¥qµLÃö¡A·q½Ð¿í¦u¡C

·q½Ð´L­«¥»ºô¤§¸gÀç²z©À¨Ã¿í¦uª©³W¡AÁÂÁ¡C


¼s§i¦X§@ ¥¼¤W¥«ÂdªÑ²¼¬d¸ß ¥¼¤W¥«ºô¯¸¾ÉÄý ¥¼¤W¥«ÂdªÑ²¼±MÃD ¿³ÂdªÑ²¼±MÃD ¥¼¤W¥«ªÑ²¼-¶°¹Î¤ÀÃþ ²§·~Âà§ë¸ê¥Í§Þ·~ ¤U³æ±Ð¾Ç
¥¼¤W¥«|¥¼¤W¥«ªÑ²¼|³Ì±M·~ªº  ¥xÆW¥¼¤W¥«ªÑ²¼  °]¸gºô¯¸-Copyright©2022¡£¥²´Iºô¡¤ §K¥I¶OªA°È±M½u:0800-035-178   ªA°È«H½c:postmaster@berich.com.tw
¥»ºô¯¸¬° ¥¼¤W¥«ÂdªÑ²¼¬d¸ß,¥¼¤W¥«ªÑ²¼§Y®É·s»D,¥¼¤W¥«¤½¥q¤½§i,¿³ÂdªÑ²¼¶R½æ,·Ç¤W¥«ªÑ²¼,¤¤ÅҪѠ ¬ÛÃö¸ê°T¤À¨É¥æ¬yªÀ¸sºô¯¸,¸ê®Æ¶È¨Ñ°Ñ¦Ò,¨Ï¥ÎªÌ½Ð¦Û¦æ·r°u!
¥»ºô¯¸¤£¤¶¤J·|­û¶¡¤§¥¼¤W¥«ªÑ²¼¶R½æ,³æ¯Â´£¨Ñ  ¥¼¤W¥«ªÑ²¼¦æ±¡,«ùªÑÂàÅý,¥¼¤W¥«ªÑ²¼¹L¤á¿Ô¸ß  ¶È´£¨Ñ¥¼¤W¥«ªÑ²¼¥æ©ö¥­¥xµ¹·|­û¨Ï¥Î,¨Ì¥»¸ê®Æ¥æ©ö«á¬ÕÁ«¦Û­t!